molecule_chembl_id,canonical_smiles,standard_type,standard_value,standard_units,pchembl_value,assay_chembl_id,assay_description,assay_type,target_organism
CHEMBL40650,COc1cccc2c1CC[C@H]1CN(CCn3c(=O)[nH]c4c(sc5cccnc54)c3=O)C[C@@H]21,Ki,3870.0,nM,5.41,CHEMBL652493,Binding affinity against adrenergic receptor subtype Beta-2 adrenergic receptor using [3H]DHA as radioligand,B,Homo sapiens
CHEMBL163262,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(CC4SC(=O)NC4=O)cc3)CC2)ccc1O,EC50,1190.0,nM,5.92,CHEMBL818910,Agonistic activity was assessed by measurement of cAMP accumulation levels in CHO cells expressing human beta-2-adrenergic receptor,F,Homo sapiens
CHEMBL424167,O=C1NC(=O)C(Cc2ccc(N3CCC(NC[C@H](O)c4ccc(O)c(NS(=O)(=O)c5ccccc5)c4)CC3)cc2)S1,EC50,620.0,nM,6.21,CHEMBL818910,Agonistic activity was assessed by measurement of cAMP accumulation levels in CHO cells expressing human beta-2-adrenergic receptor,F,Homo sapiens
CHEMBL433252,O=S(=O)(Nc1ccccc1)c1ccc2c(c1)CCN2c1cccc(CCCC2CCCC2)n1,IC50,450.0,nM,6.35,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL54750,O=S(=O)(Nc1ccccc1)c1ccc2c(c1)CCN2c1cccc(CCCC2CCCC2)c1,IC50,7500.0,nM,5.12,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL56594,CCCCCCN(C)C(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21,IC50,6500.0,nM,5.19,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL52407,CCCCCCCCc1nc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)no1,IC50,100.0,nM,7.00,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL56449,CCCCCCc1ccc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)nc1,IC50,240.0,nM,6.62,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL56752,CCCCCCC(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21,IC50,2000.0,nM,5.70,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL54749,CCCCCCCCc1cnc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)o1,IC50,180.0,nM,6.75,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL301202,CN(C)C(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21,IC50,7000.0,nM,5.16,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL292407,CCCCCCCCN(C)C(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21,IC50,1000.0,nM,6.00,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL53679,CCCCCCCCc1csc(Nc2ccc(S(=O)(=O)Nc3ccccc3)cc2)n1,IC50,340.0,nM,6.47,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL299719,CCCCCCc1cccc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)n1,IC50,140.0,nM,6.85,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL55852,CCCCCCc1ccnc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)n1,IC50,620.0,nM,6.21,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL56308,CCCCCCc1cccc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)c1,IC50,460.0,nM,6.34,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL57486,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,3000.0,nM,5.52,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL55541,O=S(=O)(Nc1ccccc1)c1ccc2c(c1)CCN2c1nc(CCCC2CCCC2)cs1,IC50,900.0,nM,6.05,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL293818,CCCCCCNC(=O)N(C)c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,10000.0,nM,5.00,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL54885,CNC(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21,IC50,7300.0,nM,5.14,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL54821,CCCCCCCCc1csc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)n1,IC50,1300.0,nM,5.89,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL53359,CCCCCCCCc1ccnc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)n1,IC50,530.0,nM,6.28,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL291467,CCCCCCCCc1cccc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)n1,IC50,63.0,nM,7.20,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL295502,O=S(=O)(Nc1ccccc1)c1ccc2c(c1)CCN2c1noc(CCCC2CCCC2)n1,IC50,42.0,nM,7.38,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL301594,CN(CCc1ccccc1)C(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21,IC50,2500.0,nM,5.60,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL53842,CCCCCCNC(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21,IC50,36000.0,nM,4.44,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL298594,CCCCCCc1csc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)n1,IC50,510.0,nM,6.29,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL56767,CCCCCCCCc1csc(N(C)c2ccc(S(=O)(=O)Nc3ccccc3)cc2)n1,IC50,440.0,nM,6.36,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL56768,CCCCCCc1nc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)no1,IC50,52.0,nM,7.28,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL433454,Cc1csc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)n1,IC50,750.0,nM,6.12,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL296380,CCCCCCCCc1cccc(N2CCc3cc(S(=O)(=O)Nc4ccccc4)ccc32)c1,IC50,1500.0,nM,5.82,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL294008,CCCCCCCCC(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21,IC50,1000.0,nM,6.00,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL57430,CCCCCCCCNC(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21,IC50,630.0,nM,6.20,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL53517,CN(C(=O)N1CCc2cc(S(=O)(=O)Nc3ccccc3)ccc21)C(C)(C)Cc1ccccc1,IC50,8000.0,nM,5.10,CHEMBL647882,In vitro binding affinity towards cloned human beta-2 adrenergic receptor using [125I]iodocyanopindolol as radioligand to stimulate increase in cAMP in CHO cells,B,Homo sapiens
CHEMBL317003,CS(=O)(=O)Nc1cc([C@@H](O)CNCC2CCN(S(=O)(=O)c3ccc(-n4cc(CC(=O)O)c5ccccc54)cc3)CC2)ccc1O,EC50,30.0,nM,7.52,CHEMBL650242,Beta-2 adrenergic receptor agonist activity as increased cAMP levels in CHO cells expressing human Beta-2-adrenoceptor,F,Homo sapiens
CHEMBL101521,CS(=O)(=O)Nc1cc([C@@H](O)CNCC2CCN(c3ccc(C(=O)N[C@@H](CC(=O)O)C(=O)O)cc3)CC2)ccc1O,EC50,5.0,nM,8.30,CHEMBL650242,Beta-2 adrenergic receptor agonist activity as increased cAMP levels in CHO cells expressing human Beta-2-adrenoceptor,F,Homo sapiens
CHEMBL101630,CC(C)C[C@H](NC(=O)c1ccc(N2CCC(CNC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1)C(=O)O,EC50,1000.0,nM,6.00,CHEMBL650242,Beta-2 adrenergic receptor agonist activity as increased cAMP levels in CHO cells expressing human Beta-2-adrenoceptor,F,Homo sapiens
CHEMBL100351,CS(=O)(=O)Nc1cc([C@@H](O)CNCC2CCN(S(=O)(=O)c3ccc(-n4ccc5c(C(=O)O)cccc54)cc3)CC2)ccc1O,EC50,60.0,nM,7.22,CHEMBL650242,Beta-2 adrenergic receptor agonist activity as increased cAMP levels in CHO cells expressing human Beta-2-adrenoceptor,F,Homo sapiens
CHEMBL98088,CS(=O)(=O)Nc1cc([C@@H](O)CNCC2CCN(c3ccc(C(=O)N[C@@H](Cc4ccccc4)C(=O)O)cc3)CC2)ccc1O,EC50,20000.0,nM,4.70,CHEMBL650242,Beta-2 adrenergic receptor agonist activity as increased cAMP levels in CHO cells expressing human Beta-2-adrenoceptor,F,Homo sapiens
CHEMBL100589,CC(C)N(Cc1cc(F)ccc1F)C(=O)Nc1ccc(S(=O)(=O)N2CCC(CNC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1,EC50,12.0,nM,7.92,CHEMBL650242,Beta-2 adrenergic receptor agonist activity as increased cAMP levels in CHO cells expressing human Beta-2-adrenoceptor,F,Homo sapiens
CHEMBL101606,CS(=O)(=O)Nc1cc([C@@H](O)CNCC2CCN(S(=O)(=O)c3ccc(-n4cc(C(=O)O)cn4)cc3)CC2)ccc1O,EC50,10.0,nM,8.00,CHEMBL650242,Beta-2 adrenergic receptor agonist activity as increased cAMP levels in CHO cells expressing human Beta-2-adrenoceptor,F,Homo sapiens
CHEMBL99599,CCCCCCCCC(=O)Nc1ccc(S(=O)(=O)N2CCC(CNC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1,EC50,30.0,nM,7.52,CHEMBL650242,Beta-2 adrenergic receptor agonist activity as increased cAMP levels in CHO cells expressing human Beta-2-adrenoceptor,F,Homo sapiens
CHEMBL99219,CS(=O)(=O)Nc1cc([C@@H](O)CNCC2CCN(S(=O)(=O)c3ccc(NC(=O)NCc4cc(F)ccc4F)cc3)CC2)ccc1O,EC50,30.0,nM,7.52,CHEMBL650240,Beta-2 adrenergic receptor agonist activity was determined by a measurement of increased cAMP levels in CHO cells expressing human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL101674,CS(=O)(=O)Nc1cc([C@@H](O)CNCC2CCN(S(=O)(=O)c3ccc(NC(=O)N[C@@H](Cc4ccccc4)C(=O)O)cc3)CC2)ccc1O,EC50,20.0,nM,7.70,CHEMBL650242,Beta-2 adrenergic receptor agonist activity as increased cAMP levels in CHO cells expressing human Beta-2-adrenoceptor,F,Homo sapiens
CHEMBL282618,NCCCCCOC[C@H]1O[C@@H](OCCc2c[nH]c3ccccc23)[C@H](OCc2ccccc2)[C@@H](OCc2ccccc2)[C@@H]1OCc1ccccc1,IC50,3000.0,nM,5.52,CHEMBL647109,Binding affinity towards cloned human Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL281200,NCCCCCOC[C@H]1O[C@@H](OCCc2c[nH]c3ccccc23)[C@H](OCc2ccccc2)C[C@@H]1OCc1ccccc1,IC50,3000.0,nM,5.52,CHEMBL647109,Binding affinity towards cloned human Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL33438,CCC(=O)CCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,12000.0,nM,4.92,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL285458,CCCCCCCCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,2500.0,nM,5.60,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL33168,Cc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,10000.0,nM,5.00,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL33755,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(CCCC3CCCCC3)n2)cc1,IC50,660.0,nM,6.18,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL284965,CC(C)CCCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,1000.0,nM,6.00,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL33725,CCCCCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,3000.0,nM,5.52,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL418411,CC(O)CCCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,44000.0,nM,4.36,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL32996,O=C(CCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1)N1CCCC1,IC50,51000.0,nM,4.29,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL288083,CCCCCCCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,1415.0,nM,5.85,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL286800,CC(=O)CCCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,57000.0,nM,4.24,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL433042,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(CCCC3CCCC3)n2)cc1,IC50,962.0,nM,6.02,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL33013,CCCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,8500.0,nM,5.07,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL286139,CCCCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,6500.0,nM,5.19,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL285242,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(CCOC3CCCC3)n2)cc1,IC50,2667.0,nM,5.57,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL285481,CCCCCCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,1000.0,nM,6.00,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL34328,CCC(O)CCc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,24000.0,nM,4.62,CHEMBL647108,Binding affinity towards Beta-2 adrenergic receptor prepared from CHO cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL67886,COc1ccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccc(I)cc3)cc2)cc1,IC50,150.0,nM,6.82,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL36568,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(C(=O)NCC(=O)O)cc3)CC2)ccc1O,EC50,40.0,nM,7.40,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL35282,CC(C)[C@H](NC(=O)c1ccc(N2CCC(NC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1)C(=O)O,Ki,3600.0,nM,5.44,CHEMBL822409,Inhibition of I-iodocyanopindolol binding to human beta 2 adrenergic receptors,B,Homo sapiens
CHEMBL284612,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(NC(=O)CC(=O)O)cc3)CC2)ccc1O,EC50,900.0,nM,6.05,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL63842,Nc1ccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccc(Br)cc3)cc2)cn1,IC50,380.0,nM,6.42,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL67461,Nc1ccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3cnc4ccccc4c3)cc2)cn1,IC50,1300.0,nM,5.89,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL32521,CCCCN(CC(=O)O)C(=O)c1ccc(N2CCC(NC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1,EC50,10500.0,nM,4.98,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL67416,COc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(N)nc3)cc2)cc1,IC50,620.0,nM,6.21,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL67534,Nc1ccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccc(Cl)cc3)cc2)cn1,IC50,990.0,nM,6.00,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL64936,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2cccnc2)cc1)c1ccc(Cl)cc1,IC50,430.0,nM,6.37,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL64201,Nc1ccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccc(I)cc3)cc2)cn1,IC50,28.0,nM,7.55,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL67251,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2cccnc2)cc1)c1ccccc1,IC50,750.0,nM,6.12,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL67993,Nc1ccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccccc3)cc2)cn1,IC50,630.0,nM,6.20,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL418600,CCCCN(C(=O)CC(=O)O)c1ccc(N2CCC(NC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1,EC50,60.0,nM,7.22,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL67672,Nc1ccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccc(F)cc3)cc2)cn1,IC50,1000.0,nM,6.00,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL304878,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(F)cc2)cc1)c1ccc(I)cc1,IC50,100.0,nM,7.00,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL12998,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,EC50,20.0,nM,7.70,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL286574,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(C(N)=O)cc3)CC2)ccc1O,EC50,270.0,nM,6.57,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL64932,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2cccnc2)cc1)c1ccc(F)cc1,IC50,900.0,nM,6.05,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL292947,CC(C)c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3cccnc3)cc2)cc1,IC50,410.0,nM,6.39,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL417325,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(C(=O)N4CCC[C@H]4C(=O)O)cc3)CC2)ccc1O,EC50,20.0,nM,7.70,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL285881,CC(C)C[C@H](NC(=O)c1ccc(N2CCC(NC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1)C(=O)O,EC50,80.0,nM,7.10,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL32590,C[C@H](Cc1ccc2c(c1)OC(C(=O)[O-])(C(=O)[O-])O2)NC[C@H](O)c1cccc(Cl)c1.[Na+].[Na+],Ki,79200.0,nM,4.10,CHEMBL822409,Inhibition of I-iodocyanopindolol binding to human beta 2 adrenergic receptors,B,Homo sapiens
CHEMBL35500,CCCCN(c1ccc(N2CCC(NC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1)S(=O)(=O)CC(=O)O,EC50,5000.0,nM,5.30,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL276257,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1ccc(I)cc1,IC50,120.0,nM,6.92,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL304090,CCc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(N)nc3)cc2)cc1,IC50,110.0,nM,6.96,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL32599,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(C(=O)N[C@@H](Cc4ccccc4)C(=O)O)cc3)CC2)ccc1O,EC50,1500.0,nM,5.82,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL286868,CCOC(=O)CNC(=O)c1ccc(N2CCC(NC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1,EC50,3200.0,nM,5.50,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL68408,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(N)nc3)cc2)cc1,IC50,640.0,nM,6.19,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL64935,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2cccnc2)cc1)c1ccc(Br)cc1,IC50,230.0,nM,6.64,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL65042,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2cccnc2)cc1)c1ccc(Cl)c(Cl)c1,IC50,360.0,nM,6.44,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL68021,CCc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3cccnc3)cc2)cc1,IC50,94.0,nM,7.03,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL442172,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccccc2)cc1)c1ccc(I)cc1,IC50,50.0,nM,7.30,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL68334,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2cccnc2)cc1)c1cnc2ccccc2c1,IC50,490.0,nM,6.31,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL64760,CC(C)c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(N)nc3)cc2)cc1,IC50,540.0,nM,6.27,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL67015,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3cccnc3)cc2)cc1,IC50,430.0,nM,6.37,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL66964,COc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3cccnc3)cc2)cc1,IC50,520.0,nM,6.28,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL66859,Nc1ccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccc(Cl)c(Cl)c3)cc2)cn1,IC50,380.0,nM,6.42,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL36060,CC(C)(C)NC[C@H](O)COc1cccc2[nH]c(O)nc12,Ki,0.1,nM,10.00,CHEMBL822409,Inhibition of I-iodocyanopindolol binding to human beta 2 adrenergic receptors,B,Homo sapiens
CHEMBL32888,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(COCC(=O)O)cc3)CC2)ccc1O,EC50,6000.0,nM,5.22,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL284788,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(CCC(=O)O)cc3)CC2)ccc1O,EC50,4700.0,nM,5.33,CHEMBL821784,Increased cAMP levels of Chinese hamster ovary (CHO) cells expressing human beta 2 adrenergic receptors,F,Homo sapiens
CHEMBL294042,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2cccnc2)cc1)c1ccc(I)cc1,IC50,110.0,nM,6.96,CHEMBL647874,Evaluated for its agonist activity and the binding affinity against human Beta-2 adrenergic receptor in membranes from chinese hamster ovary cell,B,Homo sapiens
CHEMBL285713,CCCCCCc1ncc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)o1,IC50,1200.0,nM,5.92,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL39269,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2cnc(-c3ccccc3)o2)cc1,IC50,3500.0,nM,5.46,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL290053,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2coc(-c3ccc(C(F)(F)F)cc3)n2)cc1,IC50,1400.0,nM,5.85,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL38254,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2cnc(CCC3CCCC3)o2)cc1,IC50,1800.0,nM,5.75,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL38704,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2cnc(-c3ccc(F)c(F)c3)o2)cc1,IC50,3000.0,nM,5.52,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL40898,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2coc(-c3ccc(F)c(F)c3)n2)cc1,IC50,2200.0,nM,5.66,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL287947,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2cnc(CCCC3CCCC3)o2)cc1,IC50,320.0,nM,6.50,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL37512,Cc1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)co1,IC50,30000.0,nM,4.52,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL287880,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2cnc(Cc3ccc(F)c(F)c3)o2)cc1,IC50,4700.0,nM,5.33,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL288418,Cc1ncc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)o1,IC50,3000.0,nM,5.52,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL38562,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2cnc(-c3ccc(F)cc3)o2)cc1,IC50,21000.0,nM,4.68,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL289689,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2coc(Cc3ccc(F)c(F)c3)n2)cc1,IC50,630.0,nM,6.20,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL37335,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2coc(COc3ccc(F)cc3)n2)cc1,IC50,9000.0,nM,5.05,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL290131,CCCCCCCCc1ncc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)o1,IC50,270.0,nM,6.57,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL288917,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2coc(CCC3CCCC3)n2)cc1,IC50,3700.0,nM,5.43,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL36101,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2cnc(CC3CCCC3)o2)cc1,IC50,2500.0,nM,5.60,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL38861,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2coc(COc3ccc(C(F)(F)F)cc3)n2)cc1,IC50,20000.0,nM,4.70,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL39577,CCCCCc1ncc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)o1,IC50,4000.0,nM,5.40,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL39804,CC(C)(C)CCCc1ncc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)o1,IC50,1000.0,nM,6.00,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL285520,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2coc(Cc3ccc(C(F)(F)F)cc3)n2)cc1,IC50,310.0,nM,6.51,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL36609,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2coc(COc3ccc(F)c(F)c3)n2)cc1,IC50,3500.0,nM,5.46,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL289316,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2cnc(Cc3cc(F)c(F)c(F)c3)o2)cc1,IC50,940.0,nM,6.03,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL418234,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2coc(Cc3ccc(F)cc3)n2)cc1,IC50,3300.0,nM,5.48,CHEMBL647881,In vitro binding affinity at beta-2 adrenergic receptors in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL25133,CC(Cc1c[nH]c2ccccc12)NCC(O)c1cccc(Cl)c1,EC50,23.0,nM,7.64,CHEMBL883250,Agonistic activity against human Beta-2 adrenergic receptor by measuring cAMP accumulation in CHO cells expressing beta3-AR,F,Homo sapiens
CHEMBL279260,C[C@H](Cc1c[nH]c2c(OCC(=O)O)cccc12)NC[C@H](O)c1cccc(Cl)c1,EC50,13.0,nM,7.89,CHEMBL883250,Agonistic activity against human Beta-2 adrenergic receptor by measuring cAMP accumulation in CHO cells expressing beta3-AR,F,Homo sapiens
CHEMBL26393,C[C@H](Cc1c[nH]c2ccccc12)NC[C@H](O)c1cccc(Cl)c1,EC50,25.0,nM,7.60,CHEMBL883250,Agonistic activity against human Beta-2 adrenergic receptor by measuring cAMP accumulation in CHO cells expressing beta3-AR,F,Homo sapiens
CHEMBL26183,COc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(Cl)c3)c[nH]c12,EC50,5.2,nM,8.28,CHEMBL883250,Agonistic activity against human Beta-2 adrenergic receptor by measuring cAMP accumulation in CHO cells expressing beta3-AR,F,Homo sapiens
CHEMBL39596,C[C@H](Cc1ccc(OCC(=O)NO)cc1)NC[C@H](O)c1cccc(Cl)c1,Ki,112.0,nM,6.95,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL279931,C[C@H](Cc1c[nH]c2ccccc12)NC[C@@H](O)c1cccc(Cl)c1,EC50,330.0,nM,6.48,CHEMBL883250,Agonistic activity against human Beta-2 adrenergic receptor by measuring cAMP accumulation in CHO cells expressing beta3-AR,F,Homo sapiens
CHEMBL290752,C[C@H](Cc1ccc(OC(C(=O)O)C(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,Ki,17100.0,nM,4.77,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL40966,CC(C)OP(=O)(O)COc1ccc(C[C@@H](C)NC[C@H](O)c2cccc(Cl)c2)cc1,Ki,42600.0,nM,4.37,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL38569,C[C@H](Cc1ccc(OCC(N)=O)cc1)NC[C@H](O)c1cccc(Cl)c1,Ki,170.0,nM,6.77,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL38538,C[C@H](Cc1ccc(OCS(=O)(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,Ki,2250.0,nM,5.65,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL41113,C[C@H](Cc1ccc(OCCO)cc1)NC[C@H](O)c1cccc(Cl)c1,Ki,260.0,nM,6.58,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL284782,C[C@H](Cc1ccc(OCC(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,Ki,630.0,nM,6.20,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL38486,COC(=O)COc1ccc(C[C@@H](C)NC[C@H](O)c2cccc(Cl)c2)cc1,Ki,3.2,nM,8.49,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL39334,C[C@H](Cc1ccc(OCP(C)(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,Ki,73700.0,nM,4.13,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL41948,C[C@H](Cc1ccc(OCP(=O)(O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,Ki,39700.0,nM,4.40,CHEMBL652421,Ability to bind to human Beta-2 adrenergic receptor using membranes of stably transfected CHO cells,B,Homo sapiens
CHEMBL318802,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc2ccccc2c1,IC50,1000.0,nM,6.00,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL104076,O=C(Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1)OCCc1ccccc1,IC50,820.0,nM,6.09,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL104222,CCCOC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,10000.0,nM,5.00,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL106487,CCCCC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,9000.0,nM,5.05,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL320228,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(Cl)cc1,IC50,10000.0,nM,5.00,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL106746,CNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,8000.0,nM,5.10,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL323113,CCCCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,410.0,nM,6.39,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL104377,CC(C)S(=O)(=O)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,50000.0,nM,4.30,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL104061,CCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,8000.0,nM,5.10,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL104193,O=C(NCCc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,200.0,nM,6.70,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL104981,CC(C)c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,6000.0,nM,5.22,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL318165,CCCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,10000.0,nM,5.00,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL320138,O=C(CCCc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,2000.0,nM,5.70,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL104127,CS(=O)(=O)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,10000.0,nM,5.00,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL104551,O=S(=O)(CCc1ccccc1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,8000.0,nM,5.10,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL104180,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccccc1,IC50,8000.0,nM,5.10,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL105968,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(Br)cc1,IC50,5000.0,nM,5.30,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL64697,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(I)cc1,IC50,7000.0,nM,5.16,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL107681,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1cnc2ccccc2c1,IC50,1000.0,nM,6.00,CHEMBL647873,Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol,B,Homo sapiens
CHEMBL263881,CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Ki,740.0,nM,6.13,CHEMBL652495,Binding affinity towards Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL343755,C[C@H]1C[C@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1,Ki,1100.0,nM,5.96,CHEMBL652495,Binding affinity towards Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL137781,C[C@@H]1C[C@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1,Ki,4610.0,nM,5.34,CHEMBL652494,Binding affinity against Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL25856,Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2,Ki,1200.0,nM,5.92,CHEMBL650896,Binding affinity against Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL153916,C[C@H](CNc1ccc(CNS(C)(=O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,5.012,nM,8.30,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL347616,C[C@H](CNc1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,31.62,nM,7.50,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL154036,C[C@H](CNc1cccc(CC(=O)O)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,50.12,nM,7.30,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL155092,C[C@H](CNc1ccc(C(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,3162.28,nM,5.50,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL347400,C[C@H](CNc1cccc(CCS(=O)(=O)NS(=O)(=O)c2ccccc2)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,1000.0,nM,6.00,CHEMBL654954,"Activity against human beta 2 adrenergic receptor (AR), expressed in CHO cells",F,Homo sapiens
CHEMBL154906,C[C@H](CNc1cccc(CNC(=O)NS(=O)(=O)c2ccccc2)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,251.19,nM,6.60,CHEMBL858099,"Concentration that causes 50% inhibition of human beta 2 adrenergic receptor (AR), expressed in CHO cells.",F,Homo sapiens
CHEMBL154370,Cc1ccc(CNC(=O)Cc2ccc(NC[C@@H](C)NC[C@H](O)c3cccc(Cl)c3)cc2)cc1,EC50,1.0,nM,9.00,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL154150,C[C@H](CNc1ccc(CC(=O)Nc2nccs2)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,7.943,nM,8.10,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL157210,C[C@H](CNc1ccc(CC(=O)NS(C)(=O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,19.95,nM,7.70,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL348269,Cc1ccc(S(=O)(=O)NCCc2ccc(NC[C@@H](C)NC[C@H](O)c3cccc(Cl)c3)cc2)cc1,EC50,10.0,nM,8.00,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL345304,CC(=O)NCc1ccc(NC[C@@H](C)NC[C@H](O)c2cccc(Cl)c2)cc1,EC50,3.162,nM,8.50,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL152535,C[C@H](Cc1ccc(OCC(=O)[O-])cc1)NC[C@H](O)c1cccc(Cl)c1.[Na+],EC50,50.12,nM,7.30,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL348501,Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(NC[C@@H](C)NC[C@H](O)c3cccc(Cl)c3)cc2)cc1,EC50,79.43,nM,7.10,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL154419,C[C@H](CNc1ccc(CC(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,50.12,nM,7.30,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL422876,C[C@H](CNc1ccc(CCS(=O)(=O)NC(=O)c2ccccc2)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,316.23,nM,6.50,CHEMBL858099,"Concentration that causes 50% inhibition of human beta 2 adrenergic receptor (AR), expressed in CHO cells.",F,Homo sapiens
CHEMBL434,CC(C)NCC(O)c1ccc(O)c(O)c1,EC50,0.1585,nM,9.80,CHEMBL858100,"Activity against human beta 2 adrenergic receptor (AR), expressed in CHO cells",F,Homo sapiens
CHEMBL347582,Cc1ccc(S(=O)(=O)NC(=O)Cc2cccc(NC[C@@H](C)NC[C@H](O)c3cccc(Cl)c3)c2)cc1,IC50,15848.93,nM,4.80,CHEMBL652427,Receptor binding assay(Beta-2 adrenergic receptor) carried out with membranes prepared from human recombinant Sf9 cells expressing the cloned human receptor in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL155072,C[C@H](CNc1ccccc1)NC[C@H](O)c1cccc(Cl)c1,EC50,10.0,nM,8.00,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL153558,C[C@H](CNc1ccc(CCC(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,398.11,nM,6.40,CHEMBL655820,Ability to cause cAMP accumulation in CHO cells expressing human beta-2 AR expressed as the negative logarithm of the molar drug concentration,F,Homo sapiens
CHEMBL302893,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(-c3ccc(OC(F)(F)F)cc3)n2)cc1,IC50,1600.0,nM,5.80,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL304991,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(Cc3ccc(OC(F)(F)F)cc3)n2)cc1,IC50,860.0,nM,6.07,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL63138,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(-c3ccc(F)c(F)c3)n2)cc1,IC50,1300.0,nM,5.89,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL63760,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(-c3ccc(C(F)(F)F)cc3)n2)cc1,IC50,21000.0,nM,4.68,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL65513,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(Cc3ccc(F)c(F)c3)n2)cc1,IC50,1000.0,nM,6.00,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL22318,CCCCCCCCn1nnn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,570.0,nM,6.24,CHEMBL876752,Inhibitory activity against cloned human Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol in CHO cells by receptor binding assay,B,Homo sapiens
CHEMBL277613,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(COc3ccc(C(F)(F)F)cc3)n2)cc1,IC50,730.0,nM,6.14,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL304298,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(Cc3ccc(F)cc3)n2)cc1,IC50,780.0,nM,6.11,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL302803,CCCCOc1ccc(S(=O)(=O)N2CC(NC[C@H](O)c3ccc(O)cc3)C2)cc1,EC50,920.0,nM,6.04,CHEMBL655672,Agonistic activity against cloned human beta1-AR (beta-2-adrenergic receptor) in CHO cells,F,Homo sapiens
CHEMBL63963,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(Cc3cccc(F)c3)n2)cc1,IC50,380.0,nM,6.42,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL65461,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(Cc3ccc(C(F)(F)F)cc3)n2)cc1,IC50,4700.0,nM,5.33,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL305558,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(-c3ccc(F)cc3)n2)cc1,IC50,9300.0,nM,5.03,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL63825,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(COc3ccc(OC(F)(F)F)cc3)n2)cc1,IC50,620.0,nM,6.21,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL68766,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)N2CCC(NC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)cc1,EC50,920.0,nM,6.04,CHEMBL655672,Agonistic activity against cloned human beta1-AR (beta-2-adrenergic receptor) in CHO cells,F,Homo sapiens
CHEMBL22345,CCCCCCn1nnn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,3300.0,nM,5.48,CHEMBL876752,Inhibitory activity against cloned human Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol in CHO cells by receptor binding assay,B,Homo sapiens
CHEMBL29141,CNCC(O)c1ccc(O)c2nc(O)sc12,Kd,51.0,nM,7.29,CHEMBL652417,Compound was tested for its binding affinity to human Beta-2 adrenergic receptor by using the radioligand [3H]CGP-12177,B,Homo sapiens
CHEMBL67404,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(Cc3c(F)cc(F)cc3F)n2)cc1,IC50,8800.0,nM,5.06,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL66908,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(-c3cccc(F)c3)n2)cc1,IC50,8800.0,nM,5.06,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL66789,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(Cc3c(F)cccc3F)n2)cc1,IC50,5000.0,nM,5.30,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL68301,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-n2ncc(COc3ccc(F)c(F)c3)n2)cc1,IC50,690.0,nM,6.16,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL22375,O=c1n(CCCC2CCCC2)nnn1-c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,EC50,1800.0,nM,5.75,CHEMBL650239,Agonistic activity against the cloned human Beta-2 adrenergic receptor was measured by its by its ability to stimulate adenylyl cyclase,F,Homo sapiens
CHEMBL63357,COc1ccc(-c2cnn(-c3ccc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)cc3)n2)cc1F,IC50,2500.0,nM,5.60,CHEMBL647105,Binding affinity for clone human Beta-2 adrenergic receptor from CHO cell membranes in the presence of I-iodocyanopindolol,B,Homo sapiens
CHEMBL13079,O=S(=O)(Cc1ccccc1)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,21.0,nM,7.68,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL332132,N#CN/C(=N\c1ccc2c(c1)N(c1nc(-c3ccc(OC(F)(F)F)cc3)cs1)CC2)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,710.0,nM,6.15,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL125246,O=[N+]([O-])/C=C(\Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)Nc1cc(Cl)cc(Cl)c1,IC50,5600.0,nM,5.25,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL144870,CCCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,200.0,nM,6.70,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL267545,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1ccc(Br)cc1,IC50,180.0,nM,6.75,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL12188,CS(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,220.0,nM,6.66,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL12813,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1cccc(Cl)c1,IC50,370.0,nM,6.43,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL13389,COC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,430.0,nM,6.37,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL274782,COc1ccc(CC[C@H](C)NC[C@H](O)COc2ccc(O)cc2)cc1,IC50,20.0,nM,7.70,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL276659,O=C(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1ccccc1,IC50,230.0,nM,6.64,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL124668,N#CN/C(=N\c1cccc(F)c1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,200.0,nM,6.70,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL439794,N#CN/C(=N\c1cccc2ccccc12)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,570.0,nM,6.24,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL431678,N#CN/C(=N\c1ccc2c(c1)CCN2c1nc(-c2ccc(OC(F)(F)F)cc2)cs1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,180.0,nM,6.75,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL13278,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1ccc2ccccc2c1,IC50,630.0,nM,6.20,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL12674,O=S(=O)(CCc1ccccc1)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,120.0,nM,6.92,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL125168,N#CN/C(=N\c1cccc(I)c1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,67.0,nM,7.17,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL301231,CCCCCCCCc1csc(N2CCc3cc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)ccc32)n1,IC50,1300.0,nM,5.89,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL12686,COc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,190.0,nM,6.72,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL124597,N#CN/C(=N\c1ccc2c(c1)CCN2c1nc(-c2ccc(OC(F)(F)F)cc2)cs1)Nc1ccc2cc(CCNC[C@H](O)c3cccnc3)ccc2c1,IC50,7100.0,nM,5.15,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL13432,O=C(Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1)NC1CCCCC1,IC50,5000.0,nM,5.30,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL12769,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1cnc2ccccc2c1,IC50,240.0,nM,6.62,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL126055,N#CN/C(=N\c1ccc(I)cc1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,170.0,nM,6.77,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL124863,N#CN/C(=N\c1cccc(Oc2ccccc2)c1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,40.0,nM,7.40,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL13003,O=S(=O)(CCCc1ccccc1)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,130.0,nM,6.89,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL338618,N#CN/C(=N\c1cc(Cl)cc(Cl)c1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,140.0,nM,6.85,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL12945,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1ccc(Cl)c(Cl)c1,IC50,3000.0,nM,5.52,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL274144,CCCCCCN(C)C(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,720.0,nM,6.14,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL124584,O=[N+]([O-])/C=C(\Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)Nc1cccc(F)c1,IC50,2400.0,nM,5.62,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL127451,NC(=O)c1cccc(N/C(=C/[N+](=O)[O-])Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)c1,IC50,1200.0,nM,5.92,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL410702,O=[N+]([O-])/C=C(\Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)Nc1ccc2ccccc2c1,IC50,3400.0,nM,5.47,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL13459,CCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,350.0,nM,6.46,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL13034,Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,500.0,nM,6.30,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL127422,N#CN/C(=N\c1ccc2ccccc2c1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,50.0,nM,7.30,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL127428,O=[N+]([O-])/C=C(\Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)Nc1cccc(I)c1,IC50,1200.0,nM,5.92,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL419787,O=[N+]([O-])/C=C(\Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)Nc1cccc(Oc2ccccc2)c1,IC50,220.0,nM,6.66,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL12939,CCCCCCOC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,110.0,nM,6.96,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL12911,CCOC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,400.0,nM,6.40,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL12633,C[C@@H](Cc1ccc(O)cc1)NC[C@H](O)COc1ccc(O)cc1,IC50,84.0,nM,7.08,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL276480,CCCS(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,500.0,nM,6.30,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL274807,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)C1CCCCC1,IC50,3000.0,nM,5.52,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL13106,CC(C)OC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,210.0,nM,6.68,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL127656,CCCCCCCCc1csc(N2CCc3c(N/C(=N/c4ccc(CCNC[C@H](O)c5cccnc5)cc4)NC#N)cccc32)n1,IC50,930.0,nM,6.03,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL13521,COCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,1000.0,nM,6.00,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL12994,C[C@@H](CCc1ccc(O)cc1)NC[C@H](O)COc1ccc(O)cc1,IC50,10.0,nM,8.00,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL417613,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1ccccc1,IC50,190.0,nM,6.72,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL12718,Cc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,170.0,nM,6.77,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL273428,CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,2000.0,nM,5.70,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL12498,CCCCCS(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,250.0,nM,6.60,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL338664,CCCCCCCCc1csc(N2CCc3cc(N/C(S)=N/c4ccc(CCNC[C@H](O)c5cccnc5)cc4)ccc32)n1,IC50,260.0,nM,6.58,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL13398,CNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,400.0,nM,6.40,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL13467,CCCCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,170.0,nM,6.77,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL12450,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1ccc(Cl)cc1,IC50,280.0,nM,6.55,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL124929,CCCCCCCCc1csc(N2CCc3ccc(N/C(=N/c4ccc(CCNC[C@H](O)c5cccnc5)cc4)NC#N)cc32)n1,IC50,66.0,nM,7.18,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL13238,CC(C)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,58.0,nM,7.24,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL13132,O=C(Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1)OCc1ccccc1,IC50,130.0,nM,6.89,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL275511,CCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,540.0,nM,6.27,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL274361,COc1ccc(CC[C@@H](C)NC[C@H](O)COc2ccc(O)cc2)cc1,EC50,5.0,nM,8.30,CHEMBL650244,Compound was tested for agonist activity against cloned human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL267306,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1)c1ccccc1Cl,IC50,100.0,nM,7.00,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL12876,Oc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,150.0,nM,6.82,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL417250,O=C(Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1)c1ccccc1,IC50,110.0,nM,6.96,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL12762,COc1ccc(CCCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,63.0,nM,7.20,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL12719,COc1ccc(CC[C@@H](C)NC[C@@H](O)COc2ccc(O)cc2)cc1,EC50,30.0,nM,7.52,CHEMBL650244,Compound was tested for agonist activity against cloned human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL13102,CC(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,IC50,11.0,nM,7.96,CHEMBL647879,Binding affinity against cloned human beta-2 adrenergic receptor from CHO cells using [125I]iodocyanopindolol as the radioligand,B,Homo sapiens
CHEMBL12943,CCC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,220.0,nM,6.66,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL13453,CCCC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,230.0,nM,6.64,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL338748,O=[N+]([O-])/C=C(\Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)Nc1cccc2ccccc12,IC50,370.0,nM,6.43,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL275291,CC(C)NC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,700.0,nM,6.16,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL274143,CCCCCCNC(=O)N(C)c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,290.0,nM,6.54,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL268289,CCCCCCC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,230.0,nM,6.64,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL332010,N#CN/C(=N\c1ccc(CCNC[C@H](O)c2cccnc2)cc1)Nc1cccc(C(N)=O)c1,IC50,400.0,nM,6.40,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL275114,CCCCCCN(C)C(=O)N(C)c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,120.0,nM,6.92,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL13068,CC(C)C(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc(O)cc3)cc2)cc1,IC50,450.0,nM,6.35,CHEMBL647878,In vitro affinity at Beta-2 adrenergic receptor in the presence of [125I]iodocyanopindolol.,B,Homo sapiens
CHEMBL123745,CCCCCCCCc1csc(N2CCc3cc(N/C(=N/c4ccc(CCNC[C@H](O)c5cccnc5)cc4)NC#N)ccc32)n1,IC50,50.0,nM,7.30,CHEMBL647111,Binding affinity to the human beta-2 adrenergic receptor assayed using [125I]iodocyanopindolol as radioligand in CHO cells,B,Homo sapiens
CHEMBL72168,C[C@H](Cc1ncc(CCCC(=O)O)s1)NCC(O)c1cccc(Cl)c1,Ki,13900.0,nM,4.86,CHEMBL652422,Compound was tested for its binding affinity against beta2 adrenergic receptor in CHO cell membrane using [125I]iodocyanopindolol as the radioligand.,B,Homo sapiens
CHEMBL308150,O=C(O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1,Ki,2350.0,nM,5.63,CHEMBL652422,Compound was tested for its binding affinity against beta2 adrenergic receptor in CHO cell membrane using [125I]iodocyanopindolol as the radioligand.,B,Homo sapiens
CHEMBL72169,C[C@H](Cc1ncc(CCCC(=O)O)s1)NC[C@H](O)COc1ccccc1,Ki,1600.0,nM,5.80,CHEMBL652422,Compound was tested for its binding affinity against beta2 adrenergic receptor in CHO cell membrane using [125I]iodocyanopindolol as the radioligand.,B,Homo sapiens
CHEMBL72060,C[C@H](Cc1ncc(CCC(=O)O)s1)NCC(O)c1cccc(Cl)c1,Ki,11400.0,nM,4.94,CHEMBL652422,Compound was tested for its binding affinity against beta2 adrenergic receptor in CHO cell membrane using [125I]iodocyanopindolol as the radioligand.,B,Homo sapiens
CHEMBL73220,C[C@H](Cc1ncc(CCC(=O)O)s1)NC[C@H](O)COc1ccccc1,Ki,1230.0,nM,5.91,CHEMBL652422,Compound was tested for its binding affinity against beta2 adrenergic receptor in CHO cell membrane using [125I]iodocyanopindolol as the radioligand.,B,Homo sapiens
CHEMBL419085,C[C@H](Cc1ncc(CCCCC(=O)O)s1)NC[C@H](O)COc1ccccc1,Ki,150.0,nM,6.82,CHEMBL652422,Compound was tested for its binding affinity against beta2 adrenergic receptor in CHO cell membrane using [125I]iodocyanopindolol as the radioligand.,B,Homo sapiens
CHEMBL79806,CCCCCCn1cnn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,4500.0,nM,5.35,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL83698,CCCCCCCCN1C(=O)CN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,370.0,nM,6.43,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL79363,CCCCCCCCn1c(C)cn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,7000.0,nM,5.16,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL312364,CCCCCCCCn1c(=O)[nH]n(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,3000.0,nM,5.52,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL66936,CCCCCCCCN1CC(=O)N(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,5000.0,nM,5.30,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL84190,CCCCCCCCN1CCN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,380.0,nM,6.42,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL83753,CCCCCCCCn1ccn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,330.0,nM,6.48,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL351467,CCCCCCn1c(=O)[nH]n(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,10000.0,nM,5.00,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL314893,CCCCCCn1ncn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,8500.0,nM,5.07,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL82296,CCCCCCN1CCN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,2300.0,nM,5.64,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL163579,CCCCCCCCn1cnn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,730.0,nM,6.14,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL55528,COc1ccccc1N1CCN(CCCn2c(=O)[nH]c3c([nH]c4ccccc43)c2=O)CC1,Ki,1181.0,nM,5.93,CHEMBL652419,Binding affinity towards Beta-2 adrenergic receptor in human peripheral mononuclear leukocyte membranes using [125I]pindolol,B,Homo sapiens
CHEMBL22386,CCCCCCn1ccn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,12000.0,nM,4.92,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL163531,CCCCCCCCn1ncn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,2000.0,nM,5.70,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL84117,CCCCCCN1C(=O)CN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,2000.0,nM,5.70,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL312546,CCCCCCn1c(C)cn(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)c1=O,IC50,7000.0,nM,5.16,CHEMBL647106,Binding affinity towards Beta-2 adrenergic receptor in CHO cells expressing the cloned human receptor using 125I]iodocyanopindolol,B,Homo sapiens
CHEMBL415039,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(Cc3ccc(C(F)(F)F)cc3)n2)cc1,IC50,2000.0,nM,5.70,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL287567,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(COc3ccc(OC(F)(F)F)cc3)n2)cc1,IC50,5000.0,nM,5.30,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL28405,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(Cc3ccc(F)c(F)c3)no2)cc1,IC50,2500.0,nM,5.60,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL287562,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(COc3ccc4ccccc4c3)n2)cc1,IC50,90000.0,nM,4.05,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL285240,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(Cc3ccc(F)cc3)no2)cc1,IC50,4000.0,nM,5.40,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL32411,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(COc3ccc(F)c(F)c3)n2)cc1,IC50,1430.0,nM,5.84,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL285499,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(Cc3cc(F)c(F)c(F)c3)n2)cc1,IC50,720.0,nM,6.14,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL286435,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(COc3ccc(F)cc3)n2)cc1,IC50,490.0,nM,6.31,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL288550,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(COc3ccc(F)cc3)no2)cc1,IC50,7500.0,nM,5.12,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL33515,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(Cc3cccc(OC(F)(F)F)c3)n2)cc1,IC50,5500.0,nM,5.26,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL289250,CC(=O)Nc1ccc(Cc2nc(-c3ccc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)cc3)no2)cc1,IC50,5000.0,nM,5.30,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL286438,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(Cc3ccc(-c4ccccn4)cc3)n2)cc1,IC50,4500.0,nM,5.35,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL33292,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(Cc3ccc(OC(F)(F)F)cc3)n2)cc1,IC50,7600.0,nM,5.12,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL289248,CS(=O)(=O)NC(c1ccc(F)cc1)c1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,2500.0,nM,5.60,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL286859,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(Cc3ccc(F)cc3)n2)cc1,IC50,1660.0,nM,5.78,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL289249,O=C(c1ccc(F)cc1)c1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,15000.0,nM,4.82,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL33155,COC(=O)NC(c1ccc(F)cc1)c1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,5400.0,nM,5.27,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL33384,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(COc3ccc(F)c(F)c3)no2)cc1,IC50,3500.0,nM,5.46,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL33224,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(C(O)c3ccc(F)cc3)n2)cc1,IC50,2500.0,nM,5.60,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL287561,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(Cc3cccc(F)c3)n2)cc1,IC50,695.0,nM,6.16,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL32891,NC(c1ccc(F)cc1)c1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,2000.0,nM,5.70,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL286437,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(Cc3ccc4ccccc4c3)n2)cc1,IC50,1500.0,nM,5.82,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL285001,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(Cc3ccc(F)c(F)c3)n2)cc1,IC50,980.0,nM,6.01,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL34406,COc1ccc(OCc2nc(-c3ccc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)cc3)no2)cc1,IC50,5000.0,nM,5.30,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL32418,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(COc3ccc(C4N=NN=N4)cc3)n2)cc1,IC50,8000.0,nM,5.10,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL291246,CSc1ccc(Cc2nc(-c3ccc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)cc3)no2)cc1,IC50,9500.0,nM,5.02,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL286231,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2noc(COc3ccccc3O)n2)cc1,IC50,2500.0,nM,5.60,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL405245,CNC(=O)NC(c1ccc(F)cc1)c1nc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)no1,IC50,1500.0,nM,5.82,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL285704,CC(=O)Nc1ccc(OCc2nc(-c3ccc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)cc3)no2)cc1,IC50,9500.0,nM,5.02,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL34441,CS(=O)(=O)Nc1ccc(Cc2nc(-c3ccc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)cc3)no2)cc1,IC50,3000.0,nM,5.52,CHEMBL647110,Binding affinity to recombinant human beta-2 adrenergic receptor prepared from CHO cells in the presence of [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL327519,CCCCCCCCNC(=O)Nc1ccc(S(=O)(=O)N2CCC(CNC[C@H](O)COc3ccc(O)c4c3CCC(=O)N4)CC2)cc1,EC50,680.0,nM,6.17,CHEMBL647099,In vitro agonist activity measured by increase in cAMP levels in chinese hamster ovary cells (CHO) cells expressing human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL174984,COc1cc(C[C@@H]2NCCc3cc(O)c(O)cc32)cc(OC)c1OC,EC50,3.5,nM,8.46,CHEMBL650243,Compound was evaluated for its inhibitory activity against human beta-2 adrenergic receptor (AR),F,Homo sapiens
CHEMBL73917,COc1cc(CC2NCCc3nc(N)sc32)cc(OC)c1OC,Ki,616.6,nM,6.21,CHEMBL875069,Binding Affinity against human beta-2 adrenergic receptor expressed in Chinese hamster ovary(CHO) cells was measured by using [125I]ICYP radioligand,B,Homo sapiens
CHEMBL74860,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(-c3cccc(CC4NCCc5cc(O)c(O)cc54)c3)cc2)cc1,IC50,100000.0,nM,4.00,CHEMBL647877,Inhibitory activity against CHO cells expressing human Beta-2 adrenergic receptor with [125I]-iodocyanopindolol,B,Homo sapiens
CHEMBL312074,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(-c3ccc(OCC4NCCc5cc(O)c(O)cc54)cc3)cc2)cc1,EC50,580.0,nM,6.24,CHEMBL650243,Compound was evaluated for its inhibitory activity against human beta-2 adrenergic receptor (AR),F,Homo sapiens
CHEMBL102194,CCCCCCCCNC(=O)Nc1ccc(S(=O)(=O)N2CCC(CNC[C@H](O)COc3ccc(O)cc3)CC2)cc1,IC50,4.0,nM,8.40,CHEMBL650883,Compound was tested for the antagonistic activity against Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL307647,COc1c(I)cc(CC2NCCc3nc(N)sc32)cc1I,EC50,1.0,nM,9.00,CHEMBL647101,Percent adenylyl cyclase activation at 10000 nM of compound concentration,F,Homo sapiens
CHEMBL308351,COc1c(I)cc(CC2NCCc3cc(O)c(O)cc32)cc1I,Ki,2.042,nM,8.69,CHEMBL875069,Binding Affinity against human beta-2 adrenergic receptor expressed in Chinese hamster ovary(CHO) cells was measured by using [125I]ICYP radioligand,B,Homo sapiens
CHEMBL431048,CS(=O)(=O)Nc1cc(OC[C@@H](O)CNCC2CCN(S(=O)(=O)c3ccc(NC(=O)NCc4cc(F)ccc4F)cc3)CC2)ccc1O,EC50,454.0,nM,6.34,CHEMBL647099,In vitro agonist activity measured by increase in cAMP levels in chinese hamster ovary cells (CHO) cells expressing human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL76403,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc3cc(OCC4NCCc5cc(O)c(O)cc54)ccc3c2)cc1,EC50,37.0,nM,7.43,CHEMBL647101,Percent adenylyl cyclase activation at 10000 nM of compound concentration,F,Homo sapiens
CHEMBL308860,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2cccc(-c3ccc(OCC4NCCc5cc(O)c(O)cc54)cc3)c2)cc1,IC50,990.0,nM,6.00,CHEMBL647877,Inhibitory activity against CHO cells expressing human Beta-2 adrenergic receptor with [125I]-iodocyanopindolol,B,Homo sapiens
CHEMBL308868,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2cccc(-c3cccc(CC4NCCc5cc(O)c(O)cc54)c3)c2)cc1,EC50,2700.0,nM,5.57,CHEMBL650243,Compound was evaluated for its inhibitory activity against human beta-2 adrenergic receptor (AR),F,Homo sapiens
CHEMBL67998,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc3cc(CC4NCCc5cc(O)c(O)cc54)ccc3c2)cc1,IC50,300.0,nM,6.52,CHEMBL647877,Inhibitory activity against CHO cells expressing human Beta-2 adrenergic receptor with [125I]-iodocyanopindolol,B,Homo sapiens
CHEMBL421871,COc1cc(-c2ccc(CC3NCCc4cc(O)c(O)cc43)cc2)cc(OC)c1OC,EC50,1500.0,nM,5.82,CHEMBL650243,Compound was evaluated for its inhibitory activity against human beta-2 adrenergic receptor (AR),F,Homo sapiens
CHEMBL75604,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(-c3ccc(CC4NCCc5cc(O)c(O)cc54)cc3)cc2)cc1,EC50,340.0,nM,6.47,CHEMBL650243,Compound was evaluated for its inhibitory activity against human beta-2 adrenergic receptor (AR),F,Homo sapiens
CHEMBL305891,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2cccc(-c3ccc(CC4NCCc5cc(O)c(O)cc54)cc3)c2)cc1,EC50,1300.0,nM,5.89,CHEMBL646905,Compound was evaluated for its inhibitory activity against human beta-2 adrenergic receptor (AR),F,Homo sapiens
CHEMBL308126,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(OCC3NCCc4cc(O)c(O)cc43)cc2)cc1,IC50,300.0,nM,6.52,CHEMBL647877,Inhibitory activity against CHO cells expressing human Beta-2 adrenergic receptor with [125I]-iodocyanopindolol,B,Homo sapiens
CHEMBL74085,CCCCCCNC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(CC3NCCc4cc(O)c(O)cc43)cc2)cc1,EC50,36.0,nM,7.44,CHEMBL647101,Percent adenylyl cyclase activation at 10000 nM of compound concentration,F,Homo sapiens
CHEMBL332964,CC(=O)Nc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1I,Ki,7.762,nM,8.11,CHEMBL650854,Binding affinity for human Beta-2 adrenergic receptor expressed in CHO cells by radioligand competition binding assays using [125I]iodocyanopindolol (ICYP),B,Homo sapiens
CHEMBL333438,Oc1cc2c(cc1O)C(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)NCC2,Ki,4365.16,nM,5.36,CHEMBL650854,Binding affinity for human Beta-2 adrenergic receptor expressed in CHO cells by radioligand competition binding assays using [125I]iodocyanopindolol (ICYP),B,Homo sapiens
CHEMBL83754,O=C1N(CCCC(F)(F)C(F)(F)F)CCN1c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,9000.0,nM,5.05,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL291992,CCCCCCc1csc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)n1,IC50,620.0,nM,6.21,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL291516,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3c[nH]c4ccccc34)cs2)cc1,IC50,50000.0,nM,4.30,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL61962,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(O)cc3)cs2)cc1,IC50,5700.0,nM,5.24,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL61429,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(Cc2nc(Cc3ccc4ccccc4c3)cs2)cc1,IC50,2000.0,nM,5.70,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL291306,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3cc4ccccc4s3)cs2)cc1,IC50,93000.0,nM,4.03,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL58798,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(F)cc3)cs2)cc1,IC50,1900.0,nM,5.72,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL291594,CC(=O)Nc1ccc(-c2csc(-c3ccc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)cc3)n2)cc1,IC50,2100.0,nM,5.68,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL418308,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(Cc3ccc4ccccc4c3)cs2)cc1,IC50,2300.0,nM,5.64,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL164401,CN1CCN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,2000.0,nM,5.70,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL79675,O=C1N(CCCC(F)(F)F)CCN1c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,6500.0,nM,5.19,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL293577,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3cnc4ccccc4c3)cs2)cc1,IC50,47000.0,nM,4.33,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL121964,Oc1cc2c(cc1O)C(Cc1cc(I)c(O)c(I)c1)NCC2,Ki,11.75,nM,7.93,CHEMBL650854,Binding affinity for human Beta-2 adrenergic receptor expressed in CHO cells by radioligand competition binding assays using [125I]iodocyanopindolol (ICYP),B,Homo sapiens
CHEMBL350590,O=C1N(CCC2CCCCC2)CCN1c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,1000.0,nM,6.00,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL294172,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(CCCC3CCCC3)cs2)cc1,IC50,3000.0,nM,5.52,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL349689,O=c1n(CCCC(F)(F)F)ccn1-c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,10000.0,nM,5.00,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL58407,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc4ccccc4c3)cs2)cc1,IC50,6300.0,nM,5.20,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL294753,CC(C)(C)c1ccc(-c2csc(-c3ccc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)cc3)n2)cc1,IC50,2000.0,nM,5.70,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL165177,O=C1N(CCCC2CCCCC2)CCN1c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,1000.0,nM,6.00,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL122992,CC(=O)Nc1c(I)cc(CC2NCCc3cc(O)c(O)cc32)cc1I,Ki,8.71,nM,8.06,CHEMBL650854,Binding affinity for human Beta-2 adrenergic receptor expressed in CHO cells by radioligand competition binding assays using [125I]iodocyanopindolol (ICYP),B,Homo sapiens
CHEMBL60281,CCCCCCCCc1csc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)n1,IC50,3000.0,nM,5.52,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL121704,O=C(Nc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1I)c1ccccc1,Ki,1.995,nM,8.70,CHEMBL650854,Binding affinity for human Beta-2 adrenergic receptor expressed in CHO cells by radioligand competition binding assays using [125I]iodocyanopindolol (ICYP),B,Homo sapiens
CHEMBL291593,CCCCCCCCc1csc(Cc2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)n1,IC50,1000.0,nM,6.00,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL120278,Oc1cc2c(cc1O)C(Cc1cc(I)c(I)c(I)c1)NCC2,Ki,1.514,nM,8.82,CHEMBL650854,Binding affinity for human Beta-2 adrenergic receptor expressed in CHO cells by radioligand competition binding assays using [125I]iodocyanopindolol (ICYP),B,Homo sapiens
CHEMBL434284,COCCCCN1CCN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,50000.0,nM,4.30,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL59270,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(CCc3ccccc3)cs2)cc1,IC50,910.0,nM,6.04,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL122757,Oc1cc2c(cc1O)C(Cc1cc(I)cc(I)c1)NCC2,Ki,0.302,nM,9.52,CHEMBL650854,Binding affinity for human Beta-2 adrenergic receptor expressed in CHO cells by radioligand competition binding assays using [125I]iodocyanopindolol (ICYP),B,Homo sapiens
CHEMBL349651,O=c1n(CCCC2CCCC2)ccn1-c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,760.0,nM,6.12,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL79915,O=C(CCN1CCN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O)N1CCCC1,IC50,100000.0,nM,4.00,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL430594,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(Cc3ccc(F)cc3)cs2)cc1,IC50,2500.0,nM,5.60,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL166188,O=C1N(CCCc2ccccc2)CCN1c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,2000.0,nM,5.70,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL350931,O=C1N(Cc2ccc(F)c(F)c2)CCN1c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,3500.0,nM,5.46,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL22317,O=C1N(CCCC2CCCC2)CCN1c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,760.0,nM,6.12,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL58241,CCCCCCc1ccc(-c2csc(-c3ccc(S(=O)(=O)Nc4ccc(CCNC[C@H](O)c5cccnc5)cc4)cc3)n2)cc1,IC50,90000.0,nM,4.05,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL349505,O=c1n(Cc2ccc(F)c(F)c2)ccn1-c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,13000.0,nM,4.89,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL165015,CCCCCN1CCN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,5000.0,nM,5.30,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL165513,CCCCCCCN1CCN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,1000.0,nM,6.00,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL122990,Nc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1I,Ki,6.457,nM,8.19,CHEMBL650854,Binding affinity for human Beta-2 adrenergic receptor expressed in CHO cells by radioligand competition binding assays using [125I]iodocyanopindolol (ICYP),B,Homo sapiens
CHEMBL166013,CCCCN1CCN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,5300.0,nM,5.28,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL294492,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3cccnc3)cs2)cc1,IC50,3000.0,nM,5.52,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL351967,O=C1N(CCC2CCCC2)CCN1c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,5000.0,nM,5.30,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL294849,CC(=O)NCCCCCc1csc(-c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)n1,IC50,16000.0,nM,4.80,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL293994,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(F)c(F)c3)cs2)cc1,IC50,1700.0,nM,5.77,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL57908,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3cc4ccccc4o3)cs2)cc1,IC50,49000.0,nM,4.31,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL433248,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccccn3)cs2)cc1,IC50,4000.0,nM,5.40,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL292598,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc4ncccc4c3)cs2)cc1,IC50,8000.0,nM,5.10,CHEMBL647875,Binding affinity against human Beta-2 adrenergic receptor expressed in CHO cells using [125I]iodocyanopindolol,B,Homo sapiens
CHEMBL351596,CCCCC(C)(C)CN1CCN(c2ccc(S(=O)(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)cc2)C1=O,IC50,5000.0,nM,5.30,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL162043,O=C1N(CCCc2ccc(Cl)cc2)CCN1c1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cc1,IC50,2000.0,nM,5.70,CHEMBL647107,"Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]iodocyanopindolol",B,Homo sapiens
CHEMBL123596,Nc1c(I)cc(CC2NCCc3cc(O)c(O)cc32)cc1I,Ki,1.549,nM,8.81,CHEMBL650854,Binding affinity for human Beta-2 adrenergic receptor expressed in CHO cells by radioligand competition binding assays using [125I]iodocyanopindolol (ICYP),B,Homo sapiens
CHEMBL331744,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(OC(F)(F)F)cc3)cs2)cc1,EC50,1400.0,nM,5.85,CHEMBL821232,In vitro functional efficacy in stimulating increase in cAMP in chinese hamster ovary (CHO) cells expressing the cloned human beta-2 receptor.,F,Homo sapiens
CHEMBL111201,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,EC50,2400.0,nM,5.62,CHEMBL821232,In vitro functional efficacy in stimulating increase in cAMP in chinese hamster ovary (CHO) cells expressing the cloned human beta-2 receptor.,F,Homo sapiens
CHEMBL338794,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3cccc(C(F)(F)F)c3)cs2)cc1,IC50,980.0,nM,6.01,CHEMBL647872,Binding affinity was evaluated on chinese hamster ovary (CHO) cells expressing the cloned human beta-2 adrenergic receptor in the presence of [125I]- iodocyanopindolol.,B,Homo sapiens
CHEMBL333417,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccccc3C(F)(F)F)cs2)cc1,IC50,1800.0,nM,5.75,CHEMBL647872,Binding affinity was evaluated on chinese hamster ovary (CHO) cells expressing the cloned human beta-2 adrenergic receptor in the presence of [125I]- iodocyanopindolol.,B,Homo sapiens
CHEMBL338976,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(F)cc3F)cs2)cc1,IC50,2600.0,nM,5.58,CHEMBL647872,Binding affinity was evaluated on chinese hamster ovary (CHO) cells expressing the cloned human beta-2 adrenergic receptor in the presence of [125I]- iodocyanopindolol.,B,Homo sapiens
CHEMBL125963,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3cccc(F)c3F)cs2)cc1,IC50,760.0,nM,6.12,CHEMBL647872,Binding affinity was evaluated on chinese hamster ovary (CHO) cells expressing the cloned human beta-2 adrenergic receptor in the presence of [125I]- iodocyanopindolol.,B,Homo sapiens
CHEMBL338216,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3cc(F)c(F)c(F)c3)cs2)cc1,IC50,5000.0,nM,5.30,CHEMBL647872,Binding affinity was evaluated on chinese hamster ovary (CHO) cells expressing the cloned human beta-2 adrenergic receptor in the presence of [125I]- iodocyanopindolol.,B,Homo sapiens
CHEMBL368584,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(Cn4oc(=O)[nH]c4=O)cc3)CC2)ccc1O,Ki,74000.0,nM,4.13,CHEMBL646900,Inhibition of 125 I-Iodocyanopindolol binding to Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL354906,CS(=O)(=O)Nc1cc([C@@H](O)CNC2CCN(c3ccc(CC4SC(=O)N(CC(=O)O)C4=O)cc3)CC2)ccc1O,Ki,2100.0,nM,5.68,CHEMBL650091,Inhibition of 125 I-Iodocyanopindolol binding to Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL177442,CN(C)C(=N)NC1=NC(=O)/C(=C/c2ccc(N3CCC(NC[C@H](O)COc4cccc5[nH]c(O)nc45)CC3)cc2)S1,Ki,7.2,nM,8.14,CHEMBL646907,Inhibition of 125 I-Iodocyanopindolol binding to Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL183921,CC(COc1ccc2c(c1)NC(=O)CO2)NCC(O)COc1cccc2[nH]ccc12,Ki,0.631,nM,9.20,CHEMBL852184,Binding affinity for human beta-2 adrenergic receptor by displacing [125I]iodocyanopindolol expressed in hamster CHO cells,B,Homo sapiens
CHEMBL180700,O=C1COc2ccc(OCCNCCCOc3cccc4[nH]ccc34)cc2N1,Ki,1000.0,nM,6.00,CHEMBL852184,Binding affinity for human beta-2 adrenergic receptor by displacing [125I]iodocyanopindolol expressed in hamster CHO cells,B,Homo sapiens
CHEMBL181300,C#CCNc1cccc([C@@H](O)CN[C@H](C)Cc2c[nH]c3c(OS(C)(=O)=O)cccc23)c1,EC50,9.6,nM,8.02,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL360133,CC#CCNc1cccc([C@@H](O)CN[C@H](C)Cc2c[nH]c3c(OS(C)(=O)=O)cccc23)c1,EC50,18.0,nM,7.75,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL183552,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NCc2ccc3ccccc3c2)c1,EC50,7.6,nM,8.12,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL182018,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NC/C=C/c2ccccc2)c1,EC50,13.0,nM,7.89,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL181440,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2ccccc2)c1,EC50,19.0,nM,7.72,CHEMBL829740,Effective concentration against human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL182708,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NC(=O)c2ccccc2)c1,EC50,69.0,nM,7.16,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL182614,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(OCc2ccccc2)c1,EC50,46.0,nM,7.34,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL362293,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NCc2ccccc2)c1,EC50,16.0,nM,7.80,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL182689,C=CCNc1cccc([C@@H](O)CN[C@H](C)Cc2c[nH]c3c(OS(C)(=O)=O)cccc23)c1,EC50,2.2,nM,8.66,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL425161,C/C=C/CNc1cccc([C@@H](O)CN[C@H](C)Cc2c[nH]c3c(OS(C)(=O)=O)cccc23)c1,EC50,10.0,nM,8.00,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL181603,CC/C=C/CNc1cccc([C@@H](O)CN[C@H](C)Cc2c[nH]c3c(OS(C)(=O)=O)cccc23)c1,EC50,11.0,nM,7.96,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL182770,CC(C)=CCNc1cccc([C@@H](O)CN[C@H](C)Cc2c[nH]c3c(OS(C)(=O)=O)cccc23)c1,EC50,36.0,nM,7.44,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL181964,C=C(C)CNc1cccc([C@@H](O)CN[C@H](C)Cc2c[nH]c3c(OS(C)(=O)=O)cccc23)c1,EC50,1.5,nM,8.82,CHEMBL834425,Agonistic activity was assessed by measuring cAMP accumulation in CHO cells expressing human beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL1256786,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,Ki,2.6,nM,8.59,CHEMBL876356,Binding affinity for human beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL1263,OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,Ki,1.0,nM,9.00,CHEMBL876356,Binding affinity for human beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL185262,O=CNc1cc([C@@H](O)CNCCc2ccc(Oc3ccccc3)cc2)ccc1O,Ki,35.4,nM,7.45,CHEMBL876356,Binding affinity for human beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL363260,O=CNc1cc([C@@H](O)CNCCc2ccc(OCCc3ccccc3)cc2)ccc1O,Ki,7.8,nM,8.11,CHEMBL876356,Binding affinity for human beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL363329,O=CNc1cc([C@@H](O)CNCCc2ccc(OCCCc3ccccc3)cc2)ccc1O,Ki,5.9,nM,8.23,CHEMBL876356,Binding affinity for human beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL185052,O=CNc1cc([C@@H](O)CNCCc2ccc(OCCCCc3ccccc3)cc2)ccc1O,Ki,9.2,nM,8.04,CHEMBL876356,Binding affinity for human beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL184538,O=CNc1cc([C@@H](O)CNCCc2ccc(OC3Cc4ccccc4C3)cc2)ccc1O,Ki,11.6,nM,7.94,CHEMBL876356,Binding affinity for human beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL440561,O=CNc1cc([C@@H](O)CNCCc2cccc(OCCCCc3ccccc3)c2)ccc1O,Ki,8.5,nM,8.07,CHEMBL876356,Binding affinity for human beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL183948,O=CNc1cc([C@@H](O)CNCCc2cccc(OCCCOc3ccccc3)c2)ccc1O,Ki,3.3,nM,8.48,CHEMBL876356,Binding affinity for human beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL188622,CS(=O)(=O)Oc1cccc2c(CCNC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)c[nH]c12,Ki,223.0,nM,6.65,CHEMBL839159,Binding inhibition constant was determined by inhibition of [125I]iodocyanopindolol binding to Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL184407,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,18.0,nM,7.75,CHEMBL834426,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL186247,CS(=O)(=O)c1cccc2c(CCNC[C@H](O)c3cccc(NS(=O)(=O)c4cccc(N)c4)c3)c[nH]c12,Ki,70.0,nM,7.16,CHEMBL839159,Binding inhibition constant was determined by inhibition of [125I]iodocyanopindolol binding to Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL442225,C[C@H](Cc1c[nH]c2c(S(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccc(N)c2)c1,EC50,13.0,nM,7.89,CHEMBL834426,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL361505,COc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)c[nH]c12,Ki,25.0,nM,7.60,CHEMBL839158,Binding inhibition constant was determined by inhibition of [125I]iodocyanopindolol binding to Beta-2 adrenergic receptor,B,Homo sapiens
CHEMBL186196,CCOc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)c[nH]c12,EC50,7.7,nM,8.11,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL188315,CC(C)Oc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)c[nH]c12,EC50,12.0,nM,7.92,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL185836,C[C@H](Cc1c[nH]c2ccccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,21.0,nM,7.68,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL189081,C[C@H](Cc1c[nH]c2c(OS(=O)(=O)c3cccnc3)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,1.3,nM,8.89,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL185703,C[C@H](Cc1c[nH]c2c(OCC(=O)N(C)C)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,6.8,nM,8.17,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL186271,C[C@H](Cc1c[nH]c2c(OS(=O)(=O)c3cccs3)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,1.2,nM,8.92,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL186236,CCOC(=O)c1ccc(S(=O)(=O)Oc2cccc3c(C[C@@H](C)NC[C@H](O)c4cccc(NS(=O)(=O)c5cccs5)c4)c[nH]c23)cc1,EC50,7.2,nM,8.14,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL187317,CCCCS(=O)(=O)Oc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)c[nH]c12,EC50,7.3,nM,8.14,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL186135,CCCCCCCCS(=O)(=O)Oc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)c[nH]c12,EC50,5.6,nM,8.25,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL188196,C[C@H](Cc1c[nH]c2c(OCC(=O)O)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,19.0,nM,7.72,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL185660,CC(C)S(=O)(=O)Oc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)c[nH]c12,EC50,6.2,nM,8.21,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL187209,C[C@H](Cc1c[nH]c2c(OS(=O)(=O)c3ccccc3)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,3.1,nM,8.51,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL186676,C[C@H](Cc1c[nH]c2c(OCc3ccccc3)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,6.6,nM,8.18,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL362763,C[C@H](Cc1c[nH]c2c(OS(=O)(=O)c3ccc(C(=O)O)cc3)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,60.0,nM,7.22,CHEMBL833519,Agonistic activity was determined by measuring cAMP accumulation in CHO cells expressing cloned human Beta-2 adrenergic receptor,F,Homo sapiens
CHEMBL425190,Cc1ccc2c(OCCN3CCN(Cc4cccc5cccnc45)CC3)cccc2n1,Ki,1995.26,nM,5.70,CHEMBL840095,Binding affinity for human beta-2 adrenergic receptor ,B,Homo sapiens
CHEMBL513389,Cc1ccc(OCC(O)C(C)NC(C)C)c2c1CCC2,IC50,2.3,nM,8.64,CHEMBL884282,Percent inhibition against Beta-2 adrenergic receptor at 1 uM,B,Homo sapiens
CHEMBL199824,Cn1c(=O)cnn(CCCCN2CCN(c3cccc4ccc(O[11CH3])cc34)CC2)c1=O,Ki,60.6,nM,7.22,CHEMBL868770,Binding affinity to adrenergic beta-2 receptor,B,Homo sapiens
CHEMBL204827,Cc1ccc(C(=O)O)cc1-c1cccc(NCCNC[C@H](O)c2cccc(Cl)c2)c1,EC50,630.96,nM,6.20,CHEMBL862146,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,F,Homo sapiens
CHEMBL208352,COC(=O)c1cccc(-c2cccc(NCCNC[C@H](O)c3cccc(Cl)c3)c2)c1,EC50,501.19,nM,6.30,CHEMBL862146,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,F,Homo sapiens
CHEMBL208427,O=C(O)c1cccc(-c2cccc(NCCNC[C@H](O)c3cccc(Cl)c3)c2)c1,EC50,1258.93,nM,5.90,CHEMBL862146,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,F,Homo sapiens
CHEMBL205224,C[C@H](CNc1cccc(-c2cccc(C(=O)O)c2)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,50.12,nM,7.30,CHEMBL862146,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,F,Homo sapiens
CHEMBL377028,C[C@H](CNc1cccc(-c2ccccc2C(=O)O)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,1000.0,nM,6.00,CHEMBL862146,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,F,Homo sapiens
CHEMBL383511,C[C@H](CNc1cccc(-c2ccc(C(=O)O)cc2)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,1584.89,nM,5.80,CHEMBL862146,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,F,Homo sapiens
CHEMBL424866,O=C(O)c1cccc(-c2cccc(NCCNC[C@H](O)c3cccc(Cl)c3)c2)n1,EC50,10000.0,nM,5.00,CHEMBL862146,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,F,Homo sapiens
CHEMBL205389,O=C(O)c1cncc(-c2cccc(NCCNC[C@H](O)c3cccc(Cl)c3)c2)c1,EC50,3981.07,nM,5.40,CHEMBL862146,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,F,Homo sapiens
CHEMBL208328,C[C@H](CNc1cccc(-c2ncccc2C(=O)O)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,1584.89,nM,5.80,CHEMBL862146,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,F,Homo sapiens
CHEMBL218210,CC(C)(Cc1ccc(Oc2ccc(C(N)=O)cn2)cc1)NC[C@H](O)COc1cccc2[nH]c(=O)n(CCC3CCCC3)c12,EC50,2.4,nM,8.62,CHEMBL907249,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP levels,F,Homo sapiens
CHEMBL225775,CCCCOc1ccc(C[C@@H](C)NC[C@@H](O)c2cc(Br)no2)cc1,Ki,458.0,nM,6.34,CHEMBL920283,Displacement of [125I]CYP from human adrenergic beta 2 receptor transfected in CHO cells in presence of 100 uM GTP,B,Homo sapiens
CHEMBL226349,CCCCOc1ccc(C[C@@H](C)NC[C@H](O)c2cc(Br)no2)cc1,Ki,15.5,nM,7.81,CHEMBL920283,Displacement of [125I]CYP from human adrenergic beta 2 receptor transfected in CHO cells in presence of 100 uM GTP,B,Homo sapiens
CHEMBL226348,CCOC(=O)COc1ccc(C[C@@H](C)NC[C@@H](O)c2cc(Br)no2)cc1,Ki,81.4,nM,7.09,CHEMBL920283,Displacement of [125I]CYP from human adrenergic beta 2 receptor transfected in CHO cells in presence of 100 uM GTP,B,Homo sapiens
CHEMBL387852,CCOC(=O)COc1ccc(C[C@@H](C)NC[C@H](O)c2cc(Br)no2)cc1,Ki,2.82,nM,8.55,CHEMBL920283,Displacement of [125I]CYP from human adrenergic beta 2 receptor transfected in CHO cells in presence of 100 uM GTP,B,Homo sapiens
CHEMBL226293,C[C@H](Cc1ccc(OCC(=O)O)cc1)NC[C@@H](O)c1cc(Br)no1,Ki,501.0,nM,6.30,CHEMBL920283,Displacement of [125I]CYP from human adrenergic beta 2 receptor transfected in CHO cells in presence of 100 uM GTP,B,Homo sapiens
CHEMBL387851,C[C@H](Cc1ccc(OCC(=O)O)cc1)NC[C@H](O)c1cc(Br)no1,Ki,13.9,nM,7.86,CHEMBL920283,Displacement of [125I]CYP from human adrenergic beta 2 receptor transfected in CHO cells in presence of 100 uM GTP,B,Homo sapiens
CHEMBL388570,C[C@H](Cc1ccc(O)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,350.0,nM,6.46,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL389902,Oc1cc(O)cc([C@H](O)CNCCc2ccccc2)c1,Ki,20600.0,nM,4.69,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229620,Oc1cc(O)cc([C@@H](O)CNCCc2ccccc2)c1,Ki,10500.0,nM,4.98,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL389734,CCCC[C@H](C)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,56420.0,nM,4.25,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229616,CCCC[C@@H](C)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,100000.0,nM,4.00,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229615,CCCC[C@H](C)NC[C@H](O)c1cc(O)cc(O)c1,Ki,31400.0,nM,4.50,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL425658,CCCC[C@@H](C)NC[C@H](O)c1cc(O)cc(O)c1,Ki,9280.0,nM,5.03,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL389519,C[C@@H](Cc1cccc2ccccc12)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,2540.0,nM,5.59,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL388177,C[C@H](Cc1cccc2ccccc12)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,1780.0,nM,5.75,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229614,C[C@@H](Cc1cccc2ccccc12)NC[C@H](O)c1cc(O)cc(O)c1,Ki,340.0,nM,6.47,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229401,C[C@H](Cc1cccc2ccccc12)NC[C@H](O)c1cc(O)cc(O)c1,Ki,240.0,nM,6.62,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229400,C[C@@H](Cc1ccc(N)cc1)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,28800.0,nM,4.54,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229443,C[C@H](Cc1ccc(N)cc1)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,30800.0,nM,4.51,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229442,C[C@@H](Cc1ccc(N)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,6040.0,nM,5.22,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229391,C[C@H](Cc1ccc(N)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,1860.0,nM,5.73,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229390,C[C@@H](Cc1ccccc1)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,28600.0,nM,4.54,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL387825,C[C@H](Cc1ccccc1)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,23100.0,nM,4.64,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229388,C[C@@H](Cc1ccccc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,7940.0,nM,5.10,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL389629,C[C@H](Cc1ccccc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,2930.0,nM,5.53,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL228417,COc1ccc(C[C@H](C)NC[C@@H](O)c2cc(O)cc(O)c2)cc1,Ki,15900.0,nM,4.80,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL228998,COc1ccc(C[C@@H](C)NC[C@@H](O)c2cc(O)cc(O)c2)cc1,Ki,5270.0,nM,5.28,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL228996,COc1ccc(C[C@H](C)NC[C@H](O)c2cc(O)cc(O)c2)cc1,Ki,1930.0,nM,5.71,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL228992,COc1ccc(C[C@@H](C)NC[C@H](O)c2cc(O)cc(O)c2)cc1,Ki,470.0,nM,6.33,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL389390,C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,27800.0,nM,4.56,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229477,C[C@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,10300.0,nM,4.99,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL229476,C[C@@H](Cc1ccc(O)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,3690.0,nM,5.43,CHEMBL905129,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor expressed in HEK293 cells,B,Homo sapiens
CHEMBL230203,O=C(Cc1cccc(CCNC[C@H](O)c2ccc(O)c(CO)c2)c1)NCc1ccccc1,EC50,0.096,nM,10.02,CHEMBL889143,Agonist activity at human recombinant beta-2 adrenoceptor expressed in CHO cells assessed as elevation of cAMP,F,Homo sapiens
CHEMBL230487,C[C@H](Cc1cccc(CC(=O)NCc2ccccc2)c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.096,nM,10.02,CHEMBL889143,Agonist activity at human recombinant beta-2 adrenoceptor expressed in CHO cells assessed as elevation of cAMP,F,Homo sapiens
CHEMBL230486,CC(C)(Cc1cccc(CC(=O)NCc2ccccc2)c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.02,nM,10.70,CHEMBL889143,Agonist activity at human recombinant beta-2 adrenoceptor expressed in CHO cells assessed as elevation of cAMP,F,Homo sapiens
CHEMBL500,CC(C)NCC(O)COc1cccc2[nH]ccc12,Ki,0.4,nM,9.40,CHEMBL899656,Binding affinity at human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL393648,O[C@@H](CNC1CCCCC1)COc1cccc2[nH]ccc12,Ki,3.75,nM,8.43,CHEMBL899656,Binding affinity at human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL236514,O[C@@H](CNC12CC3CC(CC(C3)C1)C2)COc1cccc2[nH]ccc12,Ki,6.63,nM,8.18,CHEMBL899656,Binding affinity at human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL236251,C[C@H](Cc1ccc2[nH]c(C(=O)NCC3CCC3)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.051,nM,10.29,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL236042,COc1cccc(CCNC(=O)c2cc3cc(C[C@@H](C)NC[C@H](O)c4ccc(O)c(CO)c4)ccc3[nH]2)c1,EC50,0.254,nM,9.60,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL236041,C[C@H](Cc1ccc2[nH]c(C(=O)N(C)Cc3ccccc3)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.022,nM,10.66,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL392056,C[C@H](Cc1ccc2[nH]c(C(=O)N[C@H](C)c3ccccc3)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.058,nM,10.24,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL430361,C[C@H](Cc1ccc2[nH]c(C(=O)NCc3nccs3)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.031,nM,10.51,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL391006,C[C@H](Cc1ccc2[nH]c(C(=O)NCc3ccccn3)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.038,nM,10.42,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL235818,C[C@H](Cc1ccc2[nH]c(C(=O)NCc3ccc(S(N)(=O)=O)cc3)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.122,nM,9.91,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL394339,C[C@H](Cc1ccc2[nH]c(C(=O)NCc3ccc(O)cc3)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.164,nM,9.79,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL235612,C[C@H](Cc1ccc2[nH]c(C(=O)NCc3c(F)cccc3F)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.053,nM,10.28,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL236040,CSc1ccccc1CNC(=O)c1cc2cc(C[C@@H](C)NC[C@H](O)c3ccc(O)c(CO)c3)ccc2[nH]1,EC50,0.038,nM,10.42,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL236039,COc1ccccc1CNC(=O)c1cc2cc(C[C@@H](C)NC[C@H](O)c3ccc(O)c(CO)c3)ccc2[nH]1,EC50,0.02,nM,10.70,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL391946,C[C@H](Cc1ccc2[nH]c(C(=O)NCc3ccccc3)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.049,nM,10.31,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL238347,COc1cccc(OC)c1CNC(=O)c1cc2cc(C[C@@H](C)NC[C@H](O)c3ccc(O)c(CO)c3)ccc2n1Cc1ccccc1,EC50,0.687,nM,9.16,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL237709,CCn1c(C(=O)NCc2c(OC)cccc2OC)cc2cc(C[C@@H](C)NC[C@H](O)c3ccc(O)c(CO)c3)ccc21,EC50,2.55,nM,8.59,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL428027,COc1cccc(OC)c1CNC(=O)c1cc2cc(C[C@@H](C)NC[C@H](O)c3ccc(O)c(CO)c3)ccc2n1C,EC50,0.706,nM,9.15,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL391308,CC[C@H](Cc1ccc2[nH]c(C(=O)NCc3c(OC)cccc3OC)cc2c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.258,nM,9.59,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL237501,COc1cccc(OC)c1CNC(=O)c1cc2cc(C[C@@H](C)NC[C@H](O)c3ccc(O)c(CO)c3)ccc2[nH]1,EC50,0.058,nM,10.24,CHEMBL900403,Agonist activity at human recombinant adrenergic beta-2 receptor expressed in CHO cells assessed as elevation in cAMP levels,F,Homo sapiens
CHEMBL398320,COc1cccc([C@@H](Cc2ccccc2)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)c1,Ki,2700.0,nM,5.57,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL250553,CS(=O)(=O)Nc1cc(C[C@H](O)CN[C@H](Cc2ccccc2)c2ccc(OC(F)F)c(OC(F)F)c2)ccc1O,Ki,102.0,nM,6.99,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL400947,COc1ccc([C@@H](Cc2ccccc2)NC[C@@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1O,Ki,1070.0,nM,5.97,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL249359,CS(=O)(=O)Nc1cc(C[C@H](O)CN[C@H](Cc2ccccc2)c2ccc(Cl)c(Cl)c2)ccc1O,Ki,38.0,nM,7.42,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL440961,COc1ccc([C@H](Cc2ccccc2)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1OC,Ki,820.0,nM,6.09,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL398557,COc1ccc([C@H](Cc2ccccc2)NC[C@@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1OC,Ki,24.0,nM,7.62,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL399329,COc1ccc([C@@H](Cc2ccccc2)NC[C@@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1OC,Ki,66.0,nM,7.18,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL248548,COc1ccc([C@@H](Cc2ccccc2)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1OC,Ki,1500.0,nM,5.82,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL251581,COc1ccc([C@@H](Cc2ccccc2)NC[C@@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1,Ki,510.0,nM,6.29,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL251580,COc1ccc([C@@H](Cc2ccccc2)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1,Ki,3100.0,nM,5.51,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL398322,COc1cccc([C@@H](Cc2ccccc2)NC[C@@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)c1,Ki,350.0,nM,6.46,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL400067,COc1ccc([C@H](CCc2ccccc2)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1OC,Ki,390.0,nM,6.41,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL251764,COc1ccc([C@H](CCc2ccc(Cl)cc2)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1OC,Ki,120.0,nM,6.92,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL398241,COc1ccc([C@H](CCc2cccc(Cl)c2)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1OC,Ki,26.0,nM,7.58,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL447786,COc1ccc([C@H](CCc2ccccc2Cl)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1OC,Ki,57.0,nM,7.24,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL251555,CS(=O)(=O)Nc1cc(C[C@@H](O)CN[C@@H](CCc2ccccc2)c2ccc(OC(F)F)c(OC(F)F)c2)ccc1O,Ki,71.0,nM,7.15,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL251554,COc1cccc([C@H](CCc2ccccc2)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)c1,Ki,200.0,nM,6.70,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL251347,COc1ccc([C@H](CCc2ccccc2)NC[C@H](O)Cc2ccc(O)c(NS(C)(=O)=O)c2)cc1,Ki,280.0,nM,6.55,CHEMBL888309,Displacement of [125I]iodocyanopindolol from human cloned adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL245875,O=C(O)c1ccsc1-c1cccc(NCCNC[C@H](O)c2cccc(Cl)c2)c1,EC50,5011.87,nM,5.30,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL245874,O=C(O)c1ccoc1-c1cccc(NCCNC[C@H](O)c2cccc(Cl)c2)c1,EC50,2511.89,nM,5.60,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL245873,C[C@H](CNc1cccc(-c2sccc2C(=O)O)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,794.33,nM,6.10,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL395834,C[C@H](CNc1ccc(-c2sccc2C(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,630.96,nM,6.20,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL245673,C[C@H](CNc1cccc(-c2occc2C(=O)O)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,125.89,nM,6.90,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL247520,C[C@H](CNc1ccc(-c2occc2C(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,79.43,nM,7.10,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL393471,C[C@H](CNc1cccc(-c2ocnc2C(=O)O)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,316.23,nM,6.50,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL247519,C[C@H](CNc1ccc(-c2ocnc2C(=O)O)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,398.11,nM,6.40,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL393470,C[C@H](CNc1cccc(-c2csc(C(=O)O)n2)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,100.0,nM,7.00,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL247518,C[C@H](CNc1ccc(-c2csc(C(=O)O)n2)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,50.12,nM,7.30,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL247315,C[C@H](CNc1cccc(-c2nc(C(=O)O)cs2)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,158.49,nM,6.80,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL430390,C[C@H](CNc1ccc(-c2nc(C(=O)O)cs2)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,50.12,nM,7.30,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL393469,C[C@H](CNc1cccc(-c2nc(C(=O)O)co2)c1)NC[C@H](O)c1cccc(Cl)c1,EC50,125.89,nM,6.90,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL246908,C[C@H](CNc1ccc(-c2nc(C(=O)O)co2)cc1)NC[C@H](O)c1cccc(Cl)c1,EC50,100.0,nM,7.00,CHEMBL887285,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL251392,O[C@@H](CNCCOc1ccc(-c2cscn2)cc1)c1cccnc1,Ki,10.0,nM,8.00,CHEMBL924393,Displacement of [125I]iodocyanopindolol from human adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL250144,O[C@@H](CNCCOc1ccc(-c2csc(-c3ccccc3)n2)cc1)c1cccnc1,Ki,500.0,nM,6.30,CHEMBL924393,Displacement of [125I]iodocyanopindolol from human adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL251599,Cc1nc(-c2ccc(OCCNC[C@H](O)c3cccnc3)cc2)cs1,Ki,120.0,nM,6.92,CHEMBL924393,Displacement of [125I]iodocyanopindolol from human adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL249336,O[C@@H](CNCCOc1ccc(-c2cocn2)cc1)c1cccnc1,Ki,10.0,nM,8.00,CHEMBL924393,Displacement of [125I]iodocyanopindolol from human adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL251180,OCc1nc(-c2ccc(OCCNC[C@H](O)c3cccnc3)cc2)co1,Ki,30.0,nM,7.52,CHEMBL924393,Displacement of [125I]iodocyanopindolol from human adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL250352,CC(C)c1nc(-c2ccc(OCCNC[C@H](O)c3cccnc3)cc2)co1,Ki,49.0,nM,7.31,CHEMBL924393,Displacement of [125I]iodocyanopindolol from human adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL400049,CCc1nc(-c2ccc(OCCNC[C@H](O)c3cccnc3)cc2)co1,Ki,37.0,nM,7.43,CHEMBL924393,Displacement of [125I]iodocyanopindolol from human adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL249534,Cc1nc(-c2ccc(OCCNC[C@H](O)c3cccnc3)cc2)co1,Ki,21.0,nM,7.68,CHEMBL924393,Displacement of [125I]iodocyanopindolol from human adrenergic beta-2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL248547,CC(C)(Cc1ccc(Oc2ccc(C(N)=O)cn2)cc1)NC[C@H](O)COc1cccc2c1C1(CC1)C(=O)N2,EC50,35.2,nM,7.45,CHEMBL924511,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as cAMP level,F,Homo sapiens
CHEMBL403297,Cc1cc2c(CO)c(CCCCC(=O)O)n(CCc3ccccc3)c2cc1C(=O)O,IC50,15000.0,nM,4.82,CHEMBL944925,Binding affinity to GST tagged human beta 2 adrenergic receptor PDZ1 domain,B,Homo sapiens
CHEMBL522708,Cc1ccc2c(OCCN3CCC(Cc4cccc(N5CCCS5(=O)=O)c4)CC3)cccc2n1,Ki,1584.89,nM,5.80,CHEMBL954063,Displacement of radioligand from human cloned adrenergic beta2 receptor,B,Homo sapiens
CHEMBL497963,Cc1ccc2c(OCCN3CCC(Cc4cccc(NS(C)(=O)=O)c4)CC3)cccc2n1,Ki,501.19,nM,6.30,CHEMBL954063,Displacement of radioligand from human cloned adrenergic beta2 receptor,B,Homo sapiens
CHEMBL458541,CC(C)NCC(O)COc1ccc2c(c1)CCCN2Cc1ccccc1,EC50,1156.0,nM,5.94,CHEMBL938626,Agonist activity at adrenergic beta-2 receptor,F,Homo sapiens
CHEMBL530556,COc1ccc(CCNCC(O)COc2ccc3c(c2)CCCN3Cc2ccccc2)cc1,EC50,5895.0,nM,5.23,CHEMBL938626,Agonist activity at adrenergic beta-2 receptor,F,Homo sapiens
CHEMBL520313,CC(=O)O.NS(=O)(=O)c1ccccc1CCCCOCCCCCCNC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.7943,nM,9.10,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL446840,NS(=O)(=O)c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1.O=C(O)/C=C/c1ccccc1,EC50,0.1585,nM,9.80,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL475389,CC(=O)O.NS(=O)(=O)c1ccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc1,EC50,0.5012,nM,9.30,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL516056,CC(=O)O.CNS(=O)(=O)c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.631,nM,9.20,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL474393,CC(=O)O.CN(C)S(=O)(=O)c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,1.0,nM,9.00,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL514032,CC(=O)O.CC(C)NS(=O)(=O)c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.5012,nM,9.30,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL500782,CC(=O)O.O=S(=O)(NC1CCCCC1)c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.1995,nM,9.70,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL506518,CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)N1CCCCC1,EC50,1.0,nM,9.00,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL456485,CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)N1CCOCC1,EC50,1.259,nM,8.90,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL475236,CC(=O)O.NS(=O)(=O)c1cccc(CCCCOCCCCCCNC[C@@H](O)c2ccc(O)c(CO)c2)c1,EC50,10.0,nM,8.00,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL475237,NS(=O)(=O)Cc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,1.585,nM,8.80,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL485847,NS(=O)(=O)O.NS(=O)(=O)c1cccc(CCCOCCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,2.512,nM,8.60,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL483202,CC(=O)O.NS(=O)(=O)c1cccc(CCCCCOCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,7.943,nM,8.10,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL483407,CC(=O)O.NS(=O)(=O)c1cccc(CCCCCCOCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,25118.86,nM,4.60,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL443435,NS(=O)(=O)c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(NC=O)c2)c1.O=C(O)/C=C/C(=O)O,EC50,0.1585,nM,9.80,CHEMBL1019681,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,F,Homo sapiens
CHEMBL529659,Nc1ccc([C@@H](O)CNCCc2ccc(-c3ccc(C(=O)O)c(OC4CCCCC4)c3)cc2)cn1,EC50,1100.0,nM,5.96,CHEMBL947245,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay,F,Homo sapiens
CHEMBL487682,CC(C)Cc1cc(-c2ccc(CCNC[C@H](O)c3ccc(N)nc3)cc2)ccc1C(=O)O,EC50,3200.0,nM,5.50,CHEMBL947245,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay,F,Homo sapiens
CHEMBL324665,CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12,Ki,0.114,nM,9.94,CHEMBL990610,Displacement of [3H]DHA from human beta2 adrenoceptor by liquid scintillation counter,B,Homo sapiens
CHEMBL314639,N#Cc1cc2c(OCC(O)CN3CCN(C(c4ccccc4)c4ccccc4)CC3)cccc2[nH]1,Ki,57.3,nM,7.24,CHEMBL990610,Displacement of [3H]DHA from human beta2 adrenoceptor by liquid scintillation counter,B,Homo sapiens
CHEMBL444553,CC(C)(C)NCC(O)COc1cccc2[nH]cc(CC(N)=O)c12,Ki,23.5,nM,7.63,CHEMBL990610,Displacement of [3H]DHA from human beta2 adrenoceptor by liquid scintillation counter,B,Homo sapiens
CHEMBL461463,Cc1c[nH]c2cccc(OCC(O)CN3CCN(C(c4ccccc4)c4ccccc4)CC3)c12,Ki,0.311,nM,9.51,CHEMBL990610,Displacement of [3H]DHA from human beta2 adrenoceptor by liquid scintillation counter,B,Homo sapiens
CHEMBL513104,CC(C)(C)NCC(O)COc1cccc2oc3ccccc3c12,Ki,0.145,nM,9.84,CHEMBL990610,Displacement of [3H]DHA from human beta2 adrenoceptor by liquid scintillation counter,B,Homo sapiens
CHEMBL458001,O=C(Nc1cccc(Cn2ncc(N3CCNCC3)c(Cl)c2=O)c1)c1ccc(-c2ccccc2)cc1,Ki,2290.87,nM,5.64,CHEMBL991394,Displacement of [125I]iodocyanopindolol from adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL458002,Cc1ccc(Cn2ncc(N3CCNCC3)c(Cl)c2=O)cc1NC(=O)c1ccc(-c2ccccc2)cc1,Ki,2398.83,nM,5.62,CHEMBL991394,Displacement of [125I]iodocyanopindolol from adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL490733,CC(C)Sc1cc(-c2ccc(CCNC[C@H](O)c3cnccc3N)cc2)ccc1C(=O)NS(C)(=O)=O,EC50,1200.0,nM,5.92,CHEMBL1007086,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay,F,Homo sapiens
CHEMBL446806,CS(=O)(=O)NC(=O)c1ccc(-c2ccc(CCNC[C@H](O)c3cnccc3N)cc2)cc1OC1CCCCC1.Cl.Cl,EC50,290.0,nM,6.54,CHEMBL1007086,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay,F,Homo sapiens
CHEMBL270964,CC(C)Nc1cc(-c2ccc(CCNC[C@H](O)c3ccccc3)cc2)ccc1C(=O)O,EC50,586.0,nM,6.23,CHEMBL1007086,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay,F,Homo sapiens
CHEMBL473702,CC(C)Cc1cc(-c2ccc(CCNC[C@H](O)c3cnccc3N)cc2)ccc1C(=O)O,EC50,3200.0,nM,5.50,CHEMBL1007086,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay,F,Homo sapiens
CHEMBL470857,Nc1ccncc1[C@@H](O)CNCCc1ccc(-c2ccc(C(=O)O)c(OC3CCCCC3)c2)cc1,EC50,1100.0,nM,5.96,CHEMBL1007086,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay,F,Homo sapiens
CHEMBL252319,Cc1cccc(OC[C@@H](O)CNC(C)C)c1,Kd,1.2,nM,8.92,CHEMBL968869,Binding affinity to beta2 adrenergic receptor,B,Homo sapiens
CHEMBL462313,CC(C)N[C@@H]1CCn2c(=O)[nH]c3cccc(c32)[C@H]1O,IC50,620.0,nM,6.21,CHEMBL1010734,Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting,B,Homo sapiens
CHEMBL2218907,CC(C)NC1CCn2c(=O)[nH]c3cccc(c32)C1O,IC50,1100.0,nM,5.96,CHEMBL1010734,Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting,B,Homo sapiens
CHEMBL49080,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,IC50,1300.0,nM,5.89,CHEMBL1010734,Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting,B,Homo sapiens
CHEMBL509336,CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1,IC50,330.0,nM,6.48,CHEMBL1010734,Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting,B,Homo sapiens
CHEMBL714,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,IC50,980.0,nM,6.01,CHEMBL1010734,Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting,B,Homo sapiens
CHEMBL486278,COc1ccc(CC(C)(C)NC[C@H](O)COc2cccc3[nH]c(=O)[nH]c23)cc1,IC50,1.3,nM,8.89,CHEMBL952690,Binding affinity to beta2 adrenoceptor,B,Homo sapiens
CHEMBL504479,COc1ccc(CC(C)(C)NCC(O)COc2ccccc2C#N)cc1,IC50,21.0,nM,7.68,CHEMBL952690,Binding affinity to beta2 adrenoceptor,B,Homo sapiens
CHEMBL523475,COc1ccc(CC(C)(C)NCC(O)COc2cccc(Cl)c2C#N)cc1,IC50,23.0,nM,7.64,CHEMBL952690,Binding affinity to beta2 adrenoceptor,B,Homo sapiens
CHEMBL2112075,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N.Cl,IC50,4300.0,nM,5.37,CHEMBL952690,Binding affinity to beta2 adrenoceptor,B,Homo sapiens
CHEMBL491251,COc1ccc(CC(C)(C)NCC(O)COc2cccc(Cl)c2Cl)cc1,IC50,21.0,nM,7.68,CHEMBL952690,Binding affinity to beta2 adrenoceptor,B,Homo sapiens
CHEMBL487508,COc1ccc(CC(C)(C)NC[C@H](O)COc2cccc(Cl)c2Cl)cc1,IC50,1.0,nM,9.00,CHEMBL952690,Binding affinity to beta2 adrenoceptor,B,Homo sapiens
CHEMBL487507,COc1ccc(CC(C)(C)NC[C@@H](O)COc2cccc(Cl)c2Cl)cc1,IC50,300.0,nM,6.52,CHEMBL952690,Binding affinity to beta2 adrenoceptor,B,Homo sapiens
CHEMBL466088,CC(Cc1ccc(NC(=O)Cc2nccn2Cc2ccccc2)cc1)NC[C@H](O)COc1ccccc1,EC50,27.0,nM,7.57,CHEMBL972492,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL59,NCCc1ccc(O)c(O)c1,Kd,64560.0,nM,4.19,CHEMBL1058735,Binding affinity to human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL1437,NC[C@H](O)c1ccc(O)c(O)c1,Kd,3980.0,nM,5.40,CHEMBL1058735,Binding affinity to human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL679,CNC[C@H](O)c1ccc(O)c(O)c1,Kd,630.0,nM,6.20,CHEMBL1058735,Binding affinity to human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL1760,CC(C)(C)NCC(O)c1cc(O)cc(O)c1,Kd,2510.0,nM,5.60,CHEMBL1058735,Binding affinity to human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL776,CC(C)NCC(O)c1cc(O)cc(O)c1,Kd,4810.0,nM,5.32,CHEMBL1058735,Binding affinity to human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL27,CC(C)NCC(O)COc1cccc2ccccc12,Kd,0.79,nM,9.10,CHEMBL1058735,Binding affinity to human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL1204003,Cl.O=S(=O)(Nc1ccccc1)c1ccc(CCNC[C@@H](O)COc2ccccc2)cc1,EC50,50.0,nM,7.30,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1204005,Cl.N#C/N=C(\Nc1ccccc1)Nc1ccc(CCNC[C@H](O)COc2ccccc2)cc1,EC50,30.0,nM,7.52,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203988,Cl.O[C@@H](CNCCc1ccc(NC(=S)NC2CCCCC2)cc1)COc1ccccc1,EC50,30.0,nM,7.52,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1204006,Cl.O[C@@H](CNCCc1ccc(NC(=S)NCc2ccccc2)cc1)COc1ccccc1,EC50,30.0,nM,7.52,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203987,Cl.O[C@@H](CNCCc1ccc(NC(=S)NCCc2ccccc2)cc1)COc1ccccc1,EC50,10.0,nM,8.00,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL2448075,Cl.O[C@@H](CNCCc1ccc(NC(=S)Nc2ccccc2Cl)cc1)COc1ccccc1,EC50,40.0,nM,7.40,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL2448074,Cl.O[C@@H](CNCCc1ccc(NC(=S)Nc2cccc(Cl)c2)cc1)COc1ccccc1,EC50,50.0,nM,7.30,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL2448072,Cl.O[C@@H](CNCCc1ccc(NC(=S)Nc2ccc(Cl)cc2)cc1)COc1ccccc1,EC50,30.0,nM,7.52,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203994,Cl.O=[N+]([O-])c1ccccc1NC(=S)Nc1ccc(CCNC[C@H](O)COc2ccccc2)cc1,EC50,20.0,nM,7.70,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203989,Cl.O=[N+]([O-])c1cccc(NC(=S)Nc2ccc(CCNC[C@H](O)COc3ccccc3)cc2)c1,EC50,30.0,nM,7.52,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203990,Cl.O=[N+]([O-])c1ccc(NC(=S)Nc2ccc(CCNC[C@H](O)COc3ccccc3)cc2)cc1,EC50,20.0,nM,7.70,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203995,COc1ccccc1NC(=S)Nc1ccc(CCNC[C@H](O)COc2ccccc2)cc1.Cl,EC50,10.0,nM,8.00,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203996,COc1cccc(NC(=S)Nc2ccc(CCNC[C@H](O)COc3ccccc3)cc2)c1.Cl,EC50,20.0,nM,7.70,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1204007,COc1ccc(NC(=S)Nc2ccc(CCNC[C@H](O)COc3ccccc3)cc2)cc1.Cl,EC50,20.0,nM,7.70,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1204001,Cl.O[C@@H](CNCCc1ccc(NC(=S)Nc2ccc(F)cc2)cc1)COc1ccccc1,EC50,10.0,nM,8.00,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203998,Cl.O[C@@H](CNCCc1ccc(NC(=S)Nc2ccc(Br)cc2)cc1)COc1ccccc1,EC50,20.0,nM,7.70,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1204002,Cl.O[C@@H](CNCCc1ccc(NC(=S)Nc2ccc(I)cc2)cc1)COc1ccccc1,EC50,10.0,nM,8.00,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203999,COC(=O)c1ccc(NC(=S)Nc2ccc(CCNC[C@H](O)COc3ccccc3)cc2)cc1.Cl,EC50,10.0,nM,8.00,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1203991,Cl.NS(=O)(=O)c1ccc(NC(=S)Nc2ccc(CCNC[C@H](O)COc3ccccc3)cc2)cc1,EC50,10.0,nM,8.00,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL1204000,Cc1ccc(NC(=S)Nc2ccc(CCNC[C@H](O)COc3ccccc3)cc2)cc1.Cl,EC50,10.0,nM,8.00,CHEMBL1051555,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,F,Homo sapiens
CHEMBL567833,Cc1cccc(CC(C)(C)NCC(O)c2ccc(O)c3c2OCC(=O)N3)c1,EC50,0.4,nM,9.40,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL568272,CC(C)(Cc1ccc(O)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,0.1,nM,10.00,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL584498,CC(C)(Cc1ccc(C(F)(F)F)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,0.4,nM,9.40,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL577289,CC(C)(Cc1ccc(C(=O)O)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,2.8,nM,8.55,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL565267,CC(C)(Cc1cc(F)cc(F)c1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,0.5,nM,9.30,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL568531,CC(C)(Cc1ccc(OC(F)(F)F)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,0.7,nM,9.15,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL568273,CC(C)(Cc1cccc(C(F)(F)F)c1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,0.6,nM,9.22,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL566973,CC(C)(Cc1cccc(C(=O)O)c1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,2.9,nM,8.54,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL565685,CC(C)(Cc1ccc(C(C)(C)C)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,13.4,nM,7.87,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL576848,CC(C)c1ccc(CC(C)(C)NCC(O)c2ccc(O)c3c2OCC(=O)N3)cc1,EC50,1.5,nM,8.82,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL568511,CC(C)(Cc1ccccc1)NCC(O)c1ccc(O)c(CO)c1,EC50,70.0,nM,7.16,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL579394,Cc1ccccc1CC(C)(C)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,0.1,nM,10.00,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL567863,CC(C)(Cc1ccccc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,0.2,nM,9.70,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL567192,CCc1ccc(CC(C)(C)NCC(O)c2ccc(O)c3c2OCC(=O)N3)cc1,EC50,0.6,nM,9.22,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL565686,CC(C)(Cc1ccc(-c2ccccc2)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,1.7,nM,8.77,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL566777,Cc1ccccc1CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,EC50,20.0,nM,7.70,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL566352,CC(C)(Cc1cccc(C(F)(F)F)c1)NCC(O)c1ccc(O)c(CO)c1,EC50,131.0,nM,6.88,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL566992,CCc1ccc(CC(C)(C)NCC(O)c2ccc(O)c(CO)c2)cc1,EC50,170.0,nM,6.77,CHEMBL1044765,Agonist activity at human adrenergic beta 2 expressed in CHO-K1 cells assessed as intracellular cAMP accumulation,F,Homo sapiens
CHEMBL180672,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N,IC50,4.3,nM,8.37,CHEMBL1052906,Inhibition of beta2 adrenergic receptor,B,Homo sapiens
CHEMBL1204009,CCOC(=O)CCc1ccc(OC[C@H](O)CNC(C)(C)Cc2ccc3ccccc3c2)c(C#N)c1.Cl,IC50,14.0,nM,7.85,CHEMBL1052906,Inhibition of beta2 adrenergic receptor,B,Homo sapiens
CHEMBL585382,CC(C)(Cc1ccc(NC(=O)CCCNC(=O)C[N+](C)(C)C)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2.[Cl-],EC50,11.6,nM,7.94,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL568667,CC(C)(Cc1ccc(NC(=O)CCCN)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,9.0,nM,8.05,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL565770,CC(C)(Cc1ccc(NC(=O)CCCNC(=N)N)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,4.1,nM,8.39,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL565747,CC(C)(Cc1ccc(NC(=O)CCCNC(=O)C(N)CCCN)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,5.4,nM,8.27,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL568239,CC(C)(Cc1ccc(NC(=O)CCCNC(=O)CCN)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,0.9,nM,9.05,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL585751,CC(C)(Cc1ccc(NC(=O)CCCNCCCS(=O)(=O)O)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,1.8,nM,8.74,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL583235,CC(C)(Cc1ccc(NC(=O)CCCNC(=O)CN)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,1.2,nM,8.92,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL587197,CC(C)(Cc1ccc(NC(=O)CCCNC(=O)C[N+](C)(C)C)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2.[Cl-],EC50,1.0,nM,9.00,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL576428,CN(C)CC(=O)NCCCC(=O)Nc1ccc(CC(C)(C)NCC(O)c2ccc(O)c3c2OCC(=O)N3)cc1,EC50,0.5,nM,9.30,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL577917,CC(C)(Cc1ccc(NC(=O)CCCNC(=N)N)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,1.0,nM,9.00,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL577702,CC(C)(Cc1ccc(NC(=O)CCCN)cc1)NCC(O)c1ccc(O)c2c1OCC(=O)N2,EC50,1.1,nM,8.96,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL570834,CN1CCN(CC(=O)NCCCC(=O)Nc2ccc(CC(C)(C)NCC(O)c3ccc(O)c4c3OCC(=O)N4)cc2)CC1,EC50,1.2,nM,8.92,CHEMBL1044606,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cell assessed as increase of intracellular cAMP level,F,Homo sapiens
CHEMBL565547,Cc1nc2c3c(nc(Cc4ccccc4)n2n1)CCNCC3,Ki,7600.0,nM,5.12,CHEMBL1041013,Inhibition of beta2 adrenergic receptor,B,Homo sapiens
CHEMBL40317,NC[C@H](O)c1cc(O)c(O)cc1F,Ki,15800.0,nM,4.80,CHEMBL1043293,Displacement of [3H]prazosin from human adrenergic beta2 receptor expressed in CHO cell membrane,B,Homo sapiens
CHEMBL295072,NC[C@H](O)c1ccc(O)c(O)c1F,Ki,70100.0,nM,4.15,CHEMBL1043300,Displacement of [3H]prazosin from human adrenergic beta2 receptor N293F mutant expressed in CHO cell membrane,B,Homo sapiens
CHEMBL604125,COc1cccc(CC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)c1,EC50,14.3,nM,7.84,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL600007,CCOc1ccc(CC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1,EC50,15.4,nM,7.81,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL600817,COc1ccc(CC(C)(C)NC[C@@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1,EC50,97.7,nM,7.01,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL603271,COc1ccc(CC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1,EC50,1.4,nM,8.85,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL600617,CC(C)(Cc1ccccc1C(F)(F)F)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,1.4,nM,8.85,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL600616,CC(C)(Cc1ccc(Br)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,10.7,nM,7.97,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL603274,CC(C)(Cc1ccc(Cl)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,1.3,nM,8.89,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL600401,CC(C)(Cc1ccc(F)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,3.4,nM,8.47,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL600400,CC(C)(Cc1ccc(OC(F)(F)F)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,11.9,nM,7.92,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL604333,CC(C)(Cc1cccc(C(F)(F)F)c1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,3.4,nM,8.47,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL601430,CC(C)(Cc1ccc(C(F)(F)F)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,12.4,nM,7.91,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL601429,CC(C)(Cc1cc(F)cc(F)c1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,12.1,nM,7.92,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL601858,CC(C)(Cc1ccc(-c2ccccc2)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,68.0,nM,7.17,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL606208,CC(C)(Cc1ccc(C(C)(C)C)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,5167.0,nM,5.29,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL605372,CC(C)c1ccc(CC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1,EC50,58.0,nM,7.24,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL602258,CCc1ccc(CC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1,EC50,49.7,nM,7.30,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL602257,Cc1cccc(CC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)c1,EC50,4.1,nM,8.39,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL601036,Cc1ccccc1CC(C)(C)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,0.7,nM,9.15,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL592879,CC(C)(Cc1ccccc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,2.4,nM,8.62,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL2133469,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.O.O=C(O)/C=C/C(=O)O,EC50,0.4,nM,9.40,CHEMBL1071508,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1086149,O=C(Cc1nc2ccccc2[nH]1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,6000.0,nM,5.22,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1092502,O=C(Cn1ncc2ccccc21)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,15000.0,nM,4.82,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1089387,O=C(Cn1nc2ccccc2n1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,13000.0,nM,4.89,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1089725,O=C(Cc1nc2ccccc2o1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,1100.0,nM,5.96,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1090425,Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cs1,IC50,8700.0,nM,5.06,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1090746,O=C(Cc1csc(-c2ccccc2)n1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,1700.0,nM,5.77,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1084137,O=C(Cc1nc(-c2ccccc2)cs1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,1700.0,nM,5.77,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1085444,O=C(CN1CC(c2ccccc2)CC1=O)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,6700.0,nM,5.17,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1084145,Cc1sc2ncn(CC(=O)Nc3ccc(CCNC[C@H](O)c4cccnc4)cc3)c(=O)c2c1C,IC50,7800.0,nM,5.11,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1085693,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1nc2ccccc2[nH]1,IC50,1100.0,nM,5.96,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1077273,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1cccc2ccnn12,IC50,600.0,nM,6.22,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1083216,O=C(Cn1nc(-c2ccccc2)cc1-c1ccccc1)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1,IC50,3600.0,nM,5.44,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1089052,CNc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)cs1,IC50,16000.0,nM,4.80,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1089396,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1cccc(-c2ccccc2)c1,IC50,400.0,nM,6.40,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1089734,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2ccccc2)cc1,IC50,60.0,nM,7.22,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1089735,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccccc1N1CCCC1,IC50,5300.0,nM,5.28,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1083832,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccccc1C1CCCCC1,IC50,3000.0,nM,5.52,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1078395,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccccc1CCn1cccc1,IC50,6900.0,nM,5.16,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1078465,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccccc1CCc1ccccc1,IC50,1700.0,nM,5.77,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1078495,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccccc1COc1ccccc1,IC50,4700.0,nM,5.33,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1078496,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1cccc(CCn2cccc2)c1,IC50,600.0,nM,6.22,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1078576,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1cccc(-c2ncc[nH]2)c1,IC50,400.0,nM,6.40,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1078749,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1cccc(CCc2ccccc2)c1,IC50,400.0,nM,6.40,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1078695,O=C(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(CCc2ccccc2)cc1,IC50,100.0,nM,7.00,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1078696,Cc1ccc(N2CCCC2)c(C(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)c1,IC50,15000.0,nM,4.82,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1078876,Cc1ccc(C(=O)Nc2ccc(CCNC[C@H](O)c3cccnc3)cc2)c(N2CCCC2)c1,IC50,16000.0,nM,4.80,CHEMBL1105983,Displacement of [125I]cyanopindolol from human beta 2 adrenergic receptor expressed in CHO cells at 10 uM after 3 to 4 hrs by scintillation counter,B,Homo sapiens
CHEMBL1094785,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,0.76,nM,9.12,CHEMBL1115585,Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay,F,Homo sapiens
CHEMBL1094487,CCc1ccc(CC)c2c1CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,EC50,115.0,nM,6.94,CHEMBL1115585,Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay,F,Homo sapiens
CHEMBL1094486,COc1cc2c(cc1OC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,EC50,18.0,nM,7.75,CHEMBL1115585,Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay,F,Homo sapiens
CHEMBL1095779,CCCCc1cc2c(cc1CCCC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,EC50,25.0,nM,7.60,CHEMBL1115585,Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay,F,Homo sapiens
CHEMBL1095778,CCCc1cc2c(cc1CCC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,EC50,14.0,nM,7.85,CHEMBL1115585,Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay,F,Homo sapiens
CHEMBL1095777,CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,EC50,11.0,nM,7.96,CHEMBL1115585,Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay,F,Homo sapiens
CHEMBL1094483,Cc1cc2c(cc1C)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,EC50,39.0,nM,7.41,CHEMBL1115585,Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay,F,Homo sapiens
CHEMBL1094323,O=c1ccc2c([C@@H](O)CNC3Cc4ccccc4C3)ccc(O)c2[nH]1,EC50,5.0,nM,8.30,CHEMBL1115585,Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay,F,Homo sapiens
CHEMBL1085395,CC(=O)O.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2ccccc2)ccc1O,EC50,2.512,nM,8.60,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1085638,CC(=O)O.NC(=O)Nc1cccc(COCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,1.585,nM,8.80,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1085399,CC(=O)O.CS(=O)(=O)Nc1cccc(COCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.2512,nM,9.60,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1084647,CC(=O)O.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,EC50,0.3981,nM,9.40,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1084648,CC(=O)O.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2cc(Cl)ccc2Cl)ccc1O,EC50,0.3981,nM,9.40,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1084891,CC(=O)O.Cc1cc(C)cc(COCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.3981,nM,9.40,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1084649,CC(=O)O.Cc1ccc(COCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc1,EC50,2.512,nM,8.60,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1084654,CC(=O)O.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2ccc(Cl)cc2)ccc1O,EC50,2.512,nM,8.60,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1084655,NS(=O)(=O)c1ccc(COCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc1,EC50,1.995,nM,8.70,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1084656,CC(=O)O.NS(=O)(=O)c1cccc(COCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,1.585,nM,8.80,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1086535,OCc1cc([C@@H](O)CNCCCCCCOCCOCc2ccc(O)cc2)ccc1O,EC50,7.943,nM,8.10,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1086536,CC(=O)O.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2cccc(O)c2)ccc1O,EC50,0.7943,nM,9.10,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1085837,CC(=O)O.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2cccc3ccccc23)ccc1O,EC50,0.1259,nM,9.90,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1083884,CC(=O)O.OCCOCCCCCCNC[C@H](O)c1ccc(O)c(CO)c1,EC50,2511.89,nM,5.60,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL605993,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1.O=C(O)/C=C/C(=O)O,EC50,0.5012,nM,9.30,CHEMBL1119458,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,F,Homo sapiens
CHEMBL1083994,Cc1ccc(C(C)C)c(OCC(O)CN2CCC(CN3C(=O)c4cccc5cccc(c45)C3=O)CC2)c1,Ki,80.0,nM,7.10,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1086005,C=CCc1ccccc1OCC(O)CN1CCC(CN2C(=O)c3cccc4cccc(c34)C2=O)CC1,Ki,80.0,nM,7.10,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083995,COc1ccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)cc1,Ki,700.0,nM,6.16,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083996,CC(C)c1ccccc1OCC(O)CN1CCC(CN2C(=O)c3cccc4cccc(c34)C2=O)CC1,Ki,230.0,nM,6.64,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1084274,C=CCc1ccc(OCC(O)CN2CCC(CN3C(=O)c4cccc5cccc(c45)C3=O)CC2)c(OC)c1,Ki,3290.0,nM,5.48,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1084526,COc1ccc(OCC(O)CN2CCC(CN3C(=O)c4cccc5cccc(c45)C3=O)CC2)c(C(C)(C)C)c1,Ki,300.0,nM,6.52,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1084527,O=C1c2cccc3cccc(c23)C(=O)N1CC1CCN(CC(O)COc2ccc3[nH]ccc3c2)CC1,Ki,1260.0,nM,5.90,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083368,O=C1c2cccc3cccc(c23)C(=O)N1CC1CCN(CC(O)COc2cccc3[nH]ccc23)CC1,Ki,120.0,nM,6.92,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1084772,O=C1c2cccc3cccc(c23)C(=O)N1CC1CCN(CC(O)COc2cccc3[nH]c4ccccc4c23)CC1,Ki,3.0,nM,8.52,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1084773,Cc1ccc(C(C)C)c(OCC(O)CN2CCN(CCN3C(=O)c4cccc5cccc(c45)C3=O)CC2)c1,Ki,110.0,nM,6.96,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083672,C=CCc1ccccc1OCC(O)CN1CCN(CCN2C(=O)c3cccc4cccc(c34)C2=O)CC1,Ki,150.0,nM,6.82,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083053,CC(C)c1ccccc1OCC(O)CN1CCN(CCN2C(=O)c3cccc4cccc(c34)C2=O)CC1,Ki,70.0,nM,7.16,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083364,C=CCc1ccccc1OCC(O)CN1CCC(N2C(=O)c3cccc4cccc(c34)C2=O)CC1,Ki,40.0,nM,7.40,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1085013,CC(C)c1ccccc1OCC(O)CN1CCC(N2C(=O)c3cccc4cccc(c34)C2=O)CC1,Ki,13.0,nM,7.89,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1085014,C=CCc1ccccc1OCC(O)CN1CCC(CN2C(=O)c3cccc4cc(O)cc(c34)C2=O)CC1,Ki,135.0,nM,6.87,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083366,C=CCc1ccccc1OCC(O)CN1CCC(CN2C(=O)c3cccc4cc(OC)cc(c34)C2=O)CC1,Ki,78.0,nM,7.11,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083666,COc1cc2c3c(cccc3c1)C(=O)N(CC1CCN(CC(O)COc3ccccc3C(C)C)CC1)C2=O,Ki,38.0,nM,7.42,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1085016,C=CCc1ccccc1OCC(O)CN1CCC(CN2C(=O)c3ccccc3C2=O)CC1,Ki,50.0,nM,7.30,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1085270,CC(C)c1ccccc1OCC(O)CN1CCC(CN2C(=O)c3ccccc3C2=O)CC1,Ki,17.0,nM,7.77,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1085009,C=CCc1ccccc1OCC(O)CN1CCC(CN2C(=O)CCCC2=O)CC1,Ki,80.0,nM,7.10,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1085010,CC(C)c1ccccc1OCC(O)CN1CCC(CN2C(=O)CCCC2=O)CC1,Ki,9.0,nM,8.05,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083667,C=CCc1ccccc1OCC(O)CN1CCOCC1,Ki,7.0,nM,8.15,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083668,CC(C)c1ccccc1OCC(O)CN1CCOCC1,Ki,1.2,nM,8.92,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083669,C=CCc1ccccc1OCC(O)CNC1CCN(C)CC1,Ki,2.4,nM,8.62,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083670,CC(C)c1ccccc1OCC(O)CNC1CCN(C)CC1,Ki,17.0,nM,7.77,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1084706,O=C1c2cccc3cc(O)cc(c23)C(=O)N1CC1CCN(CC(O)COc2cccc3[nH]c4ccccc4c23)CC1,Ki,37.0,nM,7.43,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1084707,COc1cc2c3c(cccc3c1)C(=O)N(CC1CCN(CC(O)COc3cccc4[nH]c5ccccc5c34)CC1)C2=O,Ki,8.0,nM,8.10,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1083363,O=C1c2cccc3cccc(c23)C(=O)N1C1CCN(CC(O)COc2cccc3[nH]c4ccccc4c23)CC1,Ki,57.0,nM,7.24,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1086542,OC(COc1cccc2[nH]c3ccccc3c12)CN1CCC(Cc2ccccc2)CC1,Ki,0.5,nM,9.30,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1082500,COc1ccc(CC2CCN(CC(O)COc3cccc4[nH]c5ccccc5c34)CC2)cc1,Ki,0.2,nM,9.70,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1082501,OC(COc1cccc2[nH]c3ccccc3c12)CN1CCC(Cc2cccnc2)CC1,Ki,0.1,nM,10.00,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1082827,O=C(c1ccccc1)C1CCN(CC(O)COc2cccc3[nH]c4ccccc4c23)CC1,Ki,0.2,nM,9.70,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1082828,COc1ccc(C(=O)C2CCN(CC(O)COc3cccc4[nH]c5ccccc5c34)CC2)cc1,Ki,0.2,nM,9.70,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1086077,O=C(c1ccc(F)cc1)C1CCN(CC(O)COc2cccc3[nH]c4ccccc4c23)CC1,Ki,0.3,nM,9.52,CHEMBL1120618,Displacement of [125I]cyanopindolol from human adrenergic beta2 receptor expressed in CHOK1 cells,B,Homo sapiens
CHEMBL1221540,CCC(CC)CNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12,Ki,24.7,nM,7.61,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221541,C[C@@H](NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)C1CCCCC1,Ki,1.0,nM,9.00,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221542,C[C@H](NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)C1CCCCC1,Ki,25.1,nM,7.60,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221543,CC(C)(C)CC(C)(C)NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12,Ki,1.9,nM,8.72,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221586,O=c1[nH]c2c(O)ccc([C@@H](O)CNCC34CC5CC(CC(C5)C3)C4)c2s1,Ki,26.5,nM,7.58,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221587,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccccc3)c2s1,Ki,1.8,nM,8.74,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221588,Cc1onc(-c2ccccc2)c1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12,Ki,19.8,nM,7.70,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221589,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCc3ccccc3)c2s1,Ki,1.2,nM,8.92,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221590,CC(C)(Cc1ccccc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12,Ki,0.4,nM,9.40,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221634,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@@H]3CCCc4ccccc43)c2s1,Ki,9.4,nM,8.03,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221635,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@H]3CCCc4ccccc43)c2s1,Ki,30.2,nM,7.52,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221636,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCCc3ccccc3)c2s1,Ki,1.8,nM,8.74,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221638,C[C@H](NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)c1ccc2ccccc2c1,Ki,48.9,nM,7.31,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221679,O=c1[nH]c2c(O)ccc([C@@H](O)CNC3CCCCCC3)c2s1,Ki,11.8,nM,7.93,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221680,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@@H]3CCC[C@H]3OCc3ccccc3)c2s1,Ki,0.5,nM,9.30,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221681,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@H]3CCC[C@@H]3OCc3ccccc3)c2s1,Ki,6.1,nM,8.21,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221682,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@@H]3CCC[C@@H]3C3CCCC3)c2s1,Ki,0.6,nM,9.22,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221683,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@@H]3CCC[C@H]3C3CCCC3)c2s1,Ki,0.8,nM,9.10,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221732,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@@H]3CCCC[C@H]3OCc3ccccc3)c2s1,Ki,7.2,nM,8.14,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221733,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@H]3CCCC[C@@H]3OCc3ccccc3)c2s1,Ki,362.0,nM,6.44,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221734,CC1(C)[C@@H]2CC[C@]1(C)[C@@H](NC[C@H](O)c1ccc(O)c3[nH]c(=O)sc13)C2,Ki,40.4,nM,7.39,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221735,CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](NC[C@H](O)c1ccc(O)c3[nH]c(=O)sc13)C2,Ki,3.8,nM,8.42,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221736,O=c1[nH]c2c(O)ccc([C@@H](O)CNC3CCCC3C3CCCCC3)c2s1,Ki,4.0,nM,8.40,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221801,O=c1[nH]c2c(O)ccc([C@@H](O)CNC3CCCCC3C3CCCCC3)c2s1,Ki,151.0,nM,6.82,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221802,O=c1[nH]c2c(O)ccc([C@@H](O)CNC3CCN(CCN4CCCCCC4)CC3)c2s1,Ki,6.3,nM,8.20,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221803,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCOc3ccccc3)c2s1,Ki,4.4,nM,8.36,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221804,CN(CCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)c1ccccc1,Ki,0.3,nM,9.52,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221861,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSc3ccc(Cl)cc3)c2s1,Ki,3.0,nM,8.52,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221862,CCCCN(CCCC)CCNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12,Ki,18.3,nM,7.74,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1221637,C[C@@H](NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)c1ccc2ccccc2c1,Ki,2.7,nM,8.57,CHEMBL1227592,Displacement of [3H]CGP12177 from human beta2 adrenoceptor,B,Homo sapiens
CHEMBL1242969,CCN(Cc1ccc(O)cc1Cl)C(=O)Cc1cccc(CC(C)(C)NC[C@H](O)c2ccc(O)c(NS(C)(=O)=O)c2)c1,EC50,0.37,nM,9.43,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1240967,CC(C)(Cc1cccc(CC(=O)NCc2cccc(-c3ccc(O)cc3)c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.26,nM,9.59,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1240966,CC(C)(Cc1cccc(CC(=O)NCc2ccc(-c3ccc(O)cc3)cc2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.24,nM,9.62,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1240965,CC(C)(Cc1cccc(CC(=O)NCc2ccc3cc(O)ccc3c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.21,nM,9.68,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243000,CC(C)(Cc1cccc(CC(=O)NCc2cc(Cl)ccc2O)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.17,nM,9.77,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243035,CC(C)(Cc1cccc(CC(=O)NCc2cc(Cl)cc(Cl)c2O)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.13,nM,9.89,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243068,CC(C)(Cc1cccc(CC(=O)NCc2cc(Cl)c(O)c(Cl)c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.091,nM,10.04,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243101,Cc1cc(O)cc(C)c1CNC(=O)Cc1cccc(CC(C)(C)NC[C@H](O)c2ccc(O)c(NS(C)(=O)=O)c2)c1,EC50,0.045,nM,10.35,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1242943,CC(C)(Cc1cccc(CC(=O)NCc2ccc(O)cc2Cl)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.02,nM,10.70,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243407,CC(C)(Cc1ccccc1)NCC(O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.054,nM,10.27,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL402501,C[C@H](Cc1cccc(CC(=O)NC23CC4CC(CC(C4)C2)C3)c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.064,nM,10.19,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL230490,C[C@H](Cc1cccc(CC(=O)NCc2ccc(Cl)c(Cl)c2)c1)NC[C@H](O)c1ccc(O)c(CO)c1,EC50,0.024,nM,10.62,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243348,C[C@H](Cc1cccc(CC(=O)NCC2CCCCC2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.032,nM,10.49,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243347,CC(C)(Cc1cccc(CC(=O)NCc2ccc(Cl)c(Cl)c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.066,nM,10.18,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243317,Cc1ccc(CNC(=O)Cc2cccc(C[C@@H](C)NC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)c2)cc1C,EC50,0.056,nM,10.25,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243285,CCOc1ccccc1CNC(=O)Cc1cccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NS(C)(=O)=O)c2)c1,EC50,0.048,nM,10.32,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243256,COc1ccccc1CNC(=O)Cc1cccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NS(C)(=O)=O)c2)c1,EC50,0.04,nM,10.40,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243222,C[C@H](Cc1cccc(CC(=O)NCCCc2ccccc2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.042,nM,10.38,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243190,C[C@H](Cc1cccc(CC(=O)NCCc2ccccc2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.04,nM,10.40,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243189,CC(C)(Cc1cccc(CC(=O)NCc2ccccc2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.023,nM,10.64,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1243158,C[C@H](Cc1cccc(CC(=O)NCc2ccccc2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,EC50,0.027,nM,10.57,CHEMBL1246860,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as elevation in cAMP level after 1 hr by flashplate method,F,Homo sapiens
CHEMBL1258707,OCc1cc(OCC(O)CNC2CCN(c3ncnc4ccsc34)CC2)ccc1O,Ki,165.0,nM,6.78,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258706,Oc1ccc(OCC(O)CNC2CCN(c3ncnc4ccsc34)CC2)cc1,Ki,961.0,nM,6.02,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258599,OC(CNC1CCN(c2ncnc3ccsc23)CC1)COc1ccccc1,Ki,14.0,nM,7.85,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258598,OCc1cc(OCC(O)CNC2CCN(c3ncnc4sccc34)CC2)ccc1O,Ki,440.0,nM,6.36,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257674,Oc1ccc(OCC(O)CNC2CCN(c3ncnc4sccc34)CC2)cc1,Ki,589.0,nM,6.23,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258486,OC(CNC1CCN(c2ncnc3sccc23)CC1)COc1ccccc1,Ki,189.0,nM,6.72,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258485,Cc1csc2ncnc(N3CCC(NCC(O)COc4ccc(O)c(CO)c4)CC3)c12,Ki,223.0,nM,6.65,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258373,Cc1csc2ncnc(N3CCC(NCC(O)COc4ccc(O)cc4)CC3)c12,Ki,2600.0,nM,5.58,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258372,Cc1csc2ncnc(N3CCC(NCC(O)COc4ccccc4)CC3)c12,Ki,80.0,nM,7.10,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258260,Cc1c(-c2ccccc2)sc2ncnc(N3CCC(NCC(O)COc4ccc(O)c(CO)c4)CC3)c12,Ki,94.0,nM,7.03,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258259,Cc1c(-c2ccccc2)sc2ncnc(N3CCC(NCC(O)COc4ccc(O)cc4)CC3)c12,Ki,270.0,nM,6.57,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258144,Cc1c(-c2ccccc2)sc2ncnc(N3CCC(NCC(O)COc4ccccc4)CC3)c12,Ki,100.0,nM,7.00,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258143,OCc1cc(OCC(O)CNC2CCN(c3ncnc4scc(-c5cccs5)c34)CC2)ccc1O,Ki,20.0,nM,7.70,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258026,Oc1ccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5cccs5)c34)CC2)cc1,Ki,28.0,nM,7.55,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258025,OC(CNC1CCN(c2ncnc3scc(-c4cccs4)c23)CC1)COc1ccccc1,Ki,4.0,nM,8.40,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257916,Oc1ccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccc(F)cc5)c34)CC2)cc1,Ki,175.0,nM,6.76,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257915,OC(CNC1CCN(c2ncnc3scc(-c4ccc(F)cc4)c23)CC1)COc1ccccc1,Ki,19.0,nM,7.72,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257797,CCc1cc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)ccc1O,Ki,11.0,nM,7.96,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257676,CCc1cc(O)ccc1OCC(O)CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1,Ki,7.0,nM,8.15,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257675,COCc1cc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)ccc1O,Ki,4.9,nM,8.31,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257555,OCc1cc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)ccc1O,Ki,14.0,nM,7.85,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257554,OCc1cc(O)ccc1OCC(O)CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1,Ki,25.0,nM,7.60,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257438,Oc1ccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)cc1O,Ki,873.0,nM,6.06,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257437,O=C(O)c1ccc(O)cc1OCC(O)CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1,Ki,517.0,nM,6.29,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257324,OCc1ccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)cc1O,Ki,259.0,nM,6.59,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257204,O=C(c1cccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)c1)N1CCOCC1,Ki,135.0,nM,6.87,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258940,CNC(=O)c1cccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)c1,Ki,370.0,nM,6.43,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258825,CC(=O)Nc1cccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)c1,Ki,117.0,nM,6.93,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258824,NC(=O)Nc1cccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)c1,Ki,139.0,nM,6.86,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258705,N#Cc1cccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)c1,Ki,42.0,nM,7.38,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258704,CC(C)c1ccccc1OCC(O)CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1,Ki,10.0,nM,8.00,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258597,C=CCc1ccccc1OCC(O)CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1,Ki,6.0,nM,8.22,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258596,CCc1ccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)cc1,Ki,88.0,nM,7.06,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258484,CCc1cccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)c1,Ki,10.0,nM,8.00,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258483,OCc1ccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)cc1,Ki,93.0,nM,7.03,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258371,OCc1cccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)c1,Ki,18.0,nM,7.75,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258370,OC(CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1)COc1ccc(F)cc1,Ki,55.0,nM,7.26,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258258,OC(CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1)COc1cccc(F)c1,Ki,30.0,nM,7.52,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258257,OC(CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1)COc1ccccc1F,Ki,25.0,nM,7.60,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258142,OC(CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1)COc1cccc(OC(F)(F)F)c1,Ki,68.0,nM,7.17,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258024,COc1cccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)c1,Ki,30.0,nM,7.52,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1258023,COc1ccccc1OCC(O)CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1,Ki,11.0,nM,7.96,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257914,Oc1ccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)cc1,Ki,81.0,nM,7.09,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1257913,Oc1cccc(OCC(O)CNC2CCN(c3ncnc4scc(-c5ccccc5)c34)CC2)c1,Ki,6.0,nM,8.22,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1255596,OC(CNC1CCN(c2ncnc3scc(-c4ccccc4)c23)CC1)COc1ccccc1,Ki,9.0,nM,8.05,CHEMBL1261323,Displacement of [125I]-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL1672973,Cc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O,IC50,1700.0,nM,5.77,CHEMBL1681074,Inhibition of beta2 adrenergic receptor,B,Homo sapiens
CHEMBL1683931,O=C(Nc1ccccc1-c1ccccc1)OC1CCN(CCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)CC1,Ki,19.0,nM,7.72,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683932,O=C(Nc1ccccc1-c1ccccc1)OC1CCN(CCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)CC1,Ki,10.0,nM,8.00,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683933,O=C(Nc1ccccc1-c1ccccc1)OC1CCN(CCCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)CC1,Ki,3.4,nM,8.47,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683934,O=C(Nc1ccccc1-c1ccccc1)OC1CCN(CCCCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)CC1,Ki,3.5,nM,8.46,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683935,O=CNc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)ccc1O,Ki,21.0,nM,7.68,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683936,O=C(Nc1ccccc1-c1ccccc1)OC1CCN(CCCCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)CC1,Ki,61.0,nM,7.21,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1346,NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1,Ki,61.0,nM,7.21,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683938,O=C(Nc1ccccc1-c1ccccc1)OC1CCN(CCCCCCCCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)CC1,Ki,13.0,nM,7.89,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683939,NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCCCCCCCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)C1,Ki,60.0,nM,7.22,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683940,O=C(Nc1ccccc1-c1ccccc1)NC1CCN(CCCCCCCCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)CC1,Ki,115.0,nM,6.94,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683941,O=C(Nc1ccccc1-c1ccccc1)O[C@H]1C[N+]2(CCCCCCCCCNCC(O)c3ccc(O)c4[nH]c(=O)ccc34)CCC1CC2,Ki,123.0,nM,6.91,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1683942,C[N+]1(CCCCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,Ki,36.0,nM,7.44,CHEMBL1686737,Displacement of [3H]-dihydroalprenolol from human beta2-adrenoceptor expressed in HEK cells after 4 hrs,B,Homo sapiens
CHEMBL1684578,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2ccccc2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,IC50,780.0,nM,6.11,CHEMBL1687005,Agonist activity at human beta2 adrenergic receptor,F,Homo sapiens
CHEMBL1684577,O=S(=O)(Nc1ccc(CC2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,IC50,2180.0,nM,5.66,CHEMBL1687005,Agonist activity at human beta2 adrenergic receptor,F,Homo sapiens
CHEMBL1684580,O=S(=O)(Nc1ccc(CC2CC[C@@H]([C@@H](O)c3ccccc3)N2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,IC50,3530.0,nM,5.45,CHEMBL1687005,Agonist activity at human beta2 adrenergic receptor,F,Homo sapiens
CHEMBL1684581,O=S(=O)(Nc1ccc(CC2CC[C@@H]([C@H](O)c3ccccc3)N2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,IC50,3530.0,nM,5.45,CHEMBL1687005,Agonist activity at human beta2 adrenergic receptor,F,Homo sapiens
CHEMBL1684582,O=S(=O)(Nc1ccc(CC2CC[C@H]([C@@H](O)c3ccccc3)N2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,IC50,2790.0,nM,5.55,CHEMBL1687005,Agonist activity at human beta2 adrenergic receptor,F,Homo sapiens
CHEMBL1684583,O=S(=O)(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,IC50,2509.0,nM,5.60,CHEMBL1687005,Agonist activity at human beta2 adrenergic receptor,F,Homo sapiens
CHEMBL1684584,O=S(=O)(Nc1ccc(C[C@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,IC50,297.0,nM,6.53,CHEMBL1687005,Agonist activity at human beta2 adrenergic receptor,F,Homo sapiens
CHEMBL1773196,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCCNC(=O)Cc2cccc(CC(C)(C)NC[C@H](O)c3ccc(O)c(CO)c3)c2)ccc1O)C(C)C,EC50,17.0,nM,7.77,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1773197,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCCNC(=O)Cc2cccc(CC(C)(C)NC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)c2)ccc1O)C(C)C,EC50,8.1,nM,8.09,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1773198,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCCNC(=O)Cc2cccc(C[C@@H](C)NC[C@H](O)c3cc(O)cc(O)c3)c2)ccc1O)C(C)C,EC50,15.0,nM,7.82,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1773262,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCNC[C@H](O)c2ccc(O)c(NS(C)(=O)=O)c2)ccc1O)C(C)C,EC50,10.0,nM,8.00,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1773263,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCCNC(=O)CCCCCCCCCCNC[C@H](O)c2ccc(O)c(NS(C)(=O)=O)c2)ccc1O)C(C)C,EC50,116.0,nM,6.94,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1773264,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCCCOc2ccc(CCNC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)cc2)ccc1O)C(C)C,EC50,13.0,nM,7.89,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1773074,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCCCOc2ccc(CCNC[C@H](O)c3ccc(O)c(CO)c3)cc2)ccc1O)C(C)C,EC50,129.0,nM,6.89,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1773265,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCCCOc2ccc(CCNC[C@H](O)c3ccc(O)c(O)c3)cc2)ccc1O)C(C)C,EC50,173.0,nM,6.76,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1773266,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(NS(C)(=O)=O)c2)ccc1O)C(C)C,EC50,5.7,nM,8.24,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1773267,CC(C)N(CC[C@H](c1ccccc1)c1cc(CCCCOc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)ccc1O)C(C)C,EC50,2.4,nM,8.62,CHEMBL1775311,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as stimulation of intracellular cAMP production after 30 mins of washing by wash-off assay,F,Homo sapiens
CHEMBL1233771,CCOC(=O)c1oc2cccc(OC[C@@H](O)CNC(C)C)c2c1C,Ki,9.0,nM,8.05,CHEMBL1805400,Displacement of radioligand from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL1626224,CC(O)CNCCOc1ccccc1-c1ccccc1,Ki,470.0,nM,6.33,CHEMBL1805400,Displacement of radioligand from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL1802359,CC(C)(C)NC[C@H](O)c1ccc2c(c1)CO[B-](O)(O)O2,Kd,100.0,nM,7.00,CHEMBL1805399,Binding affinity to human adrenergic beta2 receptor by radioligand binding assay,B,Homo sapiens
CHEMBL1800936,CC[C@H](Cc1ccc(O)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,1270.0,nM,5.90,CHEMBL1804509,Displacement of [3H]CGP-12177 from human beta2-adrenergic receptor expressed in HEK 293 cells,B,Homo sapiens
CHEMBL1800960,CC[C@@H](Cc1ccc(O)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,5760.0,nM,5.24,CHEMBL1804509,Displacement of [3H]CGP-12177 from human beta2-adrenergic receptor expressed in HEK 293 cells,B,Homo sapiens
CHEMBL1800961,C[C@H](Cc1ccc2ccccc2c1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,410.0,nM,6.39,CHEMBL1804509,Displacement of [3H]CGP-12177 from human beta2-adrenergic receptor expressed in HEK 293 cells,B,Homo sapiens
CHEMBL1800962,C[C@@H](Cc1ccc2ccccc2c1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,510.0,nM,6.29,CHEMBL1804509,Displacement of [3H]CGP-12177 from human beta2-adrenergic receptor expressed in HEK 293 cells,B,Homo sapiens
CHEMBL1800963,COc1ccc(C[C@@H](C)NC[C@H](O)c2cc(O)cc(O)c2)c2ccccc12,Ki,280.0,nM,6.55,CHEMBL1804509,Displacement of [3H]CGP-12177 from human beta2-adrenergic receptor expressed in HEK 293 cells,B,Homo sapiens
CHEMBL1800934,COc1ccc(C[C@H](C)NC[C@H](O)c2cc(O)cc(O)c2)c2ccccc12,Ki,320.0,nM,6.50,CHEMBL1804509,Displacement of [3H]CGP-12177 from human beta2-adrenergic receptor expressed in HEK 293 cells,B,Homo sapiens
CHEMBL1800935,OCc1cc(C(O)CNCCCCCCCCCCCc2ccccc2)ccc1O,Ki,220.0,nM,6.66,CHEMBL1804516,Displacement of [125I]-CYP from human beta2-adrenergic receptor expressed in COS-7 cells by gamma counting,B,Homo sapiens
CHEMBL111775,O=C(CCOCCc1ccccc1)NCCNCCc1ccc(O)c2nc(O)sc12,EC50,1.585,nM,8.80,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL323776,CN(CCNCCc1ccc(O)c2nc(O)sc12)C(=O)CCOCCc1ccccc1,EC50,0.5012,nM,9.30,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL1800472,CN(CCNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,0.1995,nM,9.70,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL1800474,CC(C)(CNCCc1ccc(O)c2[nH]c(=O)sc12)NC(=O)CCOCCc1ccccc1,EC50,7.943,nM,8.10,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL1800475,CCCCN(CCN(C)CCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,125.89,nM,6.90,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL1800656,CCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,1.0,nM,9.00,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL1800657,CCCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,7.943,nM,8.10,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL1800658,CC(C)N(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,7.943,nM,8.10,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL1800659,CCCCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,1.585,nM,8.80,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL1800660,CCCCN(CCNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,0.7943,nM,9.10,CHEMBL1804370,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,F,Homo sapiens
CHEMBL1807874,CN(CCOCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)CCc1ccccc1,EC50,2.512,nM,8.60,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807873,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCOCCNCCc3cccc(Cl)c3Cl)c2s1,EC50,0.7943,nM,9.10,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807872,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCOCCNCCc3cccc(Cl)c3)c2s1,EC50,0.1995,nM,9.70,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807871,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCNCCc3cccc(Cl)c3Cl)c2s1,EC50,1.585,nM,8.80,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807870,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCNCCc3ccccc3Cl)c2s1,EC50,0.3981,nM,9.40,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807869,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCNCCc3cccc(Cl)c3)c2s1,EC50,1.259,nM,8.90,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807832,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCOCCCNCCc3cccc(Cl)c3)c2s1,EC50,0.5012,nM,9.30,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807831,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCS(=O)(=O)CCCNCCc3cccc(Cl)c3)c2s1,EC50,0.631,nM,9.20,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807830,O=c1[nH]c2c(O)ccc([C@@H](O)CNCC[S+]([O-])CCCNCCc3cccc(Cl)c3)c2s1,EC50,5.012,nM,8.30,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807829,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCNCCc3cccc(Cl)c3Cl)c2s1,EC50,1.585,nM,8.80,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807828,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCNCCc3ccccc3Cl)c2s1,EC50,0.631,nM,9.20,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807827,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCNCCc3cccc(Cl)c3)c2s1,EC50,1.0,nM,9.00,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807826,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCNCCc3cccc(C(F)(F)F)c3)c2s1,EC50,3.162,nM,8.50,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807825,CCOc1ccc(CCNCCCSCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,EC50,12.59,nM,7.90,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807824,CCc1ccc(CCNCCCSCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,EC50,3.981,nM,8.40,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807823,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCNCCc3ccccc3)c2s1,EC50,0.7943,nM,9.10,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807822,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCOCCOCCc3cccc4ccccc34)c2s1,EC50,0.1259,nM,9.90,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807821,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCOCCOCCc3ccccc3)c2s1,EC50,0.1259,nM,9.90,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807820,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCOCCc3cccc4ccccc34)c2s1,EC50,0.1,nM,10.00,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807819,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCCOCCc3ccccc3)c2s1,EC50,0.07943,nM,10.10,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807818,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCOCCc3ccccc3)c2s1,EC50,0.07943,nM,10.10,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1807817,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCOCCc3ccccc3)c2s1,EC50,0.0631,nM,10.20,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL82663,O=S(=O)(CCCOCCc1ccccc1)CCNCCc1ccc(O)c2nc(O)sc12,EC50,0.631,nM,9.20,CHEMBL1810622,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as stimulation of cAMP accumulation after 60 mins,F,Homo sapiens
CHEMBL1814268,CC(=O)O.O=C1CNC(=O)N1c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.631,nM,9.20,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814270,O=C1CNC(=O)N1c1ccccc1CCCCOCCCCCCNC[C@H](O)c1ccc(O)c(CO)c1,EC50,2.512,nM,8.60,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814269,CC(=O)O.O=C1CNC(=O)N1c1ccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc1,EC50,1.995,nM,8.70,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814271,CC(=O)O.CC1(C)NC(=O)N(c2cccc(CCCCOCCCCCCNC[C@H](O)c3ccc(O)c(CO)c3)c2)C1=O,EC50,0.7943,nM,9.10,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814272,CC(=O)O.O=C1CN(c2cccc(CCCCOCCCCCCNC[C@H](O)c3ccc(O)c(CO)c3)c2)C(=O)N1,EC50,2.512,nM,8.60,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814273,CC(=O)O.O=C1CNC(=O)N1Cc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,1.259,nM,8.90,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814274,CC(=O)O.O=C1CN(Cc2cccc(CCCCOCCCCCCNC[C@H](O)c3ccc(O)c(CO)c3)c2)C(=O)N1,EC50,0.631,nM,9.20,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814275,O=C1NC(=O)N(Cc2cccc(CCCCOCCCCCCNC[C@H](O)c3ccc(O)c(CO)c3)c2)C1=O.O=CO,EC50,0.7943,nM,9.10,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814276,CC(=O)O.NC(=O)CN1C(=O)CN(c2cccc(CCCCOCCCCCCNC[C@H](O)c3ccc(O)c(CO)c3)c2)C1=O,EC50,0.2512,nM,9.60,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814277,O=c1cc[nH]c(=O)n1-c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.7943,nM,9.10,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814267,CC(=O)O.O=c1ccn(-c2cccc(CCCCOCCCCCCNC[C@H](O)c3ccc(O)c(CO)c3)c2)c(=O)[nH]1,EC50,1.259,nM,8.90,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1814279,O=C(O)CNC(=O)Nc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,1.0,nM,9.00,CHEMBL1816608,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1824264,COc1ccc2nc(-c3ccc(OCC(O)CNC(C)C)cc3)n(C)c(=O)c2c1,Ki,7700.0,nM,5.11,CHEMBL1827497,Displacement of [125I]-Iodopindolol from beta2-adrenergic receptor after 1.5 hrs by liquid scintillation counting,B,Homo sapiens
CHEMBL1830621,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCOCCOCCNCC(O)COc1cccc2[nH]ccc12,Kd,7.244,nM,8.14,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830620,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCNCC(O)COc1cccc2[nH]ccc12,Kd,30.2,nM,7.52,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830619,C=CCc1ccccc1OCC(O)CNCCOCCOCCNC(=O)CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1,Kd,0.6166,nM,9.21,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830618,C=CCc1ccccc1OC[C@@H](O)CNCCOCCOCCNC(=O)CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1,Kd,0.4266,nM,9.37,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830617,C=CCc1ccccc1OCC(O)CNCCNC(=O)CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1,Kd,1.585,nM,8.80,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830493,C=CCc1ccccc1OC[C@@H](O)CNCCNC(=O)CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1,Kd,1.82,nM,8.74,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL266195,C=CCc1ccccc1OCC(O)CNC(C)C,Kd,0.2951,nM,9.53,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830492,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCOCCOCCNCC(O)COc1cccc2ccccc12,Kd,0.4365,nM,9.36,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830491,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCOCCOCCNC[C@H](O)COc1cccc2ccccc12,Kd,0.2951,nM,9.53,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830490,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCCCCCCCNCC(O)COc1cccc2ccccc12,Kd,2.512,nM,8.60,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830489,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCCCNCC(O)COc1cccc2ccccc12,Kd,0.7413,nM,9.13,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830488,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCNCC(O)COc1cccc2ccccc12,Kd,2.57,nM,8.59,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830487,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCCCCCCCNC[C@H](O)COc1cccc2ccccc12,Kd,1.738,nM,8.76,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830486,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCCCNC[C@H](O)COc1cccc2ccccc12,Kd,0.2754,nM,9.56,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1830485,O=C(CCCCCNC(=O)COc1ccc(/C=C/c2ccc3n2[B-](F)(F)[N+]2=C(c4cccs4)C=CC2=C3)cc1)NCCNC[C@H](O)COc1cccc2ccccc12,Kd,0.4266,nM,9.37,CHEMBL1833711,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,F,Homo sapiens
CHEMBL1836647,O=c1ccc2c([C@@H](O)CNCCCCCCCCCN3CCC(Oc4nn(-c5c(O)cccc5F)c5c4CCCC5)CC3)ccc(O)c2[nH]1,EC50,14.0,nM,7.85,CHEMBL1838348,Agonist activity at human beta-2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP production,F,Homo sapiens
CHEMBL1835853,CC(=O)O.NC(=O)Nc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.7943,nM,9.10,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1835859,NC(=O)CNC(=O)Nc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1.O=CO,EC50,0.2512,nM,9.60,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1835860,CC(=O)O.O=C(CNC(=O)Nc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)NC1CCCC1,EC50,0.3162,nM,9.50,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1835862,CC(=O)O.Cc1cc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc(NC(N)=O)c1,EC50,0.1585,nM,9.80,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1835855,CC(=O)O.O=C(Nc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)NC1CCCCC1,EC50,1.0,nM,9.00,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1835857,CC(=O)O.NC(=O)NCc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.5012,nM,9.30,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1835858,CC(=O)O.CCNC(=O)NCc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,0.631,nM,9.20,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1835856,CC(=O)O.CCNC(=O)Nc1ccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc1,EC50,0.5012,nM,9.30,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1835861,CC(=O)O.NC(=O)Nc1cc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc(C(F)(F)F)c1,EC50,1.0,nM,9.00,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1835854,CC(=O)O.CCNC(=O)Nc1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1,EC50,1.0,nM,9.00,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1200811,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1.O.O=C(O)/C=C/C(=O)O,EC50,0.5012,nM,9.30,CHEMBL1840215,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL1482007,Cc1ccc(OCc2nnc(SCc3nc4ccccc4[nH]3)n2Cc2ccco2)cc1,EC50,1080.0,nM,5.97,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1457704,CC(C)Cc1nc2sc3c(NCc4ccco4)ncnc3c2c2c1COC(C)(C)C2,EC50,615.0,nM,6.21,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1401186,Cc1ccc(S(=O)(=O)N(C)CC(=O)N2CCN(c3ccccn3)CC2)cc1,EC50,167.0,nM,6.78,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1346173,CC(=O)Nc1ccc(-c2nnc(SCc3ccc(C)cc3)n2C)cc1,EC50,3600.0,nM,5.44,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1346316,Clc1ccc(OCc2nnc(SCc3nc4ccccc4[nH]3)n2Cc2ccco2)cc1,EC50,205.0,nM,6.69,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1376574,CC(Oc1ccc(Cl)cc1Cl)c1nc(-c2ccc(NC(=O)c3ccccn3)cc2)no1,EC50,973.0,nM,6.01,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1581826,Cc1ncc(CN2CCCC(C(=O)Nc3ccc(-c4cccc(F)c4)cc3)C2)cn1,EC50,695.0,nM,6.16,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1419122,C=CCn1c(CCNC(=O)c2cccs2)nnc1SCC(=O)c1ccc(Cl)cc1,EC50,167.0,nM,6.78,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1464795,CCC(=O)Nc1ccc(-c2nn3c(C)nnc3s2)cc1C,EC50,3120.0,nM,5.51,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1570111,Cn1c(N2CCN(c3ccccn3)CC2)nc2c1c(=O)n(Cc1ccc(Cl)cc1)c(=O)n2C,EC50,81.0,nM,7.09,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1319108,CCCCC(=O)Nc1ccc(S(=O)(=O)N2CCCCC2c2cccnc2)cc1,EC50,79.8,nM,7.10,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1475105,NC(=O)CC(NC(=O)c1ccccc1)c1ccc(NCCCN2CCCC2=O)c([N+](=O)[O-])c1,EC50,1400.0,nM,5.85,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1604735,CCN1CCN(c2ccc(NC(=O)c3ccc([N+](=O)[O-])o3)cc2Cl)CC1,EC50,6220.0,nM,5.21,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1319376,CN(CC(=O)N1CCN(c2ccccn2)CC1)S(=O)(=O)c1ccc(Br)cc1,EC50,82.8,nM,7.08,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1537056,C=CCn1c(SCc2ccccc2Cl)nnc1-c1sc2nc(C)cc(C)c2c1N,EC50,75.7,nM,7.12,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1575889,Cc1ccc(CS(=O)(=O)c2nc3c(c(N(C)C)n2)CCCC3)cc1,EC50,81.3,nM,7.09,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1711,CC(C)NCC(O)c1ccc(O)c(O)c1.Cl,EC50,828.0,nM,6.08,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1521880,N#Cc1cc(-c2ccccc2)nnc1Oc1ccccc1Cl,EC50,173.0,nM,6.76,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1306990,Cc1ccc(NC(=O)C(c2ccc(Cl)cc2)N2CCCCC2)cc1,EC50,2990.0,nM,5.52,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1458548,CCCNC(=O)c1nnsc1S(=O)(=O)c1ccc(Cl)cc1,EC50,9540.0,nM,5.02,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1340208,CN(CCOc1ccc(-c2ccn(S(=O)(=O)c3cccc4ccccc34)n2)cc1)c1ccccn1,EC50,2530.0,nM,5.60,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1458579,Cc1ccc(SCC(=O)Nc2ccc(-c3nc4ccccc4[nH]3)cc2)cc1,EC50,11.6,nM,7.94,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1543973,CC(=O)Nc1ccc(S(=O)(=O)N2CCCCC2c2cccnc2)cc1,EC50,262.0,nM,6.58,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1426242,C=CCn1c(CCNC(=O)c2cccs2)nnc1SCC(=O)c1cccc([N+](=O)[O-])c1,EC50,133.0,nM,6.88,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1387056,CC1(C)Cc2c(c(N3CCCC3)nc3sc4c(N5CCN(CCO)CC5)ncnc4c23)CO1,EC50,8760.0,nM,5.06,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1522050,CSc1ccc(CNC(=O)c2ccc(NC(=O)C3=CSCCO3)cc2)cc1,EC50,48.2,nM,7.32,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL531322,Cl.Oc1ccccc1Nc1nc(NCc2ccco2)c2ccccc2n1,EC50,492.0,nM,6.31,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1456621,Cc1ccc(OCC(=O)Nc2ccc(-c3nc4ncccc4o3)cc2)c(C)c1,EC50,316.0,nM,6.50,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1368804,COc1ccccc1OCCCC(=O)Nc1nccs1,EC50,5110.0,nM,5.29,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1612392,O=C(Nc1ccc2oc(-c3ccc4ccccc4c3)nc2c1)c1ccc2c(c1)OCCO2,EC50,5580.0,nM,5.25,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1527861,CCCCOc1cccc(C(=O)Nc2ccc(NC(=O)c3cccs3)cc2)c1,EC50,256.0,nM,6.59,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1370616,CSc1ccc(C(=O)C2CCCN(Cc3cccn3-c3cccnc3)C2)cc1,EC50,566.0,nM,6.25,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1347493,Cc1ccc(SCC(=O)Nc2ccc(-c3nnc(-c4ccco4)o3)cc2)cc1,EC50,629.0,nM,6.20,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL537445,Br.CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,EC50,110.0,nM,6.96,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1420188,Cc1ccc(OCc2cc(C(=O)NCc3cnn(-c4cccc(F)c4)c3)no2)cn1,EC50,195.0,nM,6.71,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1478198,Cc1ccc(Cn2ccc(NC(=O)c3cc4nc(-c5ccco5)cc(C(F)(F)F)n4n3)n2)cc1,EC50,220.0,nM,6.66,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1330871,CCOc1ccc(CNC(=O)c2ccc(NC(=O)C3=CSCCO3)cc2)cc1,EC50,60.8,nM,7.22,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1364979,N#Cc1cc(-c2ccccc2)nc(Oc2ccc(Cl)cc2)n1,EC50,1250.0,nM,5.90,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1525540,Cc1cccc(Nc2nnc(-c3ccc(C(=O)N4C[C@H]5C[C@H](C4)c4cccc(=O)n4C5)cc3)c3ccccc23)c1,EC50,2120.0,nM,5.67,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1340869,COc1ccc(CNC(=O)CCCCCNc2nc(S)nc3ccccc23)cc1,EC50,25.5,nM,7.59,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1577023,Cc1ccc(OCC(=O)Nc2ccc(-c3nc4ncccc4o3)cc2)cc1,EC50,31.6,nM,7.50,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1722488,CC(=O)Nc1ccc(S(=O)(=O)N(Cc2cccnc2)Cc2cc3ccccc3nc2O)cc1,EC50,801.0,nM,6.10,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1573444,CN(Cc1ccccc1F)c1nc(-c2cccnc2)nc2ccccc12,EC50,6080.0,nM,5.22,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1538061,C=CCn1c(SCc2ccc(F)cc2)nnc1-c1sc2nc(C)cc(C)c2c1N,EC50,29.0,nM,7.54,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1600429,O=C(c1cccc(Cl)c1)N1CCC(C(=O)N2CCN(Cc3ccccc3)CC2)CC1,EC50,5890.0,nM,5.23,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1505690,Cc1ccc(NC(=O)C(c2ccc(Cl)cc2)N2CCOCC2)cc1,EC50,2180.0,nM,5.66,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1325241,CCOC(=O)C1(C)C=C(Nc2ccc(O)cc2)C(=O)N1c1ccc(O)cc1,EC50,1090.0,nM,5.96,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1341251,CCN(Cc1ccccc1)S(=O)(=O)c1cc(C(=O)NC(C)C2CC3CCC2C3)ccc1OC,EC50,8760.0,nM,5.06,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1325250,Cc1ccccc1N1CCN(c2ncnc3c2cnn3Cc2ccc(Cl)cc2)CC1,EC50,4090.0,nM,5.39,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1522618,O=C(Nc1ccc(-c2nc3ncccc3o2)cc1)c1ccc([N+](=O)[O-])o1,EC50,636.0,nM,6.20,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1483308,O=S(=O)(Nc1cccc(-c2cn3cccnc3n2)c1)c1ccc(-c2ccccc2)cc1,EC50,4330.0,nM,5.36,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1459608,CCCCC(=O)Nc1ccc(C(=O)N2CCCC(C(=O)OCC)C2)cc1,EC50,5720.0,nM,5.24,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1337858,O=C(CSc1nnc(-c2ccncc2)n1Cc1ccco1)N1c2ccccc2Sc2ccc(Cl)cc21,EC50,343.0,nM,6.46,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1365995,CCCCCCN1C(=O)NC(=O)/C(=C\Nc2c(C)n(C)n(-c3ccccc3)c2=O)C1=O,EC50,1310.0,nM,5.88,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1528906,O=C(CCCCCn1c(=S)[nH]c2ccccc2c1=O)NCc1ccc2c(c1)OCO2,EC50,7.7,nM,8.11,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1348147,Cc1c(C(=O)N2CCc3ccccc3C2)oc2ccc(S(=O)(=O)N3CCCCCC3)cc12,EC50,1460.0,nM,5.84,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1517798,c1ccc(CSc2nnnn2-c2cccc3ccccc23)nc1,EC50,1220.0,nM,5.91,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1723653,Cc1ncc(CN2CCCC(C(=O)Nc3ccc(-c4cccc(F)c4)cc3)C2)s1,EC50,3370.0,nM,5.47,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1255663,CNCC(O)c1ccc(O)c(O)c1.Cl,EC50,2620.0,nM,5.58,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1577237,Cc1ccc(Sc2cc(N3CCOCC3)nc(-c3ccccc3)n2)cc1,EC50,4820.0,nM,5.32,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1444240,O=C(Cn1nc(-c2ccccc2)ccc1=O)Nc1ccc(NC(=O)c2ccccn2)cc1,EC50,8.16,nM,8.09,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1301481,CC1(C)Cc2c(c(-c3ccco3)nc3sc4c(NCCCO)ncnc4c23)CO1,EC50,20.7,nM,7.68,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1553183,Cn1nnnc1Sc1ncnc2scc(-c3ccc(Br)cc3)c12,EC50,8440.0,nM,5.07,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1439691,CCN(CC)S(=O)(=O)c1cc(NC(=O)C2=COCCO2)ccc1Cl,EC50,38.0,nM,7.42,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1388401,CCc1ccc(CN2CCC(Oc3ccc(C(=O)N4CCCC4)cc3)CC2)cc1,EC50,936.0,nM,6.03,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL604311,CCCc1ccc(OCc2nc(-c3ccc(NC(=O)c4cccs4)cc3)no2)cc1,EC50,539.0,nM,6.27,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1518070,O=C(Nc1ccccc1)c1ccccc1CCc1ccccc1,EC50,1700.0,nM,5.77,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1450612,O=C(CCc1ccc(S(=O)(=O)N2CCOCC2)cc1)Nc1nc(COc2ccccc2)cs1,EC50,1400.0,nM,5.85,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1606638,CCOc1ccc2nc(NC(=O)CSc3nc4cccnc4n3C)sc2c1,EC50,2440.0,nM,5.61,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1506229,CCN(CCO)c1ncnc2c1sc1nc(CC(C)C)c3c(c12)CC(C)(C)OC3,EC50,45.4,nM,7.34,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1506260,CC1=NCCc2c1[nH]c1ccccc21.O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1,EC50,6520.0,nM,5.19,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1704973,COc1ccc(C(C)=O)cc1COc1ccc(Cl)cc1Cl,EC50,2670.0,nM,5.57,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1705007,Cc1cc(C)cc(C(=O)NC(CC(N)=O)c2ccc(N3CCN(c4ccccn4)CC3)c([N+](=O)[O-])c2)c1,EC50,714.0,nM,6.15,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1724644,CC1(C)Cc2c(c(N3CCOCC3)nc3sc4c(NCCN)ncnc4c23)CO1,EC50,158.0,nM,6.80,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1506379,COc1ccc(CC(=O)Nc2ccc(-c3cn4ccccc4n3)cc2)cc1,EC50,45.0,nM,7.35,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1301877,CCn1c(COc2ccc(Cl)cc2)nnc1SCc1ccc(C#N)cc1,EC50,2110.0,nM,5.68,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1577767,Cc1ccc(O)c(NC(=O)c2cccc(NC(=O)c3ccco3)c2)c1,EC50,132.0,nM,6.88,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1506675,Cc1ccc(OCc2cc(C(=O)NCc3ccc(OC(F)(F)F)cc3)no2)cn1,EC50,792.0,nM,6.10,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1338286,Nc1cc(N)nc(SCc2cc([N+](=O)[O-])cc3c2OCOC3)n1,EC50,1180.0,nM,5.93,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1479163,O=C(C(c1ccccc1)c1ccccc1)N1CCN(c2ccccn2)CC1,EC50,37.9,nM,7.42,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL3211107,C=CCc1ccc(OCCOc2ccc(/C=N/n3cnnc3)cc2OCC)c(OC)c1,EC50,587.0,nM,6.23,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1545591,CCCCOc1cccc(C(=O)Nc2ccc(NC(=O)c3ccco3)cc2)c1,EC50,222.0,nM,6.65,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1528594,CCOC(=O)c1ccc(NC(=O)COc2ccc(S(=O)(=O)N3CCCC3)cc2)cc1,EC50,391.0,nM,6.41,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1257092,CC(C)NC[C@@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O,EC50,393.0,nM,6.41,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1318405,CC(=O)Nc1ccc(S(=O)(=O)N2CCC(Oc3ccc(-n4cnnn4)cc3)CC2)cc1,EC50,126.0,nM,6.90,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1873201,CSc1ccc(CN2CCC(Oc3ccc(C(=O)N4CCCC4)cc3)CC2)cc1,EC50,1390.0,nM,5.86,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL295234,CC1=NCCc2c1[nH]c1ccccc21,EC50,2770.0,nM,5.56,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1365203,COc1ccc(S(=O)(=O)N2CCCC(C(=O)Nc3ccc(NC(=O)c4ccccn4)cc3)C2)cc1,EC50,80.9,nM,7.09,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1378598,Cc1ccc(N(C)S(=O)(=O)c2cc(-c3cnc(C4CC4)o3)ccc2C)cc1,EC50,2460.0,nM,5.61,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1378531,O=C(c1ccc(OC2CCN(Cc3ccc(F)cc3)CC2)cc1)N1CCCC1,EC50,1600.0,nM,5.80,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1490889,CN(c1ccccc1)S(=O)(=O)c1cccc(C(=O)Nc2cccc(C(=O)NC3CC3)c2)c1,EC50,575.0,nM,6.24,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1451649,CN(C)CCNc1ncnc2c1sc1nc(N3CCCC3)c3c(c12)CC(C)(C)OC3,EC50,4020.0,nM,5.40,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1727257,CCc1ccc(CN2CCC(Oc3ccc(C(=O)N4CCCCC4)cc3)CC2)cc1,EC50,1750.0,nM,5.76,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1256958,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O,EC50,1380.0,nM,5.86,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1557985,CCc1ccccc1N(C)S(=O)(=O)c1ccc2ncc(C(=O)O)c(O)c2c1,EC50,7230.0,nM,5.14,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1562748,COCCCNc1ncnc2c1sc1nc(-c3ccco3)c3c(c12)CC(C)(C)OC3,EC50,41.7,nM,7.38,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1422244,CCOC(=O)N1CCN(C(=O)CN(C)S(=O)(=O)c2ccc(Cl)cc2)CC1,EC50,1950.0,nM,5.71,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1562838,CC(=O)Nc1ccc(S(=O)(=O)N(Cc2ccco2)Cc2cc3ccccc3nc2O)cc1,EC50,4.64,nM,8.33,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1708092,CCOc1ccccc1C(=O)NCC(=O)OCc1csc(CC(=O)Nc2ccc(C)cc2)n1,EC50,228.0,nM,6.64,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1422222,O=C(c1ccc(OC2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)cc1)N1CCCCC1,EC50,2590.0,nM,5.59,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1484690,CCCCN(CCCC)c1nc2ccccc2nc1NS(=O)(=O)c1ccc(NC(C)=O)cc1,EC50,20.3,nM,7.69,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1519042,CC(C)(C)c1ccc(OCC(=O)Nc2ccc(-c3nc4cccnc4o3)cc2)cc1,EC50,67.2,nM,7.17,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL531401,CC(Oc1ccc(Cl)cc1Cl)c1nc(-c2ccc(NC(=O)c3ccco3)cc2)no1,EC50,7060.0,nM,5.15,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1539906,COc1ccc(C2=NN(C(=O)c3cccs3)C(c3ccc(OC)cc3)C2)cc1,EC50,4840.0,nM,5.32,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1585368,CCCCN(C(=O)c1ccc(NC(=O)C(C)C)cc1)c1ccccc1,EC50,49.0,nM,7.31,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1332942,O=C(Cc1ccccc1)NC1(Cc2ccc(O)cc2)CCCCC1,EC50,7470.0,nM,5.13,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1373276,Cc1ccc(-c2nc3ncccc3o2)cc1NC(=O)c1sc2ccccc2c1Cl,EC50,722.0,nM,6.14,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1709014,O=C(CCCCCn1c(=O)[nH]c2ccsc2c1=O)NCc1ccc(F)cc1,EC50,77.6,nM,7.11,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1379002,CN(CC(=O)N1CCN(c2ncccn2)CC1)S(=O)(=O)c1ccc(Cl)cc1,EC50,117.0,nM,6.93,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL104,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,EC50,4690.0,nM,5.33,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1437255,NC(=O)CC(NC(=O)Cc1ccc(Cl)cc1)c1ccc(NCCCN2CCCC2=O)c([N+](=O)[O-])c1,EC50,2200.0,nM,5.66,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1526751,COc1ccccc1-c1cc(C(F)(F)F)nc(S(=O)(=O)CCCC(=O)NC(C)C)n1,EC50,9330.0,nM,5.03,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1303120,COc1ccc([C@H]2/C=C\CN(Cc3ccc(N(C)C)cc3)[C@@H](C)C(=O)N2Cc2ccc(F)cc2)cc1,EC50,4360.0,nM,5.36,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1500954,CC(=O)N1c2ccccc2C(C)(c2ccccc2)CC1(C)C,EC50,9290.0,nM,5.03,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1339094,CC1(C)Cc2c(c(-c3ccco3)nc3sc4c(NCCO)ncnc4c23)CO1,EC50,13.3,nM,7.88,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1361693,Cc1cccc2nc(COc3ccc4ccccc4c3Br)cn12,EC50,3710.0,nM,5.43,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1383120,CCOC(=O)N1CCN(c2nnc(-c3ccc(C)cc3)c3ccccc23)CC1,EC50,1040.0,nM,5.98,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1329712,CCc1ccc(OCC(=O)Nc2ccc(-c3nc4ccccc4o3)c(O)c2)cc1,EC50,476.0,nM,6.32,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1318214,Nc1cccc(C#Cc2ccc3c(=O)c4ccccc4oc3c2)c1,EC50,245.0,nM,6.61,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1406272,COc1ccc(CSc2ccc(-c3nc4ccccn4c3NCc3ccccc3)cc2OC)cc1.O=C(O)C(F)(F)F,EC50,1320.0,nM,5.88,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1383213,Cc1cc(C)c2c(N)c(-c3nnc(SCc4ccc(Cl)cc4)n3C)sc2n1,EC50,252.0,nM,6.60,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1876406,COc1ccc(CN2CCC(Oc3ccc(C(=O)N4CCCC4)cc3)CC2)c(F)c1,EC50,4660.0,nM,5.33,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1333885,CN(Cc1cccs1)c1nc(-c2cccnc2)nc2ccccc12,EC50,1260.0,nM,5.90,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1479957,Cc1cc(C)n2nc(C(=O)Nc3cccc(S(=O)(=O)N(C)c4ccccc4)c3)nc2n1,EC50,34.2,nM,7.47,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1728955,CCOC(=O)c1cn(C2CC2)c2c(F)c(NCCCN(C)C)c(F)cc2c1=O,EC50,353.0,nM,6.45,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1524289,O=C(NC1(Cc2ccc(O)cc2)CCCCC1)c1ccccc1,EC50,7420.0,nM,5.13,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1461759,O=C(C[n+]1cccc(NC(=O)c2ccccc2)c1)c1ccc(NC(=O)c2ccccc2)cc1.[Br-],EC50,2760.0,nM,5.56,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1308099,Cn1c(CNc2nc(-c3ccccc3)cs2)nnc1SCC(=O)N1CCc2ccccc21,EC50,666.0,nM,6.18,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1082607,O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,EC50,4.49,nM,8.35,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1570251,COc1ccc(OC)c(CCNC(=O)C2CCN(c3nnc(-n4cccc4)s3)CC2)c1,EC50,2850.0,nM,5.54,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1429919,Cc1ccc(C(=O)OCC(=O)Nc2nc(-c3ccccc3)cs2)cc1NC(=O)c1ccco1,EC50,1410.0,nM,5.85,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1373386,C=CCn1c(CCNC(=O)c2cccs2)nnc1SCC(=O)c1ccc(Br)cc1,EC50,214.0,nM,6.67,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1410048,CCCc1ccc(OCc2nc(-c3ccc(NC(=O)c4ccco4)cc3)no2)cc1,EC50,161.0,nM,6.79,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1586182,CCn1c(SCC(=O)N2CCCC2)nnc1-c1ccc(N)cc1,EC50,2070.0,nM,5.68,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1569630,CC(C)=CCC(C)(C)C1OCCN1C(=O)c1ccccc1,EC50,3300.0,nM,5.48,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1327325,O=C(CSc1ccc(Cl)cc1)Nc1ccc(-c2nc3ncccc3o2)cc1,EC50,49.2,nM,7.31,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1334494,CCc1ccc(CNC(=O)c2ccc(NC(=O)C3=CSCCO3)cc2)cc1,EC50,94.9,nM,7.02,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1531826,CN(C)c1ccc(-c2noc(C3CCN(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc1,EC50,1230.0,nM,5.91,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1531814,COc1ccc(C2/C=C\CN(Cc3ccc(N(C)C)cc3)CC(=O)N2Cc2ccc(F)cc2)cc1,EC50,4340.0,nM,5.36,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1351178,O=C(NCCCn1ccnc1)C1CCCN(S(=O)(=O)c2cc(Cl)ccc2Cl)C1,EC50,999.0,nM,6.00,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1878737,CC1CCC(NC(=O)CCS(=O)(=O)c2ccc3c(c2)CCN3C(=O)C2CC2)CC1,EC50,522.0,nM,6.28,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1469574,CC1(C)Cc2c(c(-c3ccco3)nc3sc4c(NCC5CCCO5)ncnc4c23)CO1,EC50,91.9,nM,7.04,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1491674,O=C(CCCCCn1c(=O)[nH]c2ccsc2c1=O)NCc1ccc2c(c1)OCO2,EC50,39.3,nM,7.41,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1391134,CC(=O)c1ccc(OCc2cc(C(=O)N(C)CCOc3ccc(C)cc3)no2)cc1,EC50,1910.0,nM,5.72,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1569866,CN(CC(=O)N1CCN(c2ccccn2)CC1)S(=O)(=O)c1ccccc1,EC50,274.0,nM,6.56,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1449091,CC(Sc1nc(-c2ccccc2)cc(C(F)(F)F)n1)C(=O)N1CCCC1,EC50,243.0,nM,6.61,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL417709,O=C1C2CCCCN2C(=O)N1CCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1,EC50,2520.0,nM,5.60,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1590854,NC(=O)CC(NC(=O)Cc1cccc2ccccc12)c1ccc(NCCCN2CCCC2=O)c([N+](=O)[O-])c1,EC50,801.0,nM,6.10,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1548237,O=C(CN1C(=O)CCC1=O)Nc1nc(-c2nc3ccccc3s2)cs1,EC50,44.4,nM,7.35,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1452334,O=C(c1cc2c(=O)n3ccccc3nc2s1)N1CCN(Cc2ccc3c(c2)OCO3)CC1,EC50,69.3,nM,7.16,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1559039,CCOC(=O)c1ccc(N2C(=O)c3[nH]nc(-c4ccco4)c3C2c2cccc([N+](=O)[O-])c2)cc1,EC50,571.0,nM,6.24,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1532219,CCOC(=O)c1ccc(NC(=O)Cn2nnc(-c3ccccc3)n2)cc1,EC50,1180.0,nM,5.93,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1322514,CCC(=O)N1CCc2cc(Br)cc(S(=O)(=O)N(C)c3ccc(OC)cc3)c21,EC50,27.1,nM,7.57,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1431082,CCOC(=O)c1ccc(NC(=O)Cc2coc3cc4c(cc23)CCC4)cc1,EC50,7530.0,nM,5.12,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1414874,NC(=O)CC(NC(=O)c1cccc(Br)c1)c1ccc(N2CCN(c3ccccn3)CC2)c([N+](=O)[O-])c1,EC50,225.0,nM,6.65,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1881705,CCC(=O)c1ccc(OCC(=O)N2CCN(CC(=O)Nc3ccc(C)cc3)CC2)cc1,EC50,64.6,nM,7.19,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1531486,O=S(=O)(c1cc(C(F)(F)F)ccc1Cl)N1CCN(CC(O)COCC2CCCO2)CC1,EC50,4150.0,nM,5.38,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1327806,Cc1ccc(OCc2cc(C(=O)N(C)Cc3cnn(-c4ccccc4C)c3)no2)cn1,EC50,305.0,nM,6.52,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1375364,CN(Cc1ccccc1)S(=O)(=O)c1ccc(NS(=O)(=O)Cc2ccccc2)cc1,EC50,1250.0,nM,5.90,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1541608,CC(Sc1nc(-c2ccccc2)cc(C(F)(F)F)n1)C(=O)N1CCOCC1,EC50,43.5,nM,7.36,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1392252,CC(=O)c1cccc(S(=O)(=O)N2CCCC(c3nc(-c4ccc(C)o4)no3)C2)c1,EC50,143.0,nM,6.84,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1902287,CC(Cc1ccc(O)cc1)NCC(O)c1ccc(O)c(O)c1.O=C(O)c1ccccc1,EC50,553.0,nM,6.26,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1436649,COc1cc2ncc(S(=O)(=O)c3ccccc3)c(N3CCCC(C)C3)c2cc1OC,EC50,1070.0,nM,5.97,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1510834,COC(=O)c1ccc(NC(=O)COc2ccc(S(=O)(=O)N3CCCCC3)cc2)cc1,EC50,590.0,nM,6.23,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1714856,COC(=O)C1=C(c2cccc(OCc3ccccc3)c2)C[C@@H]2CC[C@H]1N2C(=O)NCc1cccc(F)c1,EC50,4800.0,nM,5.32,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1368962,O=C(Nc1ccc2nc(SCc3ccc(Cl)cc3)sc2c1)c1ccccc1C(=O)N1CCOCC1,EC50,1740.0,nM,5.76,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1424697,Cc1ccc(-c2nc(NC(=O)c3nn(C)cc3[N+](=O)[O-])sc2C)cc1,EC50,8090.0,nM,5.09,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1415227,c1nc(NCCN2CCOCC2)c2sc3nc(N4CCOCC4)c4c(c3c2n1)CCC4,EC50,3340.0,nM,5.48,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1735137,COc1ccc([C@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1.O=C(O)/C=C/C(=O)O,EC50,10.8,nM,7.97,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1396351,Cn1nnnc1Sc1ncnc2scc(-c3ccc(Cl)cc3)c12,EC50,8380.0,nM,5.08,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1559831,NC(=O)CC(NC(=O)c1ccc(Br)cc1)c1ccc(N2CCN(c3ccccn3)CC2)c([N+](=O)[O-])c1,EC50,213.0,nM,6.67,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1424678,CCOC(=O)c1ccc(NC(=O)Cn2nnc(-c3ccc(C)cc3)n2)cc1,EC50,158.0,nM,6.80,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1598434,CN(CC(=O)N1CCN(c2ccccn2)CC1)S(=O)(=O)c1ccc(Cl)cc1,EC50,39.6,nM,7.40,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1313270,CCOc1ccc(NC(=O)CNC(=O)c2nn(-c3ccc(OC)c(OC)c3)c(=O)c3ccccc23)cc1,EC50,6570.0,nM,5.18,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1581044,CC(=O)Nc1ccc(S(=O)(=O)NCCc2csc(-c3cccnc3)n2)cc1,EC50,162.0,nM,6.79,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1581214,CC(=O)Nc1cc(C(=O)OC(C(=O)c2ccccc2)c2ccccc2)ccc1C,EC50,402.0,nM,6.40,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1405897,COc1cc(OC)nc(NC(=O)CSc2nnc(-c3ccccc3)n2C2CCCCC2)n1,EC50,1050.0,nM,5.98,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1472233,CC(Sc1nc(-c2ccccc2)cc(C(F)(F)F)n1)C(=O)N1CCCCC1,EC50,214.0,nM,6.67,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1200833,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1.Cl,EC50,7130.0,nM,5.15,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1345891,O=C(Nc1ccc(S(=O)(=O)N2CCCCC2c2cccnc2)cc1)c1c(F)cccc1F,EC50,2460.0,nM,5.61,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1886907,O=C(COc1ccccc1F)N1c2ccccc2CCc2ccccc21,EC50,1600.0,nM,5.80,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1393806,COCCc1ncc(CN2CCC(C(=O)Nc3ccc(-n4cccn4)cc3)CC2)cn1,EC50,1290.0,nM,5.89,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1305925,CC1=C(C(=O)Nc2ccc(C(=O)N3CCN(c4ccccc4F)CC3)cc2)SCCO1,EC50,3010.0,nM,5.52,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1462616,CC(=O)N1CCc2cc(C(=O)CN3CCN(c4cccc(Cl)c4)CC3)ccc21,EC50,47.2,nM,7.33,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL1201153,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1.CS(=O)(=O)O,EC50,3840.0,nM,5.42,CHEMBL1794581,"PUBCHEM_BIOASSAY: Dose response for HTS for Beta-2AR agonists via FAP method from CP1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485366, AID492947, AID504448]",F,Homo sapiens
CHEMBL24,CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,IC50,14634.0,nM,4.83,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL357995,Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1,IC50,20.0,nM,7.70,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL117405,CC(C)NC[C@H](O)COc1cccc2[nH]ccc12,IC50,1.571,nM,8.80,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL442,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,IC50,2761.0,nM,5.56,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL707,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,IC50,2748.0,nM,5.56,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL1902627,CC(C)NCC(O)c1ccccc1Cl,IC50,1993.0,nM,5.70,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL926,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,IC50,1517.0,nM,5.82,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL723,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,IC50,0.241,nM,9.62,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL275742,CC(C)NC[C@@H](O)COc1cccc2ccccc12,IC50,76.0,nM,7.12,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL631,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,IC50,52.0,nM,7.28,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL1201237,CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O,IC50,0.793,nM,9.10,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL13,COCCc1ccc(OCC(O)CNC(C)C)cc1,IC50,2573.0,nM,5.59,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL157138,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,IC50,41.0,nM,7.39,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL787,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,IC50,3488.0,nM,5.46,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL429,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1,IC50,16.0,nM,7.80,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL841,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,IC50,3005.0,nM,5.52,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL471,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,IC50,433.9,nM,6.36,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL452861,CC(C)NC[C@H](O)COc1cccc2ccccc12,IC50,0.355,nM,9.45,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL499,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,IC50,0.292,nM,9.54,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL1630578,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1,IC50,22659.0,nM,4.64,CHEMBL1909092,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),B,Homo sapiens
CHEMBL2068577,CC(C)(C)NC[C@H](O)c1ccc2c(c1)C[OH+][B-](O)(c1ccccc1)O2,Ki,6607.0,nM,5.18,CHEMBL1937030,Displacement of [3H]-DHA from recombinant human beta2 adrenoceptor expressed in HEK293T cells,B,Homo sapiens
CHEMBL2068576,CC(C)(C)NC[C@H](O)c1ccc2c(c1)C[OH+][B-](O)(O)O2,Ki,3890.0,nM,5.41,CHEMBL1937030,Displacement of [3H]-DHA from recombinant human beta2 adrenoceptor expressed in HEK293T cells,B,Homo sapiens
CHEMBL1002,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,Ki,5623.0,nM,5.25,CHEMBL1937030,Displacement of [3H]-DHA from recombinant human beta2 adrenoceptor expressed in HEK293T cells,B,Homo sapiens
CHEMBL1940682,OCc1cc(C(O)CNCCCCNCC(O)c2ccc(O)c(CO)c2)ccc1O,IC50,10000.0,nM,5.00,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940683,OCc1cc(C(O)CNCCCCCCNCC(O)c2ccc(O)c(CO)c2)ccc1O,IC50,7943.28,nM,5.10,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940685,OCc1cc(C(O)CNC2CCC(CC3CCC(NCC(O)c4ccc(O)c(CO)c4)CC3)CC2)ccc1O,IC50,19952.62,nM,4.70,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940686,OCc1cc(C(O)CN[C@H]2CC[C@H](NCC(O)c3ccc(O)c(CO)c3)CC2)ccc1O,IC50,5011.87,nM,5.30,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940808,OCc1cc(C(O)CNCC2CCCC(CNCC(O)c3ccc(O)c(CO)c3)C2)ccc1O,IC50,10000.0,nM,5.00,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940809,OCc1cc(C(O)CNCc2ccc(CNCC(O)c3ccc(O)c(CO)c3)cc2)ccc1O,IC50,50118.72,nM,4.30,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940810,OCc1cc(C(O)CNCc2cccc(CNCC(O)c3ccc(O)c(CO)c3)c2)ccc1O,IC50,19952.62,nM,4.70,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940811,OCc1cc(C(O)CNCCc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)ccc1O,IC50,100000.0,nM,4.00,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940812,OCc1cc(C(O)CNCCc2ccc(NCC(O)c3ccc(O)c(CO)c3)cc2)ccc1O,IC50,251.19,nM,6.60,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940813,OCc1cc(C(O)CNCc2ccc(NCC(O)c3ccc(O)c(CO)c3)cc2)ccc1O,IC50,1995.26,nM,5.70,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940814,OC(CNCCc1ccc(NCC(O)c2ccccc2)cc1)c1ccccc1,IC50,251.19,nM,6.60,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940815,OCc1cc(C(O)CNCCc2ccc(NCC(O)c3ccccc3)cc2)ccc1O,IC50,39.81,nM,7.40,CHEMBL1943767,Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting,B,Homo sapiens
CHEMBL1940816,OCc1cc(C(O)CNCCc2ccc(OCC(O)c3ccccc3)cc2)ccc1O,EC50,0.3981,nM,9.40,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940817,CC(C)(Cc1ccc(NCC(O)c2ccccc2)cc1)NCC(O)c1ccc(O)c(CO)c1,EC50,0.3162,nM,9.50,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940818,CN(CC(O)c1ccccc1)c1ccc(CCNCC(O)c2ccc(O)c(CO)c2)cc1,EC50,1.995,nM,8.70,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940819,OCc1cc(C(O)CNC2Cc3ccc(NCC(O)c4ccccc4)cc3C2)ccc1O,EC50,5.012,nM,8.30,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940820,OCc1cc(C(O)CNCCc2ccc(NCC(O)c3ccc(Cl)cc3)cc2)ccc1O,EC50,1.585,nM,8.80,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940821,OCc1cc(C(O)CNCCc2ccc(NCC(O)c3ccc(F)cc3)cc2)ccc1O,EC50,1.995,nM,8.70,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940822,COc1ccc(C(O)CNc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)c(OC)c1,EC50,39.81,nM,7.40,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940823,COc1ccc(OC)c(C(O)CNc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)c1,EC50,6.31,nM,8.20,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940824,OCc1cc(C(O)CNCCc2ccc(NCC(O)c3ccc(O)cc3)cc2)ccc1O,EC50,7.943,nM,8.10,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940825,Cc1ccc(C(O)CNc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)cc1,EC50,2.512,nM,8.60,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940826,CC(C)(C)c1ccc(C(O)CNc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)cc1,EC50,50.12,nM,7.30,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940827,CC(C)CCc1ccc(C(O)CNc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)cc1,EC50,63.1,nM,7.20,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940828,OCc1cc(C(O)CNCCc2ccc(NCC(O)c3ccc(-c4ccccc4)cc3)cc2)ccc1O,EC50,39.81,nM,7.40,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940829,OCc1cc(C(O)CNCCc2ccc(NCC(O)c3ccc4ccccc4c3)cc2)ccc1O,EC50,50.12,nM,7.30,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940830,OCc1cc([C@@H](O)CNCCc2ccc(NC[C@H](O)c3ccccc3)cc2)ccc1O,EC50,0.1,nM,10.00,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940831,OCc1cc([C@@H](O)CNCCc2ccc(NC[C@@H](O)c3ccccc3)cc2)ccc1O,EC50,0.3162,nM,9.50,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940832,O=CNc1cc([C@@H](O)CNCCc2ccc(NC[C@H](O)c3ccccc3)cc2)ccc1O,EC50,0.0631,nM,10.20,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940833,O=c1ccc2c([C@@H](O)CNCCc3ccc(NC[C@H](O)c4ccccc4)cc3)ccc(O)c2[nH]1,EC50,0.1259,nM,9.90,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1940834,Nc1c(Cl)cc([C@@H](O)CNCCc2ccc(NC[C@H](O)c3ccccc3)cc2)cc1Cl,EC50,0.3981,nM,9.40,CHEMBL1943768,Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay,F,Homo sapiens
CHEMBL1946761,O=c1[nH]c2c(O)ccc(CCNCCc3ccc(CNCCc4c(Cl)cccc4Cl)cc3)c2s1,EC50,100.0,nM,7.00,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1946762,O=c1[nH]c2c(O)ccc(CCNCCc3ccc(CNCCc4ccccc4F)cc3)c2s1,EC50,79.43,nM,7.10,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1946763,O=c1[nH]c2c(O)ccc(CCNCCc3ccc(CNCCc4ccccn4)cc3)c2s1,EC50,158.49,nM,6.80,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1946764,O=c1[nH]c2c(O)ccc(CCNCCc3ccc(CN4CC[C@@H](Oc5ccc(Cl)cc5)C4)cc3)c2s1,EC50,158.49,nM,6.80,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1946765,O=c1[nH]c2c(O)ccc(CCNCCc3cccc(CN[C@H]4C[C@@H]4c4ccccc4)c3)c2s1,EC50,3.981,nM,8.40,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1946766,CCN(Cc1ccncc1)Cc1cccc(-c2ccc(CCNCCc3ccc(O)c4[nH]c(=O)sc34)cc2)c1,EC50,316.23,nM,6.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1947153,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CN4CCC(c5ccccc5)CC4)c3)c2s1,EC50,1.0,nM,9.00,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1947154,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(-c4cccc(CN5Cc6ccccc6C5)c4)cc3)c2s1,EC50,10.0,nM,8.00,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1947155,C[C@@H](NCc1ccccc1-c1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1)c1ccccc1,EC50,3.981,nM,8.40,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1947156,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(-c4cccc(CNCc5ccccc5)c4)c3)c2s1,EC50,0.631,nM,9.20,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1947157,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4c(Cl)cccc4Cl)c3)c2s1,EC50,0.5012,nM,9.30,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1944689,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(CNCCc4c(Cl)cccc4Cl)cc3)c2s1,EC50,0.3162,nM,9.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1944690,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4ccccc4Cl)c3)c2s1,EC50,0.2512,nM,9.60,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1944691,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4ccccc4F)c3)c2s1,EC50,0.1585,nM,9.80,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1944692,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(CNCCc4ccccc4F)cc3)c2s1,EC50,0.3981,nM,9.40,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1944693,COc1ccccc1CCNCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,EC50,0.3162,nM,9.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1944694,COc1ccccc1CCNCc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,EC50,0.3162,nM,9.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1944695,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(CNCCc4ccccc4)cc3)c2s1,EC50,0.2512,nM,9.60,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945031,Cc1cccc2c(CCNCc3cccc(CCNC[C@H](O)c4ccc(O)c5[nH]c(=O)sc45)c3)c[nH]c12,EC50,0.3162,nM,9.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945032,Cc1cccc2c(CCNCc3ccc(CCNC[C@H](O)c4ccc(O)c5[nH]c(=O)sc45)cc3)c[nH]c12,EC50,0.2512,nM,9.60,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945033,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4ccccn4)c3)c2s1,EC50,0.5012,nM,9.30,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945034,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(CNCCc4ccccn4)cc3)c2s1,EC50,0.1995,nM,9.70,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945035,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccccc3CNCCc3ccccc3F)c2s1,EC50,1.585,nM,8.80,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945036,CC(CNCc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1)c1ccccc1,EC50,0.3981,nM,9.40,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945037,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCCc4ccccc4)c3)c2s1,EC50,0.5012,nM,9.30,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945038,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCCc4ccccn4)c3)c2s1,EC50,1.0,nM,9.00,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945039,COc1ccccc1CNCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,EC50,0.631,nM,9.20,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945040,COc1ccccc1CNCc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,EC50,3.162,nM,8.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945041,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCc4ccccc4Cl)c3)c2s1,EC50,0.3162,nM,9.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945042,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCc4ccccc4F)c3)c2s1,EC50,0.631,nM,9.20,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945043,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCc4ccccn4)c3)c2s1,EC50,0.631,nM,9.20,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945044,COc1cccc(CNCc2cccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)sc34)c2)c1,EC50,1.0,nM,9.00,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945289,COc1ccc(CNCc2cccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)sc34)c2)cc1,EC50,0.7943,nM,9.10,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945290,CCOc1ccccc1CNCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,EC50,3.162,nM,8.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945291,COc1ccccc1CN(C)Cc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,EC50,3.162,nM,8.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945292,COCCNCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,EC50,1.995,nM,8.70,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945293,COCCNCc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,EC50,15.85,nM,7.80,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945294,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CN4CCCC4)c3)c2s1,EC50,0.631,nM,9.20,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945295,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(CN4CCCC4)cc3)c2s1,EC50,39.81,nM,7.40,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945296,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCc3cccc(CNCCc4c(Cl)cccc4Cl)c3)c2s1,EC50,1.259,nM,8.90,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945297,CC(Cc1cccc(CNCCc2c(Cl)cccc2Cl)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12,EC50,0.7943,nM,9.10,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945298,O=c1[nH]c2c(O)ccc([C@@H](O)CNCCOc3cccc(CNCCc4ccccc4F)c3)c2s1,EC50,2.512,nM,8.60,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945299,COc1ccccc1CNCCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,EC50,0.3981,nM,9.40,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945300,OCc1cc([C@@H](O)CNCCc2ccc(CNCCc3ccccc3)cc2)ccc1O,EC50,31.62,nM,7.50,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945503,O=c1ccc2c([C@@H](O)CNCCc3cccc(CNCCc4ccccn4)c3)ccc(O)c2[nH]1,EC50,2.512,nM,8.60,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1945504,COc1ccccc1CNCc1ccc(CCNC[C@@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,EC50,7.943,nM,8.10,CHEMBL1947789,Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry,F,Homo sapiens
CHEMBL1946767,COc1ccccc1CCNCc1ccc(CCNCCc2ccc(O)c3[nH]c(=O)sc23)cc1,IC50,199.53,nM,6.70,CHEMBL1947791,Displacement of radiolabeled iodocyanopindolol from recombinant beta2 adrenoceptor,B,Homo sapiens
CHEMBL1946768,O=c1[nH]c2c(O)ccc(CCNCCc3cccc(CNCCc4c(Cl)cccc4Cl)c3)c2s1,IC50,0.631,nM,9.20,CHEMBL1947791,Displacement of radiolabeled iodocyanopindolol from recombinant beta2 adrenoceptor,B,Homo sapiens
CHEMBL1946769,O=c1[nH]c2c(O)ccc(CCNCCc3cccc(CN4CCC(c5ccccc5)CC4)c3)c2s1,IC50,31.62,nM,7.50,CHEMBL1947791,Displacement of radiolabeled iodocyanopindolol from recombinant beta2 adrenoceptor,B,Homo sapiens
CHEMBL1947150,O=c1[nH]c2c(O)ccc(CCNCCc3ccc(-c4cccc(CN5Cc6ccccc6C5)c4)cc3)c2s1,IC50,15.85,nM,7.80,CHEMBL1947791,Displacement of radiolabeled iodocyanopindolol from recombinant beta2 adrenoceptor,B,Homo sapiens
CHEMBL1947151,C[C@@H](NCc1ccccc1-c1ccc(CCNCCc2ccc(O)c3[nH]c(=O)sc23)cc1)c1ccccc1,IC50,0.7943,nM,9.10,CHEMBL1947791,Displacement of radiolabeled iodocyanopindolol from recombinant beta2 adrenoceptor,B,Homo sapiens
CHEMBL1947152,O=c1[nH]c2c(O)ccc(CCNCCc3cccc(-c4cccc(CNCc5ccccc5)c4)c3)c2s1,IC50,31.62,nM,7.50,CHEMBL1947791,Displacement of radiolabeled iodocyanopindolol from recombinant beta2 adrenoceptor,B,Homo sapiens
CHEMBL2012522,CC(C)(Cc1ccc(Oc2ccc(C(N)=O)cn2)cc1)NC[C@H](O)COc1cccc2[nH]c3ccccc3c12.O=C(O)CCC(=O)O,Ki,0.012,nM,10.92,CHEMBL2015443,Displacement of [125I]Iodocyanopindolol from human adrenergic beta2 receptor expressed in insect sf9 cells by scintillation counting,B,Homo sapiens
CHEMBL2070835,Cc1nc2c(CN(C)C)c(O)ccc2[nH]1,Ki,25118.86,nM,4.60,CHEMBL2073147,Displacement of [3H]dihydroalprenolol from human ADRB2 expressed in HEK293T cells after 1 hr by liquid scintillation counter,B,Homo sapiens
CHEMBL1622248,CC(=O)c1c(CSc2ccccc2)oc2ccc(O)c(CN(C)C)c12,Ki,39810.72,nM,4.40,CHEMBL2073147,Displacement of [3H]dihydroalprenolol from human ADRB2 expressed in HEK293T cells after 1 hr by liquid scintillation counter,B,Homo sapiens
CHEMBL1620339,Cc1ccc(C(C)C)c(OCC(O)CN2CCN(CCO)CC2)c1,Ki,39810.72,nM,4.40,CHEMBL2073147,Displacement of [3H]dihydroalprenolol from human ADRB2 expressed in HEK293T cells after 1 hr by liquid scintillation counter,B,Homo sapiens
CHEMBL1907082,Cc1ccc(C)c(OCC(O)CNC2CCCC2)c1,Ki,1995.26,nM,5.70,CHEMBL2073147,Displacement of [3H]dihydroalprenolol from human ADRB2 expressed in HEK293T cells after 1 hr by liquid scintillation counter,B,Homo sapiens
CHEMBL2070834,Cc1ccc(C(C)C)c(OCC(O)CN2CCCCC2)c1,Ki,794.33,nM,6.10,CHEMBL2073147,Displacement of [3H]dihydroalprenolol from human ADRB2 expressed in HEK293T cells after 1 hr by liquid scintillation counter,B,Homo sapiens
CHEMBL2088195,CCc1cc2c(cc1CC)CC(NCC(O)c1c(C)cc(O)c3[nH]c(=O)ccc13)C2,Ki,515.0,nM,6.29,CHEMBL2091584,Binding affinity to human beta2-adrenoceptor by radioligand binding assay,B,Homo sapiens
CHEMBL2088196,CCc1cc2c(cc1CC)CC(NCC(O)c1ccc(O)c3[nH]c(=O)c(C)cc13)C2,Ki,382.0,nM,6.42,CHEMBL2091584,Binding affinity to human beta2-adrenoceptor by radioligand binding assay,B,Homo sapiens
CHEMBL2088197,CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3c1CCC(=O)N3)C2,Ki,45.0,nM,7.35,CHEMBL2091584,Binding affinity to human beta2-adrenoceptor by radioligand binding assay,B,Homo sapiens
CHEMBL2088198,CCc1cc2c(cc1CC)CC(NCCc1ccc(O)c3[nH]c(=O)ccc13)C2,Ki,261.0,nM,6.58,CHEMBL2091584,Binding affinity to human beta2-adrenoceptor by radioligand binding assay,B,Homo sapiens
CHEMBL2088199,CCCCc1ccc2c(c1)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,Ki,19.4,nM,7.71,CHEMBL2091584,Binding affinity to human beta2-adrenoceptor by radioligand binding assay,B,Homo sapiens
CHEMBL2088200,Cc1c(C)c(C)c2c(c1C)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,Ki,175.0,nM,6.76,CHEMBL2091584,Binding affinity to human beta2-adrenoceptor by radioligand binding assay,B,Homo sapiens
CHEMBL2088201,CCc1cc2c(cc1CC)CC(C)(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,Ki,0.6,nM,9.22,CHEMBL2091584,Binding affinity to human beta2-adrenoceptor by radioligand binding assay,B,Homo sapiens
CHEMBL2088202,CCC1=C(CC)CC2=C(C1)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,Ki,76.6,nM,7.12,CHEMBL2091584,Binding affinity to human beta2-adrenoceptor by radioligand binding assay,B,Homo sapiens
CHEMBL2204360,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1.Cl,Ki,560.0,nM,6.25,CHEMBL2215359,Binding affinity to human beta 2 adrenergic receptor,B,Homo sapiens
CHEMBL416012,COc1cccc2c(CC(C)NC[C@H](O)c3cccc(Cl)c3)c[nH]c12,EC50,5.2,nM,8.28,CHEMBL3059445,Agonist activity at Homo sapiens (human) beta2 adrenoreceptor,F,Homo sapiens
CHEMBL282190,CC(Cc1c[nH]c2c(OCC(=O)O)cccc12)NC[C@H](O)c1cccc(Cl)c1,EC50,13.0,nM,7.89,CHEMBL3059445,Agonist activity at Homo sapiens (human) beta2 adrenoreceptor,F,Homo sapiens
CHEMBL2261203,CCN(CC)C(=O)COc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)c[nH]c12,EC50,19.0,nM,7.72,CHEMBL3059445,Agonist activity at Homo sapiens (human) beta2 adrenoreceptor,F,Homo sapiens
CHEMBL2260984,CCOC(=O)S(=O)(=O)Oc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)c[nH]c12,EC50,58.0,nM,7.24,CHEMBL3059445,Agonist activity at Homo sapiens (human) beta2 adrenoreceptor,F,Homo sapiens
CHEMBL2260985,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccc(N)c2)c1,EC50,26.0,nM,7.58,CHEMBL3059445,Agonist activity at Homo sapiens (human) beta2 adrenoreceptor,F,Homo sapiens
CHEMBL2260986,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1,EC50,13.0,nM,7.89,CHEMBL3059445,Agonist activity at Homo sapiens (human) beta2 adrenoreceptor,F,Homo sapiens
CHEMBL2260987,C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1ccc(C(=O)Nc2ccccc2)cc1,EC50,120.0,nM,6.92,CHEMBL3059445,Agonist activity at Homo sapiens (human) beta2 adrenoreceptor,F,Homo sapiens
CHEMBL2260988,COc1cccc2c(C[C@@H](C)NC[C@H](O)c3cccc(NS(=O)(=O)c4cccs4)c3)cn(Cc3ccccc3)c12,EC50,32.0,nM,7.50,CHEMBL3059445,Agonist activity at Homo sapiens (human) beta2 adrenoreceptor,F,Homo sapiens
CHEMBL2260989,C[C@H](Cc1cn2c3c(cccc13)OCCC2)NC[C@H](O)c1cccc(NS(=O)(=O)c2cccs2)c1,EC50,53.0,nM,7.28,CHEMBL3059445,Agonist activity at Homo sapiens (human) beta2 adrenoreceptor,F,Homo sapiens
CHEMBL1374751,CC(C)NCC(O)c1ccc(N)c(C#N)c1,EC50,10000.0,nM,5.00,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL2348201,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1cccc(Cl)c1,EC50,10000.0,nM,5.00,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL2348211,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccccc1,EC50,10000.0,nM,5.00,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL2348217,CCOCCOc1ccc(OCC(O)CNCCNC(=O)Nc2ccc(O)cc2)cc1,EC50,10000.0,nM,5.00,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL2348218,O=C(NCCNCC(O)COc1ccc(OCCOCCc2ccc(F)cc2)cc1)Nc1ccc(O)cc1,EC50,10000.0,nM,5.00,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL2348219,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccc(O)cc1,EC50,10000.0,nM,5.00,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL2348220,O=C(NCCNCC(O)COc1ccc(OCCOCC2CC2)cc1)Nc1ccc(O)cc1.O=CO,EC50,10000.0,nM,5.00,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL207802,N#Cc1cc(OCCOCC2CC2)ccc1OCC(O)CNCCNC(=O)Nc1ccc(O)cc1,EC50,10000.0,nM,5.00,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL3392321,N#Cc1ccccc1OCC(O)CNCCNC(=O)Nc1ccccc1.O,EC50,60.26,nM,7.22,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL75753,O=C(NCCNCC(O)COc1ccc(O)cc1)N1CCOCC1,EC50,707.95,nM,6.15,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL280822,Cn1cc(C(F)(F)F)nc1-c1ccc(OCC(O)CNCCOc2ccc(O)c(C(N)=O)c2)cc1,EC50,10000.0,nM,5.00,CHEMBL2351580,Agonist activity at human beta2 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs,F,Homo sapiens
CHEMBL2348210,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1cccc(O)c1,Kd,1412.54,nM,5.85,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348209,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccccc1O,Kd,1096.48,nM,5.96,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348208,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccc(C(F)(F)F)cc1,Kd,1737.8,nM,5.76,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348207,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1cccc(C(F)(F)F)c1,Kd,1380.38,nM,5.86,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348206,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccccc1C(F)(F)F,Kd,1445.44,nM,5.84,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348205,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccc(Br)cc1,Kd,1380.38,nM,5.86,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348204,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1cccc(Br)c1,Kd,1023.29,nM,5.99,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348203,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccccc1Br,Kd,794.33,nM,6.10,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348202,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccc(Cl)cc1,Kd,1230.27,nM,5.91,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348200,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccccc1Cl,Kd,2884.03,nM,5.54,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348199,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccc(F)cc1,Kd,1202.26,nM,5.92,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348198,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1cccc(F)c1,Kd,288.4,nM,6.54,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348197,O=C(NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1)Nc1ccccc1F,Kd,1148.15,nM,5.94,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348196,COc1ccc(NC(=O)NCCNCC(O)COc2ccc(OCCOC3CCCC3)cc2)cc1,Kd,1380.38,nM,5.86,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348216,COc1cccc(NC(=O)NCCNCC(O)COc2ccc(OCCOC3CCCC3)cc2)c1,Kd,891.25,nM,6.05,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348215,COc1ccccc1NC(=O)NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1,Kd,1174.9,nM,5.93,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348214,Cc1ccc(NC(=O)NCCNCC(O)COc2ccc(OCCOC3CCCC3)cc2)cc1,Kd,1584.89,nM,5.80,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348213,Cc1cccc(NC(=O)NCCNCC(O)COc2ccc(OCCOC3CCCC3)cc2)c1,Kd,870.96,nM,6.06,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL2348212,Cc1ccccc1NC(=O)NCCNCC(O)COc1ccc(OCCOC2CCCC2)cc1,Kd,537.03,nM,6.27,CHEMBL2351860,Displacement of [3H]-CGP12177 from human beta2 adrenoceptor expressed in CHOK1 cells after 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL1326167,CSc1nc(SCCO)c2sc3nc(-c4ccco4)c4c(c3c2n1)CC(C)(C)OC4,EC50,1810.0,nM,5.74,CHEMBL1964068,PubChem BioAssay. Dose response for HTS for Beta-2AR agonists via FAP method from Powderset3. (Class of assay: confirmatory) ,F,Homo sapiens
CHEMBL1483555,Clc1cccc(-c2nnc(SCc3nc4ccccc4[nH]3)n2Cc2ccco2)c1,EC50,8090.0,nM,5.09,CHEMBL1964068,PubChem BioAssay. Dose response for HTS for Beta-2AR agonists via FAP method from Powderset3. (Class of assay: confirmatory) ,F,Homo sapiens
CHEMBL32800,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,Kd,100.0,nM,7.00,CHEMBL2426847,Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM,B,Homo sapiens
CHEMBL489553,C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1,Kd,0.5012,nM,9.30,CHEMBL2426847,Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM,B,Homo sapiens
CHEMBL160519,CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,Kd,79.43,nM,7.10,CHEMBL2426847,Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM,B,Homo sapiens
CHEMBL2426777,CCC(NC1CCCC1)C(O)c1ccc(O)c(O)c1,Kd,10.0,nM,8.00,CHEMBL2426847,Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM,B,Homo sapiens
CHEMBL1201213,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1,Kd,1000.0,nM,6.00,CHEMBL2426847,Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM,B,Homo sapiens
CHEMBL339069,c1cc(N2CCNCC2)ccn1,Kd,141600.0,nM,3.85,CHEMBL2445017,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis in presence of maltose neopentyl glycol,B,Homo sapiens
CHEMBL2441617,Cc1ccc2nc(C(F)(F)F)cc(N3CCC(F)(F)CC3)c2c1,Kd,67100.0,nM,4.17,CHEMBL2445017,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis in presence of maltose neopentyl glycol,B,Homo sapiens
CHEMBL2441616,Cc1ccc2nc(C(F)(F)F)cc(N3CCN(C)CC3)c2c1,Kd,1800.0,nM,5.75,CHEMBL2445017,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis in presence of maltose neopentyl glycol,B,Homo sapiens
CHEMBL2441615,FC(F)(F)c1ccc2c(N3CCNCC3)ccnc2c1,Kd,8000.0,nM,5.10,CHEMBL2445017,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis in presence of maltose neopentyl glycol,B,Homo sapiens
CHEMBL1892158,FC(F)(F)c1cc(N2CCNCC2)c2ccccc2n1,Kd,84.2,nM,7.08,CHEMBL2445017,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis in presence of maltose neopentyl glycol,B,Homo sapiens
CHEMBL2441621,c1ccc2c(N3CCNCC3)ccnc2c1,Kd,348.3,nM,6.46,CHEMBL2445017,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis in presence of maltose neopentyl glycol,B,Homo sapiens
CHEMBL236696,Clc1ccc2c(N3CCNCC3)ccnc2c1,Kd,76.5,nM,7.12,CHEMBL2445017,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis in presence of maltose neopentyl glycol,B,Homo sapiens
CHEMBL2335165,Cc1cc(N2CCNCC2)c2ccccc2n1,Kd,72.5,nM,7.14,CHEMBL2445017,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis in presence of maltose neopentyl glycol,B,Homo sapiens
CHEMBL2441619,Cc1ccc2nc(C(F)(F)F)cc(N3CCNCC3)c2c1,Kd,39.0,nM,7.41,CHEMBL2445017,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis in presence of maltose neopentyl glycol,B,Homo sapiens
CHEMBL2441620,Clc1cncc(Cl)c1N1CCNCC1,Kd,3500.0,nM,5.46,CHEMBL2445023,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis,B,Homo sapiens
CHEMBL15988,c1ccc2c(C3CCNCC3)c[nH]c2c1,Kd,22200.0,nM,4.65,CHEMBL2445023,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis,B,Homo sapiens
CHEMBL1363,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,EC50,0.3162,nM,9.50,CHEMBL3100396,Agonist activity at beta2-adrenergic receptor (unknown origin),F,Homo sapiens
CHEMBL3099658,COc1ccc(CCNC[C@@H](O)c2cc(O)cc(O)c2)cc1,Ki,1150.8,nM,5.94,CHEMBL3100637,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",B,Homo sapiens
CHEMBL3099657,COc1ccc(CCNC[C@H](O)c2cc(O)cc(O)c2)cc1,Ki,100.93,nM,7.00,CHEMBL3100637,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",B,Homo sapiens
CHEMBL3099664,CCC[C@@H](Cc1ccc(OC)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,4742.42,nM,5.32,CHEMBL3100637,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",B,Homo sapiens
CHEMBL3099663,CCC[C@H](Cc1ccc(OC)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,250.03,nM,6.60,CHEMBL3100637,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",B,Homo sapiens
CHEMBL3099662,COc1ccc(C[C@@H](NC[C@H](O)c2cc(O)cc(O)c2)C(C)C)cc1,Ki,3419.79,nM,5.47,CHEMBL3100637,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",B,Homo sapiens
CHEMBL3099661,COc1ccc(C[C@H](NC[C@H](O)c2cc(O)cc(O)c2)C(C)C)cc1,Ki,29174.27,nM,4.54,CHEMBL3100637,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",B,Homo sapiens
CHEMBL3099660,CC[C@@H](Cc1ccc(OC)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,4295.36,nM,5.37,CHEMBL3100637,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",B,Homo sapiens
CHEMBL3099659,CC[C@H](Cc1ccc(OC)cc1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,35.73,nM,7.45,CHEMBL3100637,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",B,Homo sapiens
CHEMBL3128198,Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccc(Cl)c3)N2)cc1,IC50,8451.0,nM,5.07,CHEMBL3129371,Displacement of [125I]-cyanopindolol from recombinant human beta-2 adrenergic receptor expressed in CHO cell membranes after 1 hr by scintillation counting analysis,B,Homo sapiens
CHEMBL3128184,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2sc(-c3ccc(F)cc3)nc21,IC50,2513.0,nM,5.60,CHEMBL3129371,Displacement of [125I]-cyanopindolol from recombinant human beta-2 adrenergic receptor expressed in CHO cell membranes after 1 hr by scintillation counting analysis,B,Homo sapiens
CHEMBL3128185,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2sc(-c3ccc(F)cc3)nc21,IC50,2471.0,nM,5.61,CHEMBL3129371,Displacement of [125I]-cyanopindolol from recombinant human beta-2 adrenergic receptor expressed in CHO cell membranes after 1 hr by scintillation counting analysis,B,Homo sapiens
CHEMBL1160723,CC(C)NC[C@H](O)c1ccc(O)c(O)c1,EC50,39.81,nM,7.40,CHEMBL3129865,Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay,F,Homo sapiens
CHEMBL3126387,O=CO.O=S1(=O)CCCc2ccc(CCCCOCCCCCCNC[C@H](O)c3ccc(O)c(CO)c3)cc21,EC50,39.81,nM,7.40,CHEMBL3129865,Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay,F,Homo sapiens
CHEMBL3126386,CC(=O)O.O=S1(=O)CCc2ccc(CCCCOCCCCCCNC[C@H](O)c3ccc(O)c(CO)c3)cc21,EC50,7.943,nM,8.10,CHEMBL3129865,Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay,F,Homo sapiens
CHEMBL3124955,CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CC=CC1,EC50,1.0,nM,9.00,CHEMBL3129865,Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay,F,Homo sapiens
CHEMBL3126385,CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCCC1,EC50,1.585,nM,8.80,CHEMBL3129865,Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay,F,Homo sapiens
CHEMBL3126384,CC(=O)O.O=S(=O)(c1ccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc1)C1CCCC1,EC50,31.62,nM,7.50,CHEMBL3129865,Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay,F,Homo sapiens
CHEMBL3126383,CC(=O)O.Cc1cc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc(S(=O)(=O)C2CCCC2)c1,EC50,0.5012,nM,9.30,CHEMBL3129865,Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay,F,Homo sapiens
CHEMBL3126382,CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1,EC50,1.995,nM,8.70,CHEMBL3129865,Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay,F,Homo sapiens
CHEMBL3126381,CC(=O)O.CS(=O)(=O)c1ccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc1,EC50,19.95,nM,7.70,CHEMBL3129865,Agonist activity at human beta2 adrenoceptor transfected in CHO cells assessed as cyclic AMP accumulation after 45 mins by fluorescence polarization assay,F,Homo sapiens
CHEMBL3219031,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)ccc1O,EC50,74.0,nM,7.13,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219032,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3ccc(O)cc3)CC2)ccc1O,EC50,26.0,nM,7.58,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219033,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3cccc(O)c3)CC2)ccc1O,EC50,129.0,nM,6.89,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219034,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3O)CC2)ccc1O,EC50,90.0,nM,7.05,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219038,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3cc(F)cc(F)c3O)CC2)ccc1O,EC50,102.0,nM,6.99,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219039,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3cc(O)cc(F)c3)CC2)ccc1O,EC50,65.0,nM,7.19,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219040,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3ccc(O)c(F)c3)CC2)ccc1O,EC50,26.0,nM,7.58,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219041,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3cc(F)c(O)cc3F)CC2)ccc1O,EC50,22.0,nM,7.66,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219042,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3ccc(O)c(Cl)c3)CC2)ccc1O,EC50,3.7,nM,8.43,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219044,Cc1ccc(-c2ccc(O)c(Cl)c2)c(NC(=O)OC2CCN(CCCCCCCCCNC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)c1,EC50,14.0,nM,7.85,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219045,Cc1cc(C)c(NC(=O)OC2CCN(CCCCCCCCCNC[C@H](O)c3ccc(O)c(NS(C)(=O)=O)c3)CC2)c(-c2ccc(O)c(Cl)c2)c1,EC50,36.0,nM,7.44,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219046,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3ccc(F)cc3-c3ccc(O)c(Cl)c3)CC2)ccc1O,EC50,23.0,nM,7.64,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219047,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CCC(OC(=O)Nc3cc(F)ccc3-c3ccc(O)c(Cl)c3)CC2)ccc1O,EC50,57.0,nM,7.24,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219048,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3ccc(O)c(Cl)c3)CC2)ccc1O,EC50,20.0,nM,7.70,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219049,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3ccc(O)c(Cl)c3)CC2)ccc1O,EC50,21.0,nM,7.68,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219050,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCCCN2CCC(OC(=O)Nc3ccccc3-c3ccc(O)c(Cl)c3)CC2)ccc1O,EC50,195.0,nM,6.71,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219051,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2CC[C@@H](OC(=O)Nc3ccccc3-c3ccc(O)c(Cl)c3)C2)ccc1O,EC50,24.0,nM,7.62,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219052,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2C[C@H]3C[C@@]3(COC(=O)Nc3ccccc3-c3ccc(O)c(Cl)c3)C2)ccc1O,EC50,17.0,nM,7.77,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219053,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2C[C@@H]3[C@@H](COC(=O)Nc4ccccc4-c4ccc(O)c(Cl)c4)[C@@H]3C2)ccc1O,EC50,42.0,nM,7.38,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219054,CS(=O)(=O)Nc1cc([C@@H](O)CNCCCCCCCCCN2C3CCC2CC(OC(=O)Nc2ccccc2-c2ccc(O)c(Cl)c2)C3)ccc1O,EC50,23.0,nM,7.64,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3219056,CS(=O)(=O)Nc1cc([C@@H](O)CNCCc2ccc(OCCCN3CCC(OC(=O)Nc4ccccc4-c4ccc(O)c(Cl)c4)CC3)cc2)ccc1O,EC50,13.0,nM,7.89,CHEMBL3227040,Agonist activity at human beta-2 adrenoceptor expressed in CHO cells assessed as stimulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3265157,CCN(CC)CCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,7.943,nM,8.10,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265158,CCN(CC)CCN(CCNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,3.981,nM,8.40,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265159,CCN(CC)CCN(CCNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1cccc(Cl)c1,EC50,3.981,nM,8.40,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265160,CN(C)CCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,6.31,nM,8.20,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265161,NCCCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,316.23,nM,6.50,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265162,CN(C)CCCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccccc1,EC50,15.85,nM,7.80,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265163,CC(C)N(C)CCCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1cccc(Cl)c1,EC50,5.012,nM,8.30,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265164,CCN(C)CCCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1cccc(Cl)c1,EC50,10.0,nM,8.00,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265165,CN(CCCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1cccc(Cl)c1)C1CC1,EC50,7.943,nM,8.10,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265166,O=C(CCOCCc1cccc(Cl)c1)N(CCNCCc1ccc(O)c2[nH]c(=O)sc12)CCN1CCCCC1,EC50,12.59,nM,7.90,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265167,Br.CCN(CC)CCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1cccc2ccccc12,EC50,6.31,nM,8.20,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265168,CCN(CC)CCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1ccc2ccccc2c1,EC50,10.0,nM,8.00,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265169,CCN(CC)CCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1cccc(F)c1,EC50,7.943,nM,8.10,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265170,CCN(CC)CCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1cccc(OC)c1,EC50,7.943,nM,8.10,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3265171,CCN(CC)CCN(CCNCCc1ccc(O)c2[nH]c(=O)sc12)C(=O)CCOCCc1cccc(Cl)c1,EC50,6.31,nM,8.20,CHEMBL3270094,Agonist activity at human beta-2 adrenergic receptor expressed in human H292 cells assessed as accumulation of intracellular cAMP after 1 hr by AlphaScreen assay,F,Homo sapiens
CHEMBL3290971,OCc1cc(C(O)CNCCc2ccc(Br)cc2)ccc1O,EC50,25.12,nM,7.60,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290972,OCc1cc(C(O)CNCCc2ccc(NCc3ccc(Cl)c(Cl)c3)cc2)ccc1O,EC50,1584.89,nM,5.80,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290973,OCc1cc(C(O)CNCCc2ccc(NCc3ccc4ccccc4c3)cc2)ccc1O,EC50,158.49,nM,6.80,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290974,OCc1cc(C(O)CNCCc2ccc(N3CCC(c4ccccc4)CC3)cc2)ccc1O,EC50,398.11,nM,6.40,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290975,OCc1cc(C(O)CNCCc2ccc(N3CCC(Cc4ccccc4)CC3)cc2)ccc1O,EC50,501.19,nM,6.30,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290976,OCc1cc(C(O)CNCCc2ccc(N3CCC(CCCc4ccccc4)CC3)cc2)ccc1O,EC50,1584.89,nM,5.80,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290977,O=C(c1ccccc1)C1CCN(c2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)CC1,EC50,1258.93,nM,5.90,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290978,OCc1cc(C(O)CNCCc2ccc(N3CCN(c4ccccc4)CC3)cc2)ccc1O,EC50,199.53,nM,6.70,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290979,COc1ccc(CN2CCN(c3ccc(CCNCC(O)c4ccc(O)c(CO)c4)cc3)CC2)cc1,EC50,630.96,nM,6.20,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290980,CC(=O)N1CCN(c2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)CC1,EC50,10000.0,nM,5.00,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290981,O=C(Cc1ccccc1)NC1CCN(c2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)CC1,EC50,1000.0,nM,6.00,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290982,OCc1cc(C(O)CNCCc2ccc(Nc3ccc(Oc4ccccc4)cc3)cc2)ccc1O,EC50,19.95,nM,7.70,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290983,OCc1cc(C(O)CNCCc2ccc(Nc3ccc4ccccc4c3)cc2)ccc1O,EC50,2.512,nM,8.60,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290984,COc1ccc(Nc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)cc1,EC50,3.981,nM,8.40,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290985,OCc1cc(C(O)CNCCc2ccc(Nc3cccc4ccccc34)cc2)ccc1O,EC50,199.53,nM,6.70,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290986,OCc1cc(C(O)CNCCc2ccc(Nc3ccc4c(c3)CCC4)cc2)ccc1O,EC50,7.943,nM,8.10,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290987,OCc1cc(C(O)CNCCc2ccc(Nc3ccc(-c4ccccc4)cc3)cc2)ccc1O,EC50,7.943,nM,8.10,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290988,OCc1cc(C(O)CNCCc2ccc(Nc3cccc(-c4ccccc4)c3)cc2)ccc1O,EC50,1.995,nM,8.70,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290989,COc1ccc(Nc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)cc1-c1ccccc1,EC50,1.259,nM,8.90,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290990,COc1cccc(Nc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)c1,EC50,10.0,nM,8.00,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290991,CCOc1ccc(Nc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)cc1,EC50,1.259,nM,8.90,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290992,CSc1ccc(Nc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)cc1,EC50,2.512,nM,8.60,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290993,CC(C)Oc1ccc(Nc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)cc1,EC50,2.512,nM,8.60,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290994,OCc1cc(C(O)CNCCc2ccc(Nc3ccc(O)cc3)cc2)ccc1O,EC50,199.53,nM,6.70,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290995,OCc1cc(C(O)CNCCc2ccc(Nc3ccc(F)cc3)cc2)ccc1O,EC50,31.62,nM,7.50,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290996,COC(=O)c1ccc(Nc2ccc(CCNCC(O)c3ccc(O)c(CO)c3)cc2)cc1,EC50,6.31,nM,8.20,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290997,COc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c(CO)c3)cc2)cc1-c1ccccc1,EC50,0.5012,nM,9.30,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290998,COc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c(NC=O)c3)cc2)cc1-c1ccccc1,EC50,0.1259,nM,9.90,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3290999,COc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1-c1ccccc1,EC50,0.1259,nM,9.90,CHEMBL3294889,Agonist activity at human recombinant beta2 receptor assessed as cAMP accumulation by radioimmunoassay and cell based assay,F,Homo sapiens
CHEMBL3286557,CNc1nc(C(F)(F)c2ccccc2)nc2c1CCNCC2,IC50,1400.0,nM,5.85,CHEMBL3292430,Binding affinity to adrenergic beta-2 receptor (unknown origin),B,Homo sapiens
CHEMBL3298324,COc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1-c1ccccc1CN,Ki,3.162,nM,8.50,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298325,COc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1-c1cccc(CN)c1,Ki,1.585,nM,8.80,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298326,COc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1-c1ccc(CN)cc1,Ki,1.259,nM,8.90,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298327,CCOc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1,Ki,12.59,nM,7.90,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298328,NCCOc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1,Ki,6.31,nM,8.20,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298329,NCCCOc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1,Ki,5.012,nM,8.30,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298330,NCCCCOc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1,Ki,5.012,nM,8.30,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298691,NCCOCCOc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1,Ki,6.31,nM,8.20,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298692,CC(C)(C)OC(=O)NCCOc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1,Ki,19.95,nM,7.70,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298762,O=C(NCCOc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1)c1ccccc1,Ki,10.0,nM,8.00,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298831,O=c1ccc2c([C@@H](O)CNCCc3ccc(Nc4ccc(OCCN5CCOCC5)cc4)cc3)ccc(O)c2[nH]1,Ki,19.95,nM,7.70,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298832,CS(=O)(=O)N1CCN(CCOc2ccc(Nc3ccc(CCNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)cc3)cc2)CC1,Ki,31.62,nM,7.50,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298897,O=c1ccc2c([C@@H](O)CNCCc3ccc(Nc4ccc(OCCN5CCNCC5)cc4)cc3)ccc(O)c2[nH]1,Ki,10.0,nM,8.00,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298986,CC(C)(N)COc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1,Ki,6.31,nM,8.20,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298987,CC(C)(N)COc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1-c1ccccc1,Ki,1.0,nM,9.00,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3298213,CC(C)(N)COc1ccc(Nc2ccc(CCNC[C@H](O)c3ccc(O)c(NC=O)c3)cc2)cc1,Ki,25.12,nM,7.60,CHEMBL3369035,Displacement of [3H]dihydroalprenolol from human beta2 adrenergic receptor expressing cell membrane by competition binding assay,B,Homo sapiens
CHEMBL3323671,Cc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1C,Ki,32.0,nM,7.50,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323670,CCCCOc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,Ki,1.7,nM,8.77,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323669,CCCCOc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,Ki,3.9,nM,8.41,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323668,CCCCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,Ki,1.4,nM,8.85,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323667,CC(C)Cc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,Ki,6.8,nM,8.17,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323666,CCCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,Ki,3.2,nM,8.49,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323665,CCCc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,Ki,19.0,nM,7.72,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323664,CCOc1cccc([C@H]2CCC[C@H]2NC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,Ki,266.0,nM,6.58,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323663,CCc1cccc([C@H]2CCC[C@H]2NC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,Ki,12.0,nM,7.92,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323662,Cc1ccc([C@H]2CCC[C@H]2NC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1,Ki,149.0,nM,6.83,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323661,Cc1cccc([C@H]2CCC[C@H]2NC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1,Ki,15.0,nM,7.82,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323660,Cc1ccccc1[C@H]1CCC[C@H]1NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12,Ki,7.1,nM,8.15,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323659,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@@H]3CCC[C@@H]3c3ccccc3)c2s1,Ki,5.5,nM,8.26,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323658,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@@H]3CCC[C@@H]3CCc3ccccc3)c2s1,Ki,0.4,nM,9.40,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323657,CC(C)[C@H]1CCC[C@H]1NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12,Ki,4.2,nM,8.38,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323656,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@H]3CCC[C@H]3C3CCCCC3)c2s1,Ki,97.0,nM,7.01,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323655,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@@H]3CCC[C@@H]3C3CCCCC3)c2s1,Ki,2.0,nM,8.70,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323653,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@H]3CCC[C@H]3C3CCCC3)c2s1,Ki,6.7,nM,8.17,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3323654,O=c1[nH]c2c(O)ccc([C@@H](O)CN[C@H]3CCC[C@@H]3C3CCCC3)c2s1,Ki,0.6,nM,9.22,CHEMBL3378137,Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay,B,Homo sapiens
CHEMBL3426708,COc1ccc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)cc1CCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.7943,nM,9.10,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426707,COc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1NC(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.259,nM,8.90,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426706,O=C(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)Nc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1,EC50,0.1,nM,10.00,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426705,Cc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1N(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,3.981,nM,8.40,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426704,COc1cc(N(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)ccc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,50.12,nM,7.30,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426703,COc1cc(N(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.7943,nM,9.10,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426702,CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,0.2512,nM,9.60,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426701,Cc1cc(C(=O)NCCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(C)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.1585,nM,9.80,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426700,COc1cc(C(=O)NCCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)ccc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.585,nM,8.80,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426699,O=C(Nc1ccccc1-c1ccccc1)OC1CCN(CCNC(=O)c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)CC1,EC50,0.5012,nM,9.30,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426698,O=C(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)N[C@H]1CC[C@H](CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)CC1,EC50,0.1585,nM,9.80,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426697,O=C(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)NCCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.1259,nM,9.90,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426696,COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(C)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.3162,nM,9.50,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426695,COc1c(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1C,EC50,0.2512,nM,9.60,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426694,Cc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)ccc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.1995,nM,9.70,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426693,Cc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1NC(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,0.1995,nM,9.70,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3039518,COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.2512,nM,9.60,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426692,COc1c(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1Cl,EC50,0.3981,nM,9.40,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426691,COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)ccc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.2512,nM,9.60,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426690,O=C(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)Nc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c(Cl)c1,EC50,0.5012,nM,9.30,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426689,COc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1NC(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,0.5012,nM,9.30,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426688,O=C(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)Nc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1Cl,EC50,0.2512,nM,9.60,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3426687,O=C(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)Nc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,0.2512,nM,9.60,CHEMBL3428930,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting,F,Homo sapiens
CHEMBL3629353,O=C(Nc1ccccc1-c1ccc(O)c(Cl)c1)OC1CCN(CCCCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)CC1,EC50,3.7,nM,8.43,CHEMBL3630579,Agonist activity at human beta2 adrenoceptor expressed in CHO cells assessed as stumulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3629356,O=c1ccc2c([C@@H](O)CNCCCCCCCCCN3CCC(Cn4cnc(C(O)(c5ccccc5)c5ccccc5)n4)CC3)ccc(O)c2[nH]1,EC50,13.0,nM,7.89,CHEMBL3630579,Agonist activity at human beta2 adrenoceptor expressed in CHO cells assessed as stumulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3629357,O=c1ccc2c([C@@H](O)CNCCc3ccc(CCN4CCC(Cn5cnc(C(O)(c6ccccc6)c6ccccc6)n5)CC4)cc3)ccc(O)c2[nH]1,EC50,116.0,nM,6.94,CHEMBL3630579,Agonist activity at human beta2 adrenoceptor expressed in CHO cells assessed as stumulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3629358,O=c1ccc2c([C@@H](O)CNCCCCCCCCCN3CCC(Cn4cnc(C(O)(c5ccccc5)C5CCCCC5)n4)CC3)ccc(O)c2[nH]1,EC50,21.0,nM,7.68,CHEMBL3630579,Agonist activity at human beta2 adrenoceptor expressed in CHO cells assessed as stumulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3629359,O=c1ccc2c([C@@H](O)CNCCCCCCCCCN3CCC(Cn4cnc([C@](O)(c5ccccc5)C5CCCCC5)n4)CC3)ccc(O)c2[nH]1,EC50,14.0,nM,7.85,CHEMBL3630579,Agonist activity at human beta2 adrenoceptor expressed in CHO cells assessed as stumulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3629360,O=c1ccc2c([C@@H](O)CNCCc3ccc(CCN4CCC(Cn5cnc([C@](O)(c6ccccc6)C6CCCCC6)n5)CC4)cc3)ccc(O)c2[nH]1,EC50,20.9,nM,7.68,CHEMBL3630579,Agonist activity at human beta2 adrenoceptor expressed in CHO cells assessed as stumulation of intracellular cAMP production,F,Homo sapiens
CHEMBL3736433,CB1C=Cc2cccc(OCC(O)CN(C)C)c2N1,IC50,501.19,nM,6.30,CHEMBL3738004,Antagonist activity at human beta2 receptor expressed in CHO-K1 cells assessed as isoproterenol-induced cAMP level by HTRF assay,F,Homo sapiens
CHEMBL3736156,CB1C=Cc2c(cccc2OCC(O)CN(C)C)N1,IC50,100.0,nM,7.00,CHEMBL3738004,Antagonist activity at human beta2 receptor expressed in CHO-K1 cells assessed as isoproterenol-induced cAMP level by HTRF assay,F,Homo sapiens
CHEMBL3746068,Nc1nc(CNC(=O)c2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1,IC50,5200.0,nM,5.28,CHEMBL3750559,Displacement of [125I]CYP from human beta-2 adrenergic receptor expressed in CHO cell membrane after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL3747487,CCOC(=O)C1CCN(C(=O)c2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)CC1,IC50,10900.0,nM,4.96,CHEMBL3750559,Displacement of [125I]CYP from human beta-2 adrenergic receptor expressed in CHO cell membrane after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL3747244,O=C(c1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)N1CCC2(CCOC2=O)CC1,IC50,5600.0,nM,5.25,CHEMBL3750559,Displacement of [125I]CYP from human beta-2 adrenergic receptor expressed in CHO cell membrane after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL3746280,CC1(C)CC2(CCN(C(=O)c3ccc(C[C@@H]4CC[C@H]([C@H](O)c5ccccc5)N4)cc3)CC2)C(=O)O1,IC50,11000.0,nM,4.96,CHEMBL3750559,Displacement of [125I]CYP from human beta-2 adrenergic receptor expressed in CHO cell membrane after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL3747546,CCOC(=O)[C@H]1[C@@H]2CN(C(=O)c3ccc(C[C@@H]4CC[C@H]([C@H](O)c5ccccc5)N4)cc3)C[C@@H]21,IC50,13400.0,nM,4.87,CHEMBL3750559,Displacement of [125I]CYP from human beta-2 adrenergic receptor expressed in CHO cell membrane after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL3764774,O=C(Cn1cnc2ccccc2c1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1,IC50,2200.0,nM,5.66,CHEMBL3767773,Displacement of [125]I-cyanopindolol from human recombinant beta2 adrenergic receptor after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL3769968,C=CCOc1cc(F)c(F)cc1C1CC1CN.Cl,Ki,812.83,nM,6.09,CHEMBL3774023,Binding affinity to human beta-2 adrenergic receptor by radioligand binding assay,B,Homo sapiens
CHEMBL3800400,COc1cc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1,Ki,0.48,nM,9.32,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3800468,COc1cc(CCNC[C@@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1,Ki,23.0,nM,7.64,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3799455,COc1cc(CCNCCc2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1,Ki,6.3,nM,8.20,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3800303,COc1cc(CCNC[C@H](O)c2ccc(O)c(O)c2)ccc1OCCCc1ccccc1,Ki,18.0,nM,7.75,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3799427,COc1cc(CCNC[C@@H](O)c2ccc(O)c(O)c2)ccc1OCCCc1ccccc1,Ki,47.0,nM,7.33,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3800636,COc1cc(CCNCCc2ccc(O)c(O)c2)ccc1OCCCc1ccccc1,Ki,53.0,nM,7.28,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3798748,COc1cc(CCNC[C@H](O)c2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1,Ki,0.25,nM,9.60,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3797205,COc1cc(CCNC[C@@H](O)c2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1,Ki,13.0,nM,7.89,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3800341,COc1cc(CCNCCc2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1,Ki,2.8,nM,8.55,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3797876,COc1ccccc1OCCNC[C@H](O)c1ccc(O)c(O)c1,Ki,97.0,nM,7.01,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3799593,COc1ccccc1OCCNC[C@@H](O)c1ccc(O)c(O)c1,Ki,850.0,nM,6.07,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3797758,COc1ccccc1OCCNCCc1ccc(O)c(O)c1,Ki,610.0,nM,6.21,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL240773,CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21,Ki,100000.0,nM,4.00,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL269004,CCCN(CCC)[C@H]1CCc2c(O)cccc2C1,Ki,40000.0,nM,4.40,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL301559,CCCN(CCC)[C@@H]1CCc2ccc(O)cc2C1,Ki,86000.0,nM,4.07,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL301265,CCCN[C@H]1CCc2nc(N)sc2C1,Ki,100000.0,nM,4.00,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3799125,COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12,Ki,0.034,nM,10.47,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL3798017,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,Ki,0.88,nM,9.06,CHEMBL3801474,Displacement of [3H]CGP12177 from human beta2 receptor expressed in CHO cells,B,Homo sapiens
CHEMBL198059,Cc1ccc(OC[C@H](O)[C@H](C)NC(C)C)c2c1CCC2,IC50,0.74,nM,9.13,CHEMBL3876342,Displacement of [3H]CGP 12177 from human recombinant beta2 adrenergic receptor expressed in CHO cells measured after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL3704833,N#CC1CCCN1C(=O)CNCC(O)COc1ccccc1,Ki,22000.0,nM,4.66,CHEMBL3705663,"Inhibition Assay: Human recombinant adrenergic 2 receptors expressed in CHO cells are used in modified Tris-HCl buffer pH 7.4. A 50 aliquot is incubated with 0.2 nM [3H]CGP-12177 for 60 minutes at 25 C. Non-specific binding is estimated in the presence of 10 M ICI-118551. Receptors are filtered and washed, the filters are then counted to determine [3H]CGP-12177 specifically bound. Compounds are screened at 10 M.",B,Homo sapiens
CHEMBL3900995,CN(CCCn1c(=O)oc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,140.0,nM,6.85,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3961014,CN(CCCn1c(=O)[nH]c2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,120.0,nM,6.92,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3892021,CN(CCCn1ccc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,220.0,nM,6.66,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3890898,CN(CCCc1nc(-c2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)no1)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,2.7,nM,8.57,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3915401,CN(CCN(C)[C@H]1CC[C@H](OC(C(=O)O)(c2cccs2)c2cccs2)CC1)C(=O)COc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,IC50,34.0,nM,7.47,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3971284,CN(CCNC(=O)COc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,18.0,nM,7.75,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3906438,COc1cc(-c2noc(CCCN(C)[C@H]3CC[C@H](OC(=O)C(O)(c4cccs4)c4cccs4)CC3)n2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,2.2,nM,8.66,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3905320,COc1cc(OCC(=O)N(C)CCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,5.7,nM,8.24,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3908788,CN(CCCn1c(=O)sc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,4.2,nM,8.38,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3923686,CN(CCCn1c(=O)oc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)C2(C)c3ccccc3Oc3ccccc32)CC1,IC50,1.5,nM,8.82,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3926721,CN(CCCn1c(=O)oc2cc(CNC[C@H](O)c3ccc(O)c(NC=O)c3)ccc21)[C@H]1CC[C@H](c2cccc3c2C(C)(C(=O)O)c2ccccc2O3)CC1,IC50,12.0,nM,7.92,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3960091,CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)[C@](O)(c2cccs2)C2CCCC2)CC1,IC50,13.0,nM,7.89,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3963770,CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4c3OCC(=O)N4)ccc21)[C@H]1CC[C@H](OC(=O)[C@](O)(c2cccs2)C2CCCC2)CC1,IC50,1.4,nM,8.85,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3911114,CN(CCCn1c(=O)oc2cc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,62.0,nM,7.21,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3910208,CC(Cc1ccc(OCC(=O)NCCN[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,3.1,nM,8.51,CHEMBL3887836,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 ug/well for beta1 and 5 ug/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 ul, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 uM propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL4108239,COc1cccc(C[C@@H](C)NC[C@@H](O)c2cc(O)cc(O)c2)c1,Ki,5269.0,nM,5.28,CHEMBL3887980,"Beta1-AR Binding Assay: Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988). In brief, male Sprague-Dawley rats weighing 250-350 g were decapitated and their brains quickly removed. The cerebral cortices were dissected on ice, weighed and promptly transferred to a 50 ml test tube containing approximately 30 ml of 50 mM Tris-HCl, pH 7.8 (at room temperature). The tissues were homogenized with a polytron and centrifuged at 20,000xg for 12 min at 4 C. The pellet was washed again in the same manner and resuspended at a concentration of 20 mg (original wet wt) per 1 ml in the assay buffer (20 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic acid at pH 7.8). To block the beta2 sites present in the cortical membrane preparation, 30 nM ICI 118-551 was also added to the assay buffer. To wells containing 100 ul of the test drug and 100 ul of [3H]CGP-12177 (1.4 nM final concentration), 0.8 ml of tissue homogenate was added. After 2 hours at 25 C., the incubation was terminated by rapid filtration. Nonspecific binding was determined by 10 uM propranolol.",B,Homo sapiens
CHEMBL3931891,COc1cccc(C[C@H](C)NC[C@@H](O)c2cc(O)cc(O)c2)c1,Ki,15881.0,nM,4.80,CHEMBL3887980,"Beta1-AR Binding Assay: Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988). In brief, male Sprague-Dawley rats weighing 250-350 g were decapitated and their brains quickly removed. The cerebral cortices were dissected on ice, weighed and promptly transferred to a 50 ml test tube containing approximately 30 ml of 50 mM Tris-HCl, pH 7.8 (at room temperature). The tissues were homogenized with a polytron and centrifuged at 20,000xg for 12 min at 4 C. The pellet was washed again in the same manner and resuspended at a concentration of 20 mg (original wet wt) per 1 ml in the assay buffer (20 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic acid at pH 7.8). To block the beta2 sites present in the cortical membrane preparation, 30 nM ICI 118-551 was also added to the assay buffer. To wells containing 100 ul of the test drug and 100 ul of [3H]CGP-12177 (1.4 nM final concentration), 0.8 ml of tissue homogenate was added. After 2 hours at 25 C., the incubation was terminated by rapid filtration. Nonspecific binding was determined by 10 uM propranolol.",B,Homo sapiens
CHEMBL4113713,C[C@H](Cc1cccc(N)c1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,1864.0,nM,5.73,CHEMBL3887980,"Beta1-AR Binding Assay: Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988). In brief, male Sprague-Dawley rats weighing 250-350 g were decapitated and their brains quickly removed. The cerebral cortices were dissected on ice, weighed and promptly transferred to a 50 ml test tube containing approximately 30 ml of 50 mM Tris-HCl, pH 7.8 (at room temperature). The tissues were homogenized with a polytron and centrifuged at 20,000xg for 12 min at 4 C. The pellet was washed again in the same manner and resuspended at a concentration of 20 mg (original wet wt) per 1 ml in the assay buffer (20 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic acid at pH 7.8). To block the beta2 sites present in the cortical membrane preparation, 30 nM ICI 118-551 was also added to the assay buffer. To wells containing 100 ul of the test drug and 100 ul of [3H]CGP-12177 (1.4 nM final concentration), 0.8 ml of tissue homogenate was added. After 2 hours at 25 C., the incubation was terminated by rapid filtration. Nonspecific binding was determined by 10 uM propranolol.",B,Homo sapiens
CHEMBL3909417,C[C@@H](Cc1cccc(N)c1)NC[C@H](O)c1cc(O)cc(O)c1,Ki,6035.0,nM,5.22,CHEMBL3887980,"Beta1-AR Binding Assay: Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988). In brief, male Sprague-Dawley rats weighing 250-350 g were decapitated and their brains quickly removed. The cerebral cortices were dissected on ice, weighed and promptly transferred to a 50 ml test tube containing approximately 30 ml of 50 mM Tris-HCl, pH 7.8 (at room temperature). The tissues were homogenized with a polytron and centrifuged at 20,000xg for 12 min at 4 C. The pellet was washed again in the same manner and resuspended at a concentration of 20 mg (original wet wt) per 1 ml in the assay buffer (20 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic acid at pH 7.8). To block the beta2 sites present in the cortical membrane preparation, 30 nM ICI 118-551 was also added to the assay buffer. To wells containing 100 ul of the test drug and 100 ul of [3H]CGP-12177 (1.4 nM final concentration), 0.8 ml of tissue homogenate was added. After 2 hours at 25 C., the incubation was terminated by rapid filtration. Nonspecific binding was determined by 10 uM propranolol.",B,Homo sapiens
CHEMBL4115254,C[C@H](Cc1cccc(N)c1)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,30773.0,nM,4.51,CHEMBL3887980,"Beta1-AR Binding Assay: Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988). In brief, male Sprague-Dawley rats weighing 250-350 g were decapitated and their brains quickly removed. The cerebral cortices were dissected on ice, weighed and promptly transferred to a 50 ml test tube containing approximately 30 ml of 50 mM Tris-HCl, pH 7.8 (at room temperature). The tissues were homogenized with a polytron and centrifuged at 20,000xg for 12 min at 4 C. The pellet was washed again in the same manner and resuspended at a concentration of 20 mg (original wet wt) per 1 ml in the assay buffer (20 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic acid at pH 7.8). To block the beta2 sites present in the cortical membrane preparation, 30 nM ICI 118-551 was also added to the assay buffer. To wells containing 100 ul of the test drug and 100 ul of [3H]CGP-12177 (1.4 nM final concentration), 0.8 ml of tissue homogenate was added. After 2 hours at 25 C., the incubation was terminated by rapid filtration. Nonspecific binding was determined by 10 uM propranolol.",B,Homo sapiens
CHEMBL3903905,C[C@@H](Cc1cccc(N)c1)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,28749.0,nM,4.54,CHEMBL3887980,"Beta1-AR Binding Assay: Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988). In brief, male Sprague-Dawley rats weighing 250-350 g were decapitated and their brains quickly removed. The cerebral cortices were dissected on ice, weighed and promptly transferred to a 50 ml test tube containing approximately 30 ml of 50 mM Tris-HCl, pH 7.8 (at room temperature). The tissues were homogenized with a polytron and centrifuged at 20,000xg for 12 min at 4 C. The pellet was washed again in the same manner and resuspended at a concentration of 20 mg (original wet wt) per 1 ml in the assay buffer (20 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic acid at pH 7.8). To block the beta2 sites present in the cortical membrane preparation, 30 nM ICI 118-551 was also added to the assay buffer. To wells containing 100 ul of the test drug and 100 ul of [3H]CGP-12177 (1.4 nM final concentration), 0.8 ml of tissue homogenate was added. After 2 hours at 25 C., the incubation was terminated by rapid filtration. Nonspecific binding was determined by 10 uM propranolol.",B,Homo sapiens
CHEMBL4108123,CCCCC[C@@H](C)NC[C@H](O)c1cc(O)cc(O)c1,Ki,9275.0,nM,5.03,CHEMBL3887980,"Beta1-AR Binding Assay: Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988). In brief, male Sprague-Dawley rats weighing 250-350 g were decapitated and their brains quickly removed. The cerebral cortices were dissected on ice, weighed and promptly transferred to a 50 ml test tube containing approximately 30 ml of 50 mM Tris-HCl, pH 7.8 (at room temperature). The tissues were homogenized with a polytron and centrifuged at 20,000xg for 12 min at 4 C. The pellet was washed again in the same manner and resuspended at a concentration of 20 mg (original wet wt) per 1 ml in the assay buffer (20 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic acid at pH 7.8). To block the beta2 sites present in the cortical membrane preparation, 30 nM ICI 118-551 was also added to the assay buffer. To wells containing 100 ul of the test drug and 100 ul of [3H]CGP-12177 (1.4 nM final concentration), 0.8 ml of tissue homogenate was added. After 2 hours at 25 C., the incubation was terminated by rapid filtration. Nonspecific binding was determined by 10 uM propranolol.",B,Homo sapiens
CHEMBL3930835,CCCCC[C@H](C)NC[C@H](O)c1cc(O)cc(O)c1,Ki,31440.0,nM,4.50,CHEMBL3887980,"Beta1-AR Binding Assay: Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988). In brief, male Sprague-Dawley rats weighing 250-350 g were decapitated and their brains quickly removed. The cerebral cortices were dissected on ice, weighed and promptly transferred to a 50 ml test tube containing approximately 30 ml of 50 mM Tris-HCl, pH 7.8 (at room temperature). The tissues were homogenized with a polytron and centrifuged at 20,000xg for 12 min at 4 C. The pellet was washed again in the same manner and resuspended at a concentration of 20 mg (original wet wt) per 1 ml in the assay buffer (20 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic acid at pH 7.8). To block the beta2 sites present in the cortical membrane preparation, 30 nM ICI 118-551 was also added to the assay buffer. To wells containing 100 ul of the test drug and 100 ul of [3H]CGP-12177 (1.4 nM final concentration), 0.8 ml of tissue homogenate was added. After 2 hours at 25 C., the incubation was terminated by rapid filtration. Nonspecific binding was determined by 10 uM propranolol.",B,Homo sapiens
CHEMBL3918348,CCCCC[C@H](C)NC[C@@H](O)c1cc(O)cc(O)c1,Ki,56420.0,nM,4.25,CHEMBL3887980,"Beta1-AR Binding Assay: Beta1-AR binding was done on rat cortical membrane following a previously described procedure (Beer et al., Biochem. Pharmacol. 37: 1145-1151, 1988). In brief, male Sprague-Dawley rats weighing 250-350 g were decapitated and their brains quickly removed. The cerebral cortices were dissected on ice, weighed and promptly transferred to a 50 ml test tube containing approximately 30 ml of 50 mM Tris-HCl, pH 7.8 (at room temperature). The tissues were homogenized with a polytron and centrifuged at 20,000xg for 12 min at 4 C. The pellet was washed again in the same manner and resuspended at a concentration of 20 mg (original wet wt) per 1 ml in the assay buffer (20 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, 0.1 mM ascorbic acid at pH 7.8). To block the beta2 sites present in the cortical membrane preparation, 30 nM ICI 118-551 was also added to the assay buffer. To wells containing 100 ul of the test drug and 100 ul of [3H]CGP-12177 (1.4 nM final concentration), 0.8 ml of tissue homogenate was added. After 2 hours at 25 C., the incubation was terminated by rapid filtration. Nonspecific binding was determined by 10 uM propranolol.",B,Homo sapiens
CHEMBL4110387,CCCCC[C@@H](C)NC[C@@H](O)c1cc(O)cc(O)c1,Kd,100000.0,nM,4.00,CHEMBL3887981,"Beta2-AR Binding Assay: HEK 293 cells stability transfected with cDNA encoding human beta2-AR (provided by Dr. Brian Kobilka, Stanford Medical Center, Palo Alto, Calif.) were grown in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS), 0.05% penicillin-streptomycin, and 400 g/ml G418 as previously described (Pauwels et al., Biochem. Pharmacol. 42: 1683-1689, 1991). The cells were scraped from the 150x25 mm plates and centrifuged at 500xg for 5 minutes. The pellet was homogenized in 50 mM Tris-HCl, pH 7.7, with a Polytron, centrifuged at 27,000xg, and resuspended in the same buffer. The latter process was repeated, and the pellet was resuspended in 25 mM Tris-HCl containing 120 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, and 5 mM glucose, pH 7.4. The binding assays contained 0.3 nM [3H]CGP-12177 in a volume of 1.0 ml. Nonspecific binding was determined by 1 uM propranolol.",B,Homo sapiens
CHEMBL3934254,CN(CCCCCCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)C1CCC(OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,6.4,nM,8.19,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3902803,CN(CCOc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)C1CCC(OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,36.0,nM,7.44,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3978112,COc1cc(NC(=O)CCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,8.5,nM,8.07,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3948979,CN(CCC(=O)Nc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1Cl)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,6.7,nM,8.17,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3916700,COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,1.6,nM,8.80,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3892218,COc1cc(NC(=O)CCN(C)[C@H]2CC[C@](C)(OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,2.2,nM,8.66,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3962171,COc1cc(NC(=O)CCCN[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,2.1,nM,8.68,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3934681,COc1cc(NC(=O)CCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(F)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,4.8,nM,8.32,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3963417,CN(CCC(=O)Nc1cc(F)c(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1F)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,13.0,nM,7.89,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3940214,COc1cc(NC(=O)CCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,5.3,nM,8.28,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3943564,COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(C#N)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,4.5,nM,8.35,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3915601,COc1cc(OCCCCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,9.6,nM,8.02,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3947244,COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2c1OCC(=O)N2,IC50,0.38,nM,9.42,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3973386,COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@H](OC(=O)[C@](O)(c3ccccc3)C3CCCC3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,1.3,nM,8.89,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3906808,COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@H](OC(=O)[C@](O)(c3cccs3)C3CCCC3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,IC50,1.1,nM,8.96,CHEMBL3888303,"Adrenergic Receptor Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4.",B,Homo sapiens
CHEMBL3645362,CN(CCCC(=O)Nc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,3.0,nM,8.52,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645275,COc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1NC(=O)CCCN(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645277,Cc1cc(NC(=O)CCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(C)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645365,C[C@H](Cc1cccc(CCNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645279,COc1ccc(NC(=O)CCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)cc1CCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,6.0,nM,8.22,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645281,CC(Cc1cccc(CC(=O)NCCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3896828,C[C@@H](Cc1cccc(CC(=O)NCCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645283,Cc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1NC(=O)CCCCN(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645285,COc1cc(NC(=O)CCCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)ccc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645286,COc1cc(NC(=O)CCCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645288,CN(CCCCC(=O)Nc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645290,C[C@H](Cc1cccc(CC(=O)NCCCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645293,Cc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1NC(=O)c1cccc(N(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645295,COc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1NC(=O)c1cccc(N(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3981221,COc1cc(NC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c(C)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645299,Cc1ccc(C(=O)Nc2cccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)cc1N(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645361,Cc1ccc(C(=O)Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1N(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645302,Cc1ccc(C(=O)Nc2cccc(CC(C)NC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)cc1N(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645304,C[C@@H](Cc1cccc(NC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3952427,Cc1ccc(C(=O)Nc2ccc(CC(C)NC[C@H](C)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1N(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645308,C[C@@H](Cc1ccc(NC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645310,Cc1ccc(C(=O)NCc2cccc(CC(C)NC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)cc1N(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645312,Cc1ccc(C(=O)NCc2ccc(CC(C)NC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1N(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,3.0,nM,8.52,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645314,C[C@@H](Cc1ccc(CNC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645316,C[C@@H](Cc1cccc(CNC(=O)c2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645311,CC(Cc1ccc(CNC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645320,C[C@H](Cc1cccc(CCNC(=O)c2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL4114219,C[C@@H](NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)c1cccc(CCNC(=O)c2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645324,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1cccc(CC(=O)Nc2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)c1,EC50,3.0,nM,8.52,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645326,COc1cc(NC(=O)Cc2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645328,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1cccc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)c1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645330,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1ccc(CC(=O)NCc2cccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)cc1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3965175,CC(Cc1ccc(CNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1)NCCc1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645333,C[C@@H](Cc1cccc(CNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645335,Cc1c(CNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cccc1CC(C)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645337,CC(Cc1cc(CNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)ccc1F)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645339,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1ccc(CNC(=O)Cc2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1,EC50,2.0,nM,8.70,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645341,CC(Cc1cccc(CC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645343,C[C@@H](Cc1cccc(CC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645345,COc1ccc(CC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1CC(C)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645347,COc1ccc(CC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1C[C@H](C)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,2.0,nM,8.70,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645349,CC(Cc1cccc(CCNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,2.0,nM,8.70,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645350,C[C@@H](Cc1cccc(CCNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645352,C[C@@H](Cc1ccc(CCNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645353,CC(Cc1cccc(CCC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645355,C[C@@H](Cc1cccc(CCC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,11.0,nM,7.96,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645357,CC(Cc1ccc(F)c(CC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645274,Cc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1NC(=O)CCCN(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645276,COc1cc(NC(=O)CCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)ccc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,2.0,nM,8.70,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645278,COc1cc(NC(=O)CCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645359,CN(CCCC(=O)Nc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645280,CC(Cc1cccc(NC(=O)CCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645282,C[C@H](Cc1cccc(CC(=O)NCCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645363,CN(CCCCC(=O)Nc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645284,COc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1NC(=O)CCCCN(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3666068,Cc1cc(NC(=O)CCCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(C)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645287,CN(CCCCC(=O)Nc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645289,CC(Cc1cccc(CC(=O)NCCCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645291,C[C@@H](Cc1cccc(CC(=O)NCCCCN(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645292,Cc1ccc(C(=O)Nc2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1N(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645294,Cc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1NC(=O)c1ccc(C)c(N(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645296,Cc1cc(NC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c(C)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645298,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1cccc(C(=O)Nc2cccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)c1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645301,CC(Cc1cccc(NC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645303,C[C@H](Cc1cccc(NC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645305,CC(Cc1ccc(NC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645307,C[C@H](Cc1ccc(NC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645309,CC(Cc1cccc(CNC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645313,C[C@H](Cc1ccc(CNC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645317,CC(Cc1cccc(CC(=O)Nc2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645319,COc1ccc(CC(=O)Nc2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)cc1CC(C)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,2.0,nM,8.70,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645321,C[C@@H](Cc1cccc(CCNC(=O)c2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645323,C[C@@H](Cc1ccc(CCNC(=O)c2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645325,Cc1cc(NC(=O)Cc2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c(C)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,3.0,nM,8.52,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645327,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1cccc(CC(=O)Nc2cccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)c1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645329,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1ccc(CC(=O)NCc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645331,CC(Cc1ccc(CNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645332,C[C@H](Cc1cccc(CNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645334,Cc1ccc(CNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1CC(C)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645336,COc1ccc(CNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1CC(C)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,4.0,nM,8.40,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645338,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1ccc(CNC(=O)Cc2cccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)cc1,EC50,2.0,nM,8.70,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645340,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1ccc(CNC(=O)Cc2cccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)cc1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645342,C[C@H](Cc1cccc(CC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645344,CC(Cc1ccc(CC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645346,COc1ccc(CC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1C[C@@H](C)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645348,CC(Cc1cc(CC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)ccc1F)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645351,CC(Cc1ccc(CCNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3639442,C[C@H](Cc1ccc(CCNC(=O)Cc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645354,C[C@H](Cc1cccc(CCC(=O)NCc2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645356,COc1ccc(CC(C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1CC(=O)NCc1ccc(N(C)C(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)cc1,EC50,1.0,nM,9.00,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL3645358,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1ccc(CNC(=O)CCc2cccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)cc1,EC50,3.0,nM,8.52,CHEMBL3888782,"cAMP Assay: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and re-suspended in stimulation buffer containing TBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.).",F,Homo sapiens
CHEMBL4076830,Cc1cc(O)c(CN2CCCC2)c2c1C(=O)/C(=C\c1ccco1)O2,Ki,9.0,nM,8.05,CHEMBL3997588,Displacement of [3H]DHA from beta2-AR (unknown origin) expressed in baculovirus infected sf9 cell membranes after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL1623548,CN(C)CCOCCOc1ccccc1-c1ccccc1,Kd,3801.89,nM,5.42,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL1621144,C=CCNCCOc1ccccc1-c1ccccc1,Kd,2630.27,nM,5.58,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4092412,CC(C)(C)NC[C@@H](O)COc1ccccc1-c1ccccc1,Kd,0.03548,nM,10.45,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4071616,CN(C)CCOc1ccc2ccccc2c1C=O,Kd,23442.29,nM,4.63,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4067230,C[n+]1c(/C=C/Nc2ccccc2)sc2ccccc21,Kd,38904.51,nM,4.41,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4094678,COc1cccc(/C=C2\Oc3c(CN4CCN(C)CC4)c(O)cc(C)c3C2=O)c1,Kd,17378.01,nM,4.76,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4104850,COc1cccc(/C=C2\Oc3c(CN(C)C)c(O)cc(C)c3C2=O)c1,Kd,21877.62,nM,4.66,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4086982,Cc1cc(O)c(CN(C)C)c2c1C(=O)/C(=C/c1ccccc1)O2,Kd,25118.86,nM,4.60,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4097144,Cc1cc(O)c(CN2CCCC2)c2c1C(=O)/C(=C/c1cc3ccccc3o1)O2,Kd,14454.4,nM,4.84,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4079127,CCOC(=O)c1cc(/C=C/c2sc3ccccc3[n+]2C)c2sc3ccccc3n12,Kd,891.25,nM,6.05,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4089434,C[n+]1c(/C=C/c2ccccc2Cl)sc2ccccc21,Kd,4897.79,nM,5.31,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4068256,CCCCN(C)Cc1c(O)cc(C)c2c1O/C(=C\c1cc3cc(Br)ccc3o1)C2=O,Kd,17782.79,nM,4.75,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL193627,CCN1C(=Cc2sc3ccccc3[n+]2C)C=Cc2cccc(C)c21,Ki,9.0,nM,8.05,CHEMBL3997588,Displacement of [3H]DHA from beta2-AR (unknown origin) expressed in baculovirus infected sf9 cell membranes after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL4062049,CCNCCOc1ccccc1-c1ccccc1,Ki,9.0,nM,8.05,CHEMBL3997588,Displacement of [3H]DHA from beta2-AR (unknown origin) expressed in baculovirus infected sf9 cell membranes after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL1625333,COCCNCCOc1ccccc1-c1ccccc1,Ki,9.0,nM,8.05,CHEMBL3997588,Displacement of [3H]DHA from beta2-AR (unknown origin) expressed in baculovirus infected sf9 cell membranes after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL4099306,CCOC(=O)C1Oc2cccc(OCC(O)CNC(C)C)c2C1C,Ki,9.0,nM,8.05,CHEMBL3997588,Displacement of [3H]DHA from beta2-AR (unknown origin) expressed in baculovirus infected sf9 cell membranes after 1 hr by scintillation counting method,B,Homo sapiens
CHEMBL2104145,CC(C)(C)NCC(O)COc1ccccc1-c1ccccc1,Kd,0.035,nM,10.46,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL4101524,COc1cccc(/C=C2\Oc3c(CN4CCCC4)c(O)cc(C)c3C2=O)c1,Kd,5495.41,nM,5.26,CHEMBL3997586,Displacement of [3H](-)CGP12177 from human beta2-AR expressed in CHOK1 cells after 2 hrs by TopCount microscintillation counting method,B,Homo sapiens
CHEMBL3354065,CCCCC1CCN(CCCN2C(=O)CCc3ccccc32)CC1,Ki,43651.58,nM,4.36,CHEMBL4048898,Displacement of [3H]CGP12177 from human recombinant beta2 adrenergic receptor expressed in HEK293 cell membranes after 90 mins by beta counting method,B,Homo sapiens
CHEMBL4072818,O=C1CCc2ccccc2N1CCCN1CCC(Cc2ccccc2)CC1,Ki,9549.93,nM,5.02,CHEMBL4048898,Displacement of [3H]CGP12177 from human recombinant beta2 adrenergic receptor expressed in HEK293 cell membranes after 90 mins by beta counting method,B,Homo sapiens
CHEMBL4085780,O=C1CCc2ccccc2N1CCCN1CCN(c2ccccc2)CC1,Ki,35481.34,nM,4.45,CHEMBL4048898,Displacement of [3H]CGP12177 from human recombinant beta2 adrenergic receptor expressed in HEK293 cell membranes after 90 mins by beta counting method,B,Homo sapiens
CHEMBL4174345,CNCC(O)COc1ccc(S(=O)(=O)NC(C)C)cc1.Cl,Ki,31622.78,nM,4.50,CHEMBL4145115,Displacement of [3H]-CGP12177 from human beta2 ADR expressed in HEK293T cell membrane after 90 mins by scintillation counting,B,Homo sapiens
CHEMBL4163665,CNCC(O)COc1ccc(S(=O)(=O)NC(C)C(C)C)cc1.Cl,Ki,30199.52,nM,4.52,CHEMBL4145115,Displacement of [3H]-CGP12177 from human beta2 ADR expressed in HEK293T cell membrane after 90 mins by scintillation counting,B,Homo sapiens
CHEMBL4161638,CNCC(O)COc1ccc(S(=O)(=O)NC(C)(C)C)cc1.Cl,Ki,5011.87,nM,5.30,CHEMBL4145115,Displacement of [3H]-CGP12177 from human beta2 ADR expressed in HEK293T cell membrane after 90 mins by scintillation counting,B,Homo sapiens
CHEMBL4162590,CNCC(O)COc1ccc(S(=O)(=O)NCCc2ccccc2)cc1.Cl,Ki,39810.72,nM,4.40,CHEMBL4145115,Displacement of [3H]-CGP12177 from human beta2 ADR expressed in HEK293T cell membrane after 90 mins by scintillation counting,B,Homo sapiens
CHEMBL4170519,CNCC(O)COc1ccc(S(=O)(=O)NCCOc2ccccc2)cc1.Cl,Ki,28183.83,nM,4.55,CHEMBL4145115,Displacement of [3H]-CGP12177 from human beta2 ADR expressed in HEK293T cell membrane after 90 mins by scintillation counting,B,Homo sapiens
CHEMBL4214761,CC(N)c1ccc(Cl)cc1,Ki,33800.0,nM,4.47,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL3358195,CNCc1cc2ccccc2s1,Ki,43200.0,nM,4.37,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4202934,CNCc1ccc(-c2nccs2)cc1,Ki,33500.0,nM,4.47,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4210507,NCc1ccc(-c2ncccn2)cc1,Ki,78100.0,nM,4.11,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4209786,COc1ccc2c(c1)c(CCN)cn2C,Ki,20400.0,nM,4.69,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4204907,CC(CC(F)(F)F)NCc1ccc(-c2nccs2)cc1,Ki,52300.0,nM,4.28,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4202968,OCC(NCc1ccc(-c2nccs2)cc1)c1ccco1,Ki,95400.0,nM,4.02,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4217119,Cc1ccccc1C(C)NCc1ccc(-c2ncccn2)cc1,Ki,4390.0,nM,5.36,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4218602,CC(NC1CC(c2ccc(F)cc2)C1)c1ccc(Cl)cc1,Ki,7890.0,nM,5.10,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4214185,COc1ccc2c(c1)c(CCNCCCc1ccc(Cl)cc1)cn2C,Ki,520.0,nM,6.28,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4209269,COc1ccc2c(c1)c(CCNCCCc1cccc(C(F)(F)F)c1)cn2C,Ki,10400.0,nM,4.98,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4208846,COc1ccc2c(c1)c(CCNCc1cc(OC(F)(F)F)ccc1F)cn2C,Ki,80400.0,nM,4.09,CHEMBL4187604,Displacement of [3H]-DHA from Nb80-fused beta2 adrenergic receptor (unknown origin) expressed in Sf9 cell membranes after 2 hrs by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4238084,CC(=O)NCc1cccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)c3ccccc3)cc2)c1,EC50,23490.0,nM,4.63,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4248093,CCc1ccccc1OC[C@@H](O)CNCCc1ccc(NS(=O)(=O)c2ccccc2)cc1,EC50,954.3,nM,6.02,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4250215,CCc1ccccc1OC[C@@H](O)CNCCc1ccc(NC(=O)c2ccccc2)cc1,EC50,294.5,nM,6.53,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4245968,CCc1ccccc1OC[C@@H](O)CNCCc1ccc(NC(=O)Cc2ccccc2)cc1,EC50,280.8,nM,6.55,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4248727,CCc1ccccc1OC[C@@H](O)CNCCc1ccc(NC(=S)Nc2ccccc2)cc1,EC50,1419.0,nM,5.85,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4246134,CC(=O)NCc1cccc(OC[C@@H](O)CNCCc2ccc(NC(=O)c3ccccc3)cc2)c1,EC50,6058.0,nM,5.22,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4244929,CC(=O)NCc1cccc(OC[C@@H](O)CNCCc2ccc(NC(=O)Cc3ccccc3)cc2)c1,EC50,15930.0,nM,4.80,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4237802,CC(=O)NCc1cccc(OC[C@@H](O)CNCCc2ccc(NC(=O)Nc3ccccc3)cc2)c1,EC50,9842.0,nM,5.01,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4241176,CC(=O)NCc1cccc(OC[C@@H](O)CNCCc2ccc(NS(=O)(=O)Nc3ccccc3)cc2)c1,EC50,8433.0,nM,5.07,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4245391,O=S(=O)(Nc1ccc(CCNC[C@H](O)COc2cccc3[nH]ccc23)cc1)c1ccccc1,EC50,353.1,nM,6.45,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4237453,O=C(Nc1ccc(CCNC[C@H](O)COc2cccc3[nH]ccc23)cc1)c1ccccc1,EC50,117.8,nM,6.93,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4241613,O=C(Cc1ccccc1)Nc1ccc(CCNC[C@H](O)COc2cccc3[nH]ccc23)cc1,EC50,83.14,nM,7.08,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4249564,O=C(Nc1ccccc1)Nc1ccc(CCNC[C@H](O)COc2cccc3[nH]ccc23)cc1,EC50,52.21,nM,7.28,CHEMBL4231527,Antagonist activity at human beta2 adrenergic receptor expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of isoproterenol-induced intercellular calcium mobilization pre-incubated for 10 mins before isoproterenol addition by Fluo-4AM dye-based fluorescence assay,F,Homo sapiens
CHEMBL4282215,Oc1cc2c(cc1O)C(c1ccco1)=NCC2,EC50,5100.0,nM,5.29,CHEMBL4255517,Agonist activity at human beta2-AR expressed in CHOK1 cells co-expressing Galpha15 measured after 21 secs to 120 secs by Calcium-4 dye based FLIPR assay,F,Homo sapiens
CHEMBL4292818,Oc1cc2c(cc1O)[C@@H](Cc1ccccc1)NCC2,EC50,87.9,nM,7.06,CHEMBL4255517,Agonist activity at human beta2-AR expressed in CHOK1 cells co-expressing Galpha15 measured after 21 secs to 120 secs by Calcium-4 dye based FLIPR assay,F,Homo sapiens
CHEMBL4285281,COc1cc2c3c(c1OC)-c1ccccc1[C@@H](O)[C@@H]3NCC2,IC50,1.4,nM,8.85,CHEMBL4258826,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor,B,Homo sapiens
CHEMBL4279962,COc1cc2c3c(c1OC)-c1ccccc1[C@H](O)[C@H]3NCC2,IC50,1600.0,nM,5.80,CHEMBL4258826,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor,B,Homo sapiens
CHEMBL4279531,COc1cc2c3c(c1OC)-c1ccccc1[C@@H](O)[C@H]3NCC2,IC50,210.0,nM,6.68,CHEMBL4258826,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor,B,Homo sapiens
CHEMBL4290197,COc1cc2c3c(c1OC)-c1ccccc1[C@@H](O)[C@]3(C)NCC2,IC50,20.0,nM,7.70,CHEMBL4258826,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor,B,Homo sapiens
CHEMBL4280606,COc1ccc(CCNC[C@H](O)c2ccccc2)cc1OC,IC50,8400.0,nM,5.08,CHEMBL4258826,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor,B,Homo sapiens
CHEMBL4279466,CCc1cc2c(cc1CC)CC(NC(CO)c1ccc(O)c3[nH]c(=O)ccc13)C2,EC50,316.23,nM,6.50,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4289813,O=c1ccc2c(C(CO)NCCc3ccccc3)ccc(O)c2[nH]1,EC50,1.585,nM,8.80,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4294937,O=c1ccc2c(C(CO)NCCCc3ccccc3)ccc(O)c2[nH]1,EC50,10.0,nM,8.00,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4287029,O=c1ccc2c(C(CO)NCCCCc3ccccc3)ccc(O)c2[nH]1,EC50,12.59,nM,7.90,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4279788,O=c1ccc2c(C(CO)NCCc3c[nH]c4ccccc34)ccc(O)c2[nH]1,EC50,316.23,nM,6.50,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4290441,O=c1ccc2c(C(CO)NCCCCOCCCCc3ccccc3)ccc(O)c2[nH]1,EC50,251.19,nM,6.60,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4288132,O=c1ccc2c(C(CO)NCCCCCCOCCCCc3ccccc3)ccc(O)c2[nH]1,EC50,5.012,nM,8.30,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4280227,O=c1ccc2c(C(CO)NCCc3ccccc3O)ccc(O)c2[nH]1,EC50,10.0,nM,8.00,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4291538,O=c1ccc2c(C(CO)NCCc3cccc(O)c3)ccc(O)c2[nH]1,EC50,794.33,nM,6.10,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4283676,O=c1ccc2c(C(CO)NCCc3ccc(O)cc3)ccc(O)c2[nH]1,EC50,3.162,nM,8.50,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4281324,COc1ccccc1CCNC(CO)c1ccc(O)c2[nH]c(=O)ccc12,EC50,5.012,nM,8.30,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4291941,COc1cccc(CCNC(CO)c2ccc(O)c3[nH]c(=O)ccc23)c1,EC50,1.995,nM,8.70,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4289233,COc1ccc(CCNC(CO)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,19.95,nM,7.70,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4278577,O=c1ccc2c(C(CO)NCCc3ccccc3Cl)ccc(O)c2[nH]1,EC50,1.995,nM,8.70,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4292648,O=c1ccc2c(C(CO)NCCc3cccc(Cl)c3)ccc(O)c2[nH]1,EC50,2.512,nM,8.60,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4282047,O=c1ccc2c(C(CO)NCCc3ccc(Cl)cc3)ccc(O)c2[nH]1,EC50,39.81,nM,7.40,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4277527,CC(C)(Cc1ccccc1)NC(CO)c1ccc(O)c2[nH]c(=O)ccc12,EC50,50.12,nM,7.30,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4285474,O=c1ccc2c(C(CO)NCC(c3ccccc3)c3ccccc3)ccc(O)c2[nH]1,EC50,630.96,nM,6.20,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4280939,Nc1ccc(CCNC(CO)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,79.43,nM,7.10,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4288842,O=C(Nc1ccc(CCNC(CO)c2ccc(O)c3[nH]c(=O)ccc23)cc1)c1ccccc1,EC50,50.12,nM,7.30,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4284345,O=C(Cc1ccccc1)Nc1ccc(CCNC(CO)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,3.981,nM,8.40,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4292249,CC(C)C(=O)Nc1ccc(CCNC(CO)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,50.12,nM,7.30,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4276877,CCCCC(=O)Nc1ccc(CCNC(CO)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,316.23,nM,6.50,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4287518,CC(C)CC(=O)Nc1ccc(CCNC(CO)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,630.96,nM,6.20,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4284146,O=c1ccc2c([C@@H](CO)NCCc3ccc(O)cc3)ccc(O)c2[nH]1,EC50,1.26,nM,8.90,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4288610,O=c1ccc2c([C@H](CO)NCCc3ccc(O)cc3)ccc(O)c2[nH]1,EC50,328.0,nM,6.48,CHEMBL4271650,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL152067,CC(C)(C)NCC(O)COc1ccc(NC(=O)NC2CCCCC2)cc1,Ki,900.0,nM,6.05,CHEMBL4306790,Binding affinity to beta2 adrenergic receptor (unknown origin) by radioligand binding assay,B,Homo sapiens
CHEMBL4472703,CC[C@H]1c2cc(OC)ccc2CC[C@@]1(C)N,Ki,5011.87,nM,5.30,CHEMBL4308622,Displacement of [3H]-CGP12177 from human recombinant adrenergic Beta2 receptor expressed in Flp-In HEK cells after 90 mins by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4447975,COc1cc(OC)c2c(c1)OC[C@@]1(C)NCC[C@@H]21,Ki,575.44,nM,6.24,CHEMBL4308622,Displacement of [3H]-CGP12177 from human recombinant adrenergic Beta2 receptor expressed in Flp-In HEK cells after 90 mins by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4459696,COC(=O)CSCCCc1ccccc1OCC(O)CNC(C)C,Ki,15.0,nM,7.82,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4542960,CC(C)NCC(O)COc1ccccc1CCCSCC(=O)NCCOCCOCCNC(=O)OC(C)(C)C,Ki,3.2,nM,8.49,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4458797,CC(C)NCC(O)COc1ccccc1CCCSCC(=O)NCCOCCOCCN,Ki,2.9,nM,8.54,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4452249,CC(C)NCC(O)COc1ccccc1CCCSCC(=O)NCCOCCOCCNC(=O)CCCCCC1(C)C(/C=C/C=C/C=C2/N(CCCS(=O)(=O)O)c3ccc(S(=O)(=O)O)cc3C2(C)C)=[N+](CCCS(=O)(=O)[O-])c2ccc(S(=O)(=O)O)cc21,Ki,26.0,nM,7.58,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4475573,CC(C)NCC(O)COc1ccccc1CCCSCC(=O)NCCOCCOCCNC(=O)CS(=O)(=O)O,Ki,16.4,nM,7.79,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4454523,CC(C)NCC(O)COc1ccccc1CCCSCC(=O)NCCOCCOCCNC(=O)C1C(C(=O)O)C(C(=O)O)C1C(=O)O,Ki,78.6,nM,7.11,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4466532,C=CCc1ccccc1OCC(O)CNCCOCCOCCOCCOCCNC(=O)OC(C)(C)C,Ki,3.7,nM,8.43,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4587648,C=CCc1ccccc1OCC(O)CNCCOCCOCCOCCOCCN,Ki,10.3,nM,7.99,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4527905,C=CCc1ccccc1OCC(O)CNCCOCCOCCOCCOCCNC(=O)CCCCCC1(C)C(/C=C/C=C/C=C2/N(CCCS(=O)(=O)O)c3ccc(S(=O)(=O)O)cc3C2(C)C)=[N+](CCCS(=O)(=O)[O-])c2ccc(S(=O)(=O)O)cc21,Ki,547.0,nM,6.26,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4545079,C=CCc1ccccc1OCC(O)CNCCOCCOCCOCCOCCNC(=O)CS(=O)(=O)O,Ki,752.0,nM,6.12,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4440189,C=CCc1ccccc1OCC(O)CNCCOCCOCCOCCOCCNC(=O)C1C(C(=O)O)C(C(=O)O)C1C(=O)O,Ki,512.0,nM,6.29,CHEMBL4312072,Displacement of [3H](-)CGP 12177 from human recombinant beta2 adrenoceptor after 120 mins by scintillation counting method,B,Homo sapiens
CHEMBL4442460,COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccccc2)CC1,Ki,1800.0,nM,5.75,CHEMBL4323490,Displacement of [3H] CGP12177 from beta2 adrenergic receptor (unknown origin),B,Homo sapiens
CHEMBL4544086,COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(F)cc2)c2ccccc2)CC1,Ki,4500.0,nM,5.35,CHEMBL4323490,Displacement of [3H] CGP12177 from beta2 adrenergic receptor (unknown origin),B,Homo sapiens
CHEMBL4445289,CC(C)(CCc1ccccc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.021,nM,10.68,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4469364,CC(C)(CCc1ccccc1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.04074,nM,10.39,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4438531,CC(C)(CC(c1ccc(F)cc1)c1ccc(F)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.08128,nM,10.09,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4537644,CC(C)(CC(c1ccc(F)cc1)c1ccc(F)cc1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.07586,nM,10.12,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4575759,CC(C)(CC(c1ccccc1)c1ccccc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.06457,nM,10.19,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4473349,CC(C)(CC(c1ccccc1)c1ccccc1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.2188,nM,9.66,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4516838,CC(CC(=O)Nc1ccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)CC(C)(C)C,EC50,2.512,nM,8.60,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4441752,CC(C)C(=O)Nc1ccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,0.5012,nM,9.30,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4460095,CC(C)CCC(=O)Nc1cccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1,EC50,0.2239,nM,9.65,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4566727,O=C(Nc1cccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1)c1ccccc1,EC50,0.302,nM,9.52,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4576089,CC(CC(=O)Nc1cccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1)CC(C)(C)C,EC50,0.05129,nM,10.29,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4541169,CC(C)C(=O)Nc1cccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1,EC50,0.5012,nM,9.30,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4518961,CC(C)CC(=O)Nc1cccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1,EC50,0.9333,nM,9.03,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4473790,COc1ccccc1CCCNCC(O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,0.04266,nM,10.37,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4577508,COc1cccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1,EC50,0.04074,nM,10.39,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4588479,COc1ccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,EC50,0.07413,nM,10.13,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4561253,O=c1ccc2c(C(O)CNCCCc3ccccc3O)ccc(O)c2[nH]1,EC50,0.04898,nM,10.31,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4473515,O=c1ccc2c(C(O)CNCCCc3cccc(O)c3)ccc(O)c2[nH]1,EC50,0.036,nM,10.44,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4556022,O=c1ccc2c(C(O)CNCCCc3ccc(O)cc3)ccc(O)c2[nH]1,EC50,0.05012,nM,10.30,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4541263,O=c1ccc2c(C(O)CNCCCCc3ccccc3)ccc(O)c2[nH]1,EC50,0.1514,nM,9.82,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4454489,O=c1ccc2c(C(O)CNCCCc3ccc(-c4ccccc4)cc3)ccc(O)c2[nH]1,EC50,0.1318,nM,9.88,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4550290,O=c1ccc2c(C(O)CNCCCc3ccc4ccccc4c3)ccc(O)c2[nH]1,EC50,9.12,nM,8.04,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4542430,O=c1ccc2c(C(O)CNCCOc3ccccc3)ccc(O)c2[nH]1,EC50,0.1622,nM,9.79,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4536813,O=c1ccc2c(C(O)CNCCCc3ccccc3)ccc(O)c2[nH]1,EC50,0.07413,nM,10.13,CHEMBL4340581,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as increase in cAMP accumulation after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4594173,CC(C)NC[C@H](O)COc1ccccc1CCCC(=O)NCCNC(=O)CCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,6.607,nM,8.18,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4459989,CC(C)NC[C@H](O)COc1ccccc1CCC(=O)NCCCNC(=O)CCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,8.318,nM,8.08,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4584173,CC(C)NC[C@H](O)COc1ccccc1CCCC(=O)NCCCNC(=O)CCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,6.457,nM,8.19,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4472564,CC(C)NC[C@H](O)COc1ccccc1CCCC(=O)NCCCCNC(=O)CCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,11.22,nM,7.95,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4556017,CC(C)NC[C@@H](O)COc1ccccc1CCCC(=O)NCCNC(=O)CCCc1ccccc1OC[C@H](O)CNC(C)C,IC50,213.8,nM,6.67,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4530266,CC(C)NC[C@H](O)COc1ccccc1-n1cc(CNCc2cn(-c3ccccc3OC[C@@H](O)CNC(C)C)nn2)nn1,IC50,169.82,nM,6.77,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4442559,CC(C)NC[C@H](O)COc1ccccc1Cn1cc(CNCc2cn(Cc3ccccc3OC[C@@H](O)CNC(C)C)nn2)nn1,IC50,64.57,nM,7.19,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4462252,CC(C)NC[C@H](O)COc1ccccc1CCn1cc(CNCc2cn(CCc3ccccc3OC[C@@H](O)CNC(C)C)nn2)nn1,IC50,4.677,nM,8.33,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4514723,CC(C)NC[C@H](O)COc1ccccc1CCCn1cc(CNCc2cn(CCCc3ccccc3OC[C@@H](O)CNC(C)C)nn2)nn1,IC50,2.884,nM,8.54,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4593049,COc1ccccc1CCCNC(=O)NCCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,13.8,nM,7.86,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4564495,CC(C)NC[C@H](O)COc1ccccc1CCCNC(=O)NCCCc1ccccc1,IC50,14.13,nM,7.85,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4468271,CCCNC(=O)NCCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,85.11,nM,7.07,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4532142,COc1ccccc1CCCC(=O)NCCNC(=O)CCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,3.89,nM,8.41,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4515576,CC(C)NC[C@H](O)COc1ccccc1CCCC(=O)NCCNC(=O)CCCc1ccccc1,IC50,5.888,nM,8.23,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4578042,CCCC(=O)NCCNC(=O)CCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,64.57,nM,7.19,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL1160734,C=CCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,0.7244,nM,9.14,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL1395661,C=CCc1ccccc1OC[C@H](O)CNC(C)C,IC50,2.344,nM,8.63,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL4473518,CC(C)NC[C@H](O)COc1ccccc1CCCCCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,3.236,nM,8.49,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL4527821,CC(C)NC[C@H](O)COc1ccccc1CCCCCCCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,5.248,nM,8.28,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL4434772,CC(C)NC[C@H](O)COc1ccccc1CCCCCCCCCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,13.8,nM,7.86,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL4441975,CC(C)NC[C@H](O)COc1ccccc1CCCCCCCCCCCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,25.7,nM,7.59,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL4574652,CC(C)NC[C@H](O)COc1ccccc1CCNC(=O)NCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,2.188,nM,8.66,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL4446394,CC(C)NC[C@H](O)COc1ccccc1CCCNC(=O)NCCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,1.585,nM,8.80,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL4564189,CC(C)NC[C@H](O)COc1ccccc1CCCCNC(=O)NCCCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,1.778,nM,8.75,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL4474813,CC(C)NC[C@H](O)COc1ccccc1CC(=O)NCCNC(=O)Cc1ccccc1OC[C@@H](O)CNC(C)C,IC50,213.8,nM,6.67,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL4450606,CC(C)NC[C@H](O)COc1ccccc1CCC(=O)NCCNC(=O)CCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,3.311,nM,8.48,CHEMBL4375058,Antagonist activity at beta2 adrenergic receptor (unknown origin) expressed in HEK293 cell assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 15 mins,F,Homo sapiens
CHEMBL41189,CC(C)NC[C@H](O)COc1ccccc1OCCOCCOc1ccccc1OC[C@@H](O)CNC(C)C,IC50,46.77,nM,7.33,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4557995,CC(C)NC[C@H](O)COc1ccccc1OCCOCCOCCOc1ccccc1OC[C@@H](O)CNC(C)C,IC50,74.13,nM,7.13,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4465278,CC(C)NC[C@H](O)COc1ccccc1CCCCCNC(=O)NCCCCCc1ccccc1OC[C@@H](O)CNC(C)C,IC50,1.738,nM,8.76,CHEMBL4375056,Antagonist activity at beta2 adrenergic receptor (unknown origin) stably expressed in HEK293 cell membranes assessed as inhibition of isoproterenol-induced cAMP production preincubated for 15 mins followed by isoproterenol addition and measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL4277264,Cc1cc(Oc2nccc3occc23)ccc1-c1c(C)ncc2nccn12,Ki,9300.0,nM,5.03,CHEMBL4392150,Displacement of [3H]-CGP12177 from recombinant human beta2 adrenergic receptor expressed in HEK Flp-In cells measured after 90 mins by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4469848,FC(F)(F)c1cc(Oc2nccc3occc23)ccc1-c1cccc2nccn12,Ki,8600.0,nM,5.07,CHEMBL4392150,Displacement of [3H]-CGP12177 from recombinant human beta2 adrenergic receptor expressed in HEK Flp-In cells measured after 90 mins by microbeta scintillation counting method,B,Homo sapiens
CHEMBL4466483,FC(F)(F)c1cc(Oc2nccc3ccsc23)ccc1-c1cccc2nccn12,Ki,5900.0,nM,5.23,CHEMBL4392150,Displacement of [3H]-CGP12177 from recombinant human beta2 adrenergic receptor expressed in HEK Flp-In cells measured after 90 mins by microbeta scintillation counting method,B,Homo sapiens
CHEMBL1160694,CC(C)NC[C@H](O)COc1ccc(O)c(O)c1,EC50,316.23,nM,6.50,CHEMBL4397570,Agonist activity at beta2-adrenergic receptor (unknown origin) expressed in HEK293T cells harboring GFP/Rluc2-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment incubated for 5 mins in presence of GSK2 and coelenterazine 400a by BRET assay,B,Homo sapiens
CHEMBL4593181,COc1cc(CCNC[C@H](O)COc2ccc(O)c(O)c2)ccc1OCCCc1ccccc1,EC50,1995.26,nM,5.70,CHEMBL4397572,Agonist activity at beta2-adrenergic receptor (unknown origin) expressed in HEK293T cells harboring GFP/Rluc2-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment incubated for 5 mins in presence of GSK5 and coelenterazine 400a by BRET assay,B,Homo sapiens
CHEMBL4435895,COc1ccccc1OCCNC[C@H](O)COc1ccc(O)c(O)c1,EC50,630.96,nM,6.20,CHEMBL4397572,Agonist activity at beta2-adrenergic receptor (unknown origin) expressed in HEK293T cells harboring GFP/Rluc2-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment incubated for 5 mins in presence of GSK5 and coelenterazine 400a by BRET assay,B,Homo sapiens
CHEMBL4437939,COc1cc(CCNCCCOc2ccc(O)c(O)c2)ccc1OCCCc1ccccc1,Ki,700.0,nM,6.16,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4518727,COc1ccccc1OCCNC[C@H](O)Cc1ccc(O)c(O)c1,Ki,5200.0,nM,5.28,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4459109,COc1ccccc1OCCNC[C@@H](O)Cc1ccc(O)c(O)c1,Ki,740.0,nM,6.13,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4525632,COc1ccccc1OCCNCCCc1ccc(O)c(O)c1,Ki,920.0,nM,6.04,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4513932,COc1ccccc1OCCNCCCOc1cccc2[nH]c3ccccc3c12,Ki,5.4,nM,8.27,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4436343,COc1ccccc1OCCNCCc1cccc2[nH]c3ccccc3c12,Ki,26.0,nM,7.58,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4451135,COc1ccccc1OCCNC[C@H](O)c1cccc2[nH]c3ccccc3c12,Ki,3.3,nM,8.48,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4450756,COc1ccccc1OCCNC[C@@H](O)c1cccc2[nH]c3ccccc3c12,Ki,170.0,nM,6.77,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4439238,CC(C)NC[C@@H](O)COc1ccc(O)c(O)c1,Ki,420.0,nM,6.38,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4561683,CC(C)NCCCOc1ccc(O)c(O)c1,Ki,6900.0,nM,5.16,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4515498,COc1ccccc1OCCNC[C@@H](O)COc1ccc(O)c(O)c1,Ki,7900.0,nM,5.10,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4459541,COc1ccccc1OCCNCCCOc1ccc(O)c(O)c1,Ki,3800.0,nM,5.42,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4470694,COc1cc(CCNC[C@@H](O)COc2ccc(O)c(O)c2)ccc1OCCCc1ccccc1,Ki,120.0,nM,6.92,CHEMBL4397556,Displacement of [3H]-CGP-12177 from human beta2-adrenergic receptor expressed in CHO cells after 60 mins by radioligand competition binding assay,B,Homo sapiens
CHEMBL4576034,Cn1cc(C(F)(F)F)nc1-c1ccc(OC[C@@H](O)CNCCOc2ccc(OCCCSSCCN)c(C(N)=O)c2)cc1,Ki,1400.0,nM,5.85,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4443911,Cn1cc(C(F)(F)F)nc1-c1ccc(OC[C@@H](O)CNCCOc2ccc(OCCSSCCN)c(C(N)=O)c2)cc1,Ki,2000.0,nM,5.70,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4450085,COc1cc(CCNC[C@H](O)COc2ccc(-c3nc(C(F)(F)F)cn3C)cc2)ccc1OCCSSCCN,Ki,2200.0,nM,5.66,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4437569,COc1cc(CCNC[C@H](O)COc2ccc(COCCOC(C)C)cc2)ccc1OCCSSCCN,Ki,51.0,nM,7.29,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL645,CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,Ki,250.0,nM,6.60,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4473272,COCCc1ccc(OC[C@H](O)CNCCc2ccc(OCCCSSCCN)c(OC)c2)cc1,Ki,320.0,nM,6.50,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4566666,COCCc1ccc(OC[C@@H](O)CNCCc2ccc(OCCCSSCCN)c(OC)c2)cc1,Ki,20.0,nM,7.70,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4456505,COCCc1ccc(OC[C@H](O)CNCCc2ccc(OCCSSCCN)c(OC)c2)cc1,Ki,1300.0,nM,5.89,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4553747,COCCc1ccc(OC[C@@H](O)CNCCc2ccc(OCCSSCCN)c(OC)c2)cc1,Ki,57.0,nM,7.24,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4463925,COc1cc(CCNC[C@@H](O)COc2cccc3ccccc23)ccc1OCCCSSCCN,Ki,1.1,nM,8.96,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4456301,COc1cc(CCNC[C@H](O)COc2cccc3ccccc23)ccc1OCCCSSCCN,Ki,0.073,nM,10.14,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4463246,COc1cc(CCNC[C@@H](O)COc2cccc3ccccc23)ccc1OCCSSCCN,Ki,3.4,nM,8.47,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4537221,COc1cc(CCNC[C@H](O)COc2cccc3ccccc23)ccc1OCCSSCCN,Ki,0.16,nM,9.80,CHEMBL4402768,Displacement of [3H]CGP12177 from human beta2 adrenoceptor expressed in CHO cell membranes,B,Homo sapiens
CHEMBL4297483,CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,EC50,0.2512,nM,9.60,CHEMBL4406928,Agonist activity at human beta2 adrenoceptor,B,Homo sapiens
CHEMBL4465556,CC(C)c1ncc(C(=O)N2CCOC3(CCN(Cc4ccc(F)c(CCNC[C@H](O)c5ccc(O)c6[nH]c(=O)sc56)c4)CC3)C2)s1,EC50,0.2512,nM,9.60,CHEMBL4406928,Agonist activity at human beta2 adrenoceptor,B,Homo sapiens
CHEMBL4565954,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)Nc5ccc(C#CCCCNC[C@H](O)c6ccc(O)c7[nH]c(=O)ccc67)cc5)c4)cc23)c1,IC50,11.0,nM,7.96,CHEMBL4406938,Inhibition of beta2 adrenoceptor (unknown origin),B,Homo sapiens
CHEMBL1233766,Cc1ccc(OC[C@@H](O)[C@H](C)NC(C)C)c2c1CCC2,Kd,630.0,nM,6.20,CHEMBL4425965,Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes assessed as intrinsic Kd by liquid scintillation counting,B,Homo sapiens
CHEMBL521606,CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2,Kd,70.0,nM,7.16,CHEMBL4425965,Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes assessed as intrinsic Kd by liquid scintillation counting,B,Homo sapiens
CHEMBL420746,CC(C)(C)NCC(O)COc1cccc2[nH]c(=O)[nH]c12,Kd,19.0,nM,7.72,CHEMBL4425965,Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes assessed as intrinsic Kd by liquid scintillation counting,B,Homo sapiens
CHEMBL378501,CC(C)(C)NCC(O)COc1cccc2[nH]c(C#N)cc12,Kd,0.7,nM,9.15,CHEMBL4425965,Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes assessed as intrinsic Kd by liquid scintillation counting,B,Homo sapiens
CHEMBL4641339,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCc2ccccc2)N1,EC50,2.399,nM,8.62,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4649718,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCc2ccc(F)cc2)N1,EC50,4.898,nM,8.31,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4642893,COc1ccc(CCNCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1.Cl,EC50,1.622,nM,8.79,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4643148,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCCCc2ccccc2)N1,EC50,0.2512,nM,9.60,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4648975,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCCc2ccccc2)N1,EC50,0.3162,nM,9.50,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4645932,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCCc2ccc(F)cc2)N1,EC50,0.7413,nM,9.13,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4643561,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCCc2ccc(O)cc2)N1,EC50,0.8913,nM,9.05,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4636111,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCCc2ccccc2O)N1,EC50,0.2138,nM,9.67,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4648663,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCCc2cccc(O)c2)N1,EC50,0.1738,nM,9.76,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4632700,COc1ccc(CCCNCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1.Cl,EC50,0.9333,nM,9.03,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4645720,COc1ccccc1CCCNCC(O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.3802,nM,9.42,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4632876,COc1cccc(CCCNCC(O)c2cc(O)cc3c2OCC(=O)N3)c1.Cl,EC50,0.4266,nM,9.37,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4636080,Cc1ccc(CCCNCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1.Cl,EC50,2.239,nM,8.65,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4648695,Cc1cccc(CCCNCC(O)c2cc(O)cc3c2OCC(=O)N3)c1.Cl,EC50,0.6918,nM,9.16,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4647449,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCCc2cccc(C(F)(F)F)c2)N1,EC50,1.349,nM,8.87,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4639822,Cl.O=C1COc2c(cc(O)cc2C(O)CNCCCc2cc(F)cc(F)c2)N1,EC50,0.1288,nM,9.89,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4638864,CC(C)(CCc1ccccc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2,EC50,0.03236,nM,10.49,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4649233,COc1ccc(CCC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1.Cl,EC50,0.04898,nM,10.31,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4642770,COc1ccccc1CCC(C)(C)NCC(O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.02884,nM,10.54,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4645694,COc1cccc(CCC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)c1.Cl,EC50,0.04898,nM,10.31,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4644638,CC(C)(CCc1ccc(O)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.03981,nM,10.40,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4636255,CC(C)(CCc1cccc(O)c1)NCC(O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.0309,nM,10.51,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4632435,CC(C)(CC(c1ccccc1)c1ccccc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.6166,nM,9.21,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4648440,CC(C)(CC(c1ccc(F)cc1)c1ccc(F)cc1)NCC(O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.7943,nM,9.10,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4645203,COc1ccc(CCC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1.Cl,EC50,0.03548,nM,10.45,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4635163,COc1ccccc1CCC(C)(C)NC[C@H](O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.02399,nM,10.62,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4641262,COc1cccc(CCC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)c1.Cl,EC50,0.02754,nM,10.56,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4646881,CC(C)(CCc1ccc(O)cc1)NC[C@H](O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.0257,nM,10.59,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4634131,CC(C)(CCc1cccc(O)c1)NC[C@H](O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.01622,nM,10.79,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4648525,CC(C)(CC(c1ccccc1)c1ccccc1)NC[C@H](O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.1413,nM,9.85,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4640925,CC(C)(CC(c1ccc(F)cc1)c1ccc(F)cc1)NC[C@H](O)c1cc(O)cc2c1OCC(=O)N2.Cl,EC50,0.1738,nM,9.76,CHEMBL4610312,Agonist activity at human beta2 adrenoreceptor overexpressed in human HEK293 cells assessed as cAMP accumulation incubated for 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4633760,CC(=O)Nc1ccc(/N=N/c2ccccc2OC[C@@H](O)CNC(C)C)cc1,IC50,1.72,nM,8.76,CHEMBL4630500,Antagonist activity at ADRB2 endogenously expressed in HEK293 cells transfected with cAMP FRET biosensor assessed as inhibition of cimaterol-induced response pre-incubated for 45 mins under dark conditions by FRET assay,F,Homo sapiens
CHEMBL4634403,CC(=O)Nc1ccc(/N=N/c2cccc(OC[C@@H](O)CNC(C)C)c2)cc1,IC50,593.88,nM,6.23,CHEMBL4630500,Antagonist activity at ADRB2 endogenously expressed in HEK293 cells transfected with cAMP FRET biosensor assessed as inhibition of cimaterol-induced response pre-incubated for 45 mins under dark conditions by FRET assay,F,Homo sapiens
CHEMBL4789047,Cc1ccc(CN(CC(O)COc2cccc3[nH]ccc23)C(C)(C)C)cc1,Ki,1300.0,nM,5.89,CHEMBL4713444,Binding affinity to beta2 adrenoceptor (unknown origin),B,Homo sapiens
CHEMBL4746212,COc1cccc(Nc2c(C(N)=O)ccc3c(C)cc(S(=O)(=O)c4cccc(C(=O)Nc5ccc(C#CCCCNC[C@@H](O)c6ccc(O)c7[nH]c(=O)ccc67)cc5)c4)cc23)c1,EC50,8.0,nM,8.10,CHEMBL4725736,Agonist activity at recombinant human beta2 adrenergic receptor expressed in CHO cells in presence of [3H](-)CGP12177,B,Homo sapiens
CHEMBL4850904,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(c2ccc3nncn3n2)CC1,EC50,12000.0,nM,4.92,CHEMBL4810678,Antagonist activity at ADRB2 (unknown origin),F,Homo sapiens
CHEMBL4878395,O=C(NC(c1ccccc1)c1ccc(OCCCCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)O[C@H]1CN2CCC1CC2,Ki,0.2512,nM,9.60,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4846536,O=C(NC(c1ccccc1)c1cccc(OCCCCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1)O[C@H]1CN2CCC1CC2,Ki,0.1995,nM,9.70,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4852629,O=C(NC(c1ccccc1)c1cccc(OCCCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1)O[C@H]1CN2CCC1CC2,Ki,0.1995,nM,9.70,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4854418,O=C(NC(c1ccccc1)c1cccc(OCCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1)O[C@H]1CN2CCC1CC2,Ki,0.1,nM,10.00,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4863525,O=C(NC(c1ccccc1)c1cccc(OCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1)O[C@H]1CN2CCC1CC2,Ki,0.01585,nM,10.80,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4874819,O=C(NC(c1ccccc1)c1cccc(OCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1)O[C@H]1CN2CCC1CC2,Ki,0.02512,nM,10.60,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4857743,O=C(N[C@H](c1ccccc1)c1cccc(OCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1)O[C@H]1CN2CCC1CC2,Ki,0.03981,nM,10.40,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4847910,O=C(N[C@@H](c1ccccc1)c1cccc(OCCCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1)O[C@H]1CN2CCC1CC2,Ki,0.5012,nM,9.30,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4871517,O=C(N[C@@H](c1ccccc1)c1ccc(-c2cccc(OCc3ccc(C(=O)NCCCNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)cc3)c2)cc1)O[C@H]1CN2CCC1CC2,Ki,0.01259,nM,10.90,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4866806,CCN(CCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)C(=O)c1ccc(COc2cccc(-c3ccc([C@@H](NC(=O)O[C@H]4CN5CCC4CC5)c4ccccc4)cc3)c2)cc1,Ki,0.05012,nM,10.30,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4871702,O=C(N[C@@H](c1ccccc1)c1ccc(-c2cccc(OCc3ccc(C(=O)N(CCCNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)Cc4ccccc4)cc3)c2)cc1)O[C@H]1CN2CCC1CC2,Ki,0.1,nM,10.00,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4854091,O=C(N[C@@H](c1ccccc1)c1cccc(OCc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)c1)O[C@H]1CN2CCC1CC2,Ki,0.2512,nM,9.60,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4878138,COc1cc(C(=O)NCCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Ki,0.1585,nM,9.80,CHEMBL4817488,Displacement of 125I-cyanopindolol from human adrenergic beta2 receptor,B,Homo sapiens
CHEMBL4874511,CC(C)(C)NC(CO)c1cc(Cl)c(N)c(C(F)(F)F)c1,EC50,21.8,nM,7.66,CHEMBL4819529,Agonist activity at beta2 adrenoceptor (unknown origin),F,Homo sapiens
CHEMBL1615159,Cc1ccccc1CC(C)(C)NC[C@H](O)c1ccc(O)c2c1OCC(=O)N2,EC50,27.0,nM,7.57,CHEMBL4819529,Agonist activity at beta2 adrenoceptor (unknown origin),F,Homo sapiens
CHEMBL605846,COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1,EC50,0.02,nM,10.70,CHEMBL4819529,Agonist activity at beta2 adrenoceptor (unknown origin),F,Homo sapiens
CHEMBL4859326,CN(C)C(=O)CNc1ccc2c(c1)C[C@@H](NC[C@H](O)c1ccc(O)c(CCO)c1)CC2,EC50,2.9,nM,8.54,CHEMBL4819530,Agonist activity at human beta2 adrenoceptor expressed in CHO cells assessed as increase in cAMP level incubated for 30 mins by immunoassay,F,Homo sapiens
CHEMBL3039530,O=c1ccc2c([C@@H](O)CNCCCCCCOCC(F)(F)c3ccccc3)ccc(O)c2[nH]1,EC50,0.6,nM,9.22,CHEMBL4819532,Inhibition of 3H]CGP12177 binding to human beta2 adrenoceptor expressed in sf9 cell membranes incubated for 60 mins by scintillation counting method,B,Homo sapiens
CHEMBL6913,CC(C)N[C@@H]1CCc2c(ccc(O)c2O)[C@H]1O,Ki,32.0,nM,7.50,CHEMBL4819534,Binding affinity to beta2 adrenoceptor (unknown origin),B,Homo sapiens
CHEMBL4869517,Oc1ccc2c(c1O)CC[C@@H](NC1CCCC1)[C@@H]2O,Ki,25.0,nM,7.60,CHEMBL4819534,Binding affinity to beta2 adrenoceptor (unknown origin),B,Homo sapiens
CHEMBL4871979,Oc1ccc2c(c1O)CC[C@@H](NCCCF)[C@@H]2O,Ki,97.0,nM,7.01,CHEMBL4819534,Binding affinity to beta2 adrenoceptor (unknown origin),B,Homo sapiens
CHEMBL4860571,Oc1ccc2c(c1O)CC[C@@H](NCC1CC(F)(F)C1)[C@@H]2O,Ki,25.0,nM,7.60,CHEMBL4819534,Binding affinity to beta2 adrenoceptor (unknown origin),B,Homo sapiens
CHEMBL4874899,COc1cc(CCC(O)CC(O)CCc2cc(O)c(O)c(OC)c2)ccc1O,EC50,23840.0,nM,4.62,CHEMBL4819535,Agonist activity at beta2 adrenoceptor in human A431 cells measured for 24 hrs,F,Homo sapiens
CHEMBL4850211,COc1cc(CCC(O)CC(O)CCc2ccc(O)c(O)c2)ccc1O,EC50,5925.0,nM,5.23,CHEMBL4819535,Agonist activity at beta2 adrenoceptor in human A431 cells measured for 24 hrs,F,Homo sapiens
CHEMBL4860455,CC(C)NC(CO)c1cc(F)c(N)c(C#N)c1,EC50,0.251,nM,9.60,CHEMBL4819538,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as increase in cAMP accumulation measured after 60 mins by HTRF assay,F,Homo sapiens
CHEMBL4225747,CNC(=O)[C@H](Cc1cccc(Br)c1)NC(=O)[C@H](Cc1ccc(C(N)=O)cc1)NC(=O)C(c1ccccc1)C1CCCCC1,EC50,5400.0,nM,5.27,CHEMBL4819540,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as increase in isoproterenol-induced cAMP production preincubated for 20 mins followed by isoproterenol stimulation and measured after 5 mins by chemiluminescence-based assay,F,Homo sapiens
CHEMBL4858076,COc1ccc(Sc2ccc(S(=O)(=O)N(C)C(C)C)cc2C(=O)N[C@@H](CC(N)=O)Cc2ccc(C(C)(C)C)cc2)cc1,EC50,3200.0,nM,5.50,CHEMBL4819541,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells co-expressing V2 receptor assessed as induction of beta-arrestin 2 recruitment preincubated for 20 mins followed by beta2 receptor agonist and measured after 6 hrs by Bright-Glo reagent based chemiluminescence assay,F,Homo sapiens
CHEMBL4878555,CC(C)NC(CO)c1ccc(O)c2[nH]c(=O)ccc12,EC50,19000.0,nM,4.72,CHEMBL4819542,Agonist activity at beta2 adrenoceptor in HEK293 cells co-expressing V2 receptor assessed as increase in cAMP accumulation measured after 30 mins by HTRF assay,F,Homo sapiens
CHEMBL4876155,CC(C)(C)NC(CO)c1ccc(O)c2[nH]c(=O)ccc12,EC50,17400.0,nM,4.76,CHEMBL4819542,Agonist activity at beta2 adrenoceptor in HEK293 cells co-expressing V2 receptor assessed as increase in cAMP accumulation measured after 30 mins by HTRF assay,F,Homo sapiens
CHEMBL4866730,CCCCCCNC(CO)c1ccc(O)c2[nH]c(=O)ccc12,EC50,35500.0,nM,4.45,CHEMBL4819542,Agonist activity at beta2 adrenoceptor in HEK293 cells co-expressing V2 receptor assessed as increase in cAMP accumulation measured after 30 mins by HTRF assay,F,Homo sapiens
CHEMBL4869271,Nc1nc(Nc2ccccc2)nc2ccc(Br)cc12,EC50,5200.0,nM,5.28,CHEMBL4819545,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in sf9 cells assessed as reversal of norepinephrine inhibition of [3H]DHAP binding to beta2 adrenoceptor by radioligand binding assay,F,Homo sapiens
CHEMBL4859591,Cc1ccccc1CCCNCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.05754,nM,10.24,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4870623,Cc1cccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1.Cl,EC50,0.03802,nM,10.42,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4873280,Cc1ccc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1.Cl,EC50,0.0955,nM,10.02,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4846631,Cl.O=c1ccc2c(C(O)CNCCCc3cccc(F)c3)ccc(O)c2[nH]1,EC50,0.02455,nM,10.61,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4874945,Cl.O=c1ccc2c(C(O)CNCCCc3ccc(F)cc3)ccc(O)c2[nH]1,EC50,0.04677,nM,10.33,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4872480,Cl.O=c1ccc2c(C(O)CNCCCc3cc(F)cc(F)c3)ccc(O)c2[nH]1,EC50,0.02138,nM,10.67,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4872653,Cl.O=c1ccc2c(C(O)CNCCCc3cccc(C(F)(F)F)c3)ccc(O)c2[nH]1,EC50,0.02818,nM,10.55,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4867311,COc1cc(CCCNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc(OC)c1OC.Cl,EC50,0.08318,nM,10.08,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4860764,CC(CCc1ccccc1Cl)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.03388,nM,10.47,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4847767,CC(CCc1cccc(Cl)c1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.07244,nM,10.14,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4853372,CC(CCc1ccc(Cl)cc1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.03311,nM,10.48,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4854569,COc1ccccc1CCC(C)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.01479,nM,10.83,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4863282,COc1cccc(CCC(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1.Cl,EC50,0.02138,nM,10.67,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4860454,COc1ccc(CCC(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1.Cl,EC50,0.0182,nM,10.74,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4868684,CC(CCc1cccc(F)c1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.02344,nM,10.63,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4868763,CC(CCc1ccc(F)cc1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.02818,nM,10.55,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4848018,Cc1ccccc1CCC(C)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.01738,nM,10.76,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4865833,Cc1ccc(CCC(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1.Cl,EC50,0.03802,nM,10.42,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4873082,Cc1cccc(CCC(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1.Cl,EC50,0.01288,nM,10.89,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4847536,CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.01072,nM,10.97,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4848793,CC(CCc1cccc(O)c1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.01349,nM,10.87,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4865514,COc1cc(CCC(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc(OC)c1OC.Cl,EC50,0.04467,nM,10.35,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4848617,COc1ccccc1CC[C@@H](C)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.02884,nM,10.54,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4848775,COc1ccc(CCC(C)(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1.Cl,EC50,0.0309,nM,10.51,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4863847,COc1cccc(CCC(C)(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1.Cl,EC50,0.0263,nM,10.58,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4857267,COc1ccccc1CCC(C)(C)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.02239,nM,10.65,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4865710,Cc1ccc(CCC(C)(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1.Cl,EC50,0.0166,nM,10.78,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4855974,Cc1cccc(CCC(C)(C)NCC(O)c2ccc(O)c3[nH]c(=O)ccc23)c1.Cl,EC50,0.0195,nM,10.71,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4848704,Cc1ccccc1CCC(C)(C)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.01778,nM,10.75,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4871708,CC(C)(CCc1ccc(Cl)cc1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.01259,nM,10.90,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4868938,CC(C)(CCc1ccccc1Cl)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.0182,nM,10.74,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4866766,CC(C)(CCc1ccc(O)cc1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.03631,nM,10.44,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4854261,CC(C)(CCc1cccc(O)c1)NCC(O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.0182,nM,10.74,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4862449,CC(C)(CCc1ccc(Cl)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.01778,nM,10.75,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL4868585,CC(C)(CCc1cccc(Cl)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12.Cl,EC50,0.02239,nM,10.65,CHEMBL4843198,Agonist activity at human beta2 adrenoreceptor overexpressed in HEK293 cells assessed as cAMP accumulation,F,Homo sapiens
CHEMBL3480577,Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1,Ki,10000.0,nM,5.00,CHEMBL4880056,GPCRScan assay: inhibition of Beta2,B,Homo sapiens
CHEMBL5208201,O=C(NC(c1ccccc1)c1cccc(OCc2ccc(C(=O)OCCCCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)c1)O[C@H]1CN2CCC1CC2,Ki,0.03981,nM,10.40,CHEMBL5129800,Displacement of 125I-cyanopindolol from human beta2 adrenoceptor expressed in CHO-K1 cell membrane measured after 1 hr by Cheng-prusoff equation analysis,B,Homo sapiens
CHEMBL5184455,O=C(N[C@@H](c1ccccc1)c1cccc(OCc2ccc(C(=O)OCCCCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)c1)O[C@H]1CN2CCC1CC2,Ki,0.01995,nM,10.70,CHEMBL5129800,Displacement of 125I-cyanopindolol from human beta2 adrenoceptor expressed in CHO-K1 cell membrane measured after 1 hr by Cheng-prusoff equation analysis,B,Homo sapiens
CHEMBL5184598,O=C(N[C@H](c1ccccc1)c1cccc(OCc2ccc(C(=O)OCCCCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)c1)O[C@H]1CN2CCC1CC2,Ki,0.05012,nM,10.30,CHEMBL5129800,Displacement of 125I-cyanopindolol from human beta2 adrenoceptor expressed in CHO-K1 cell membrane measured after 1 hr by Cheng-prusoff equation analysis,B,Homo sapiens
CHEMBL5201712,O=c1ccc2c([C@@H](O)CNCCCCO)ccc(O)c2[nH]1,Ki,25.12,nM,7.60,CHEMBL5129800,Displacement of 125I-cyanopindolol from human beta2 adrenoceptor expressed in CHO-K1 cell membrane measured after 1 hr by Cheng-prusoff equation analysis,B,Homo sapiens
CHEMBL5190387,O=C(N[C@@H](c1ccccc1)c1cccc(OCc2ccc(C(=O)OCCCCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)o2)c1)O[C@H]1CN2CCC1CC2,Ki,0.02512,nM,10.60,CHEMBL5129800,Displacement of 125I-cyanopindolol from human beta2 adrenoceptor expressed in CHO-K1 cell membrane measured after 1 hr by Cheng-prusoff equation analysis,B,Homo sapiens
CHEMBL5208957,O=C(N[C@@H](c1ccccc1)c1cccc(OCc2nc(C(=O)OCCCCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)co2)c1)O[C@H]1CN2CCC1CC2,Ki,0.05012,nM,10.30,CHEMBL5129800,Displacement of 125I-cyanopindolol from human beta2 adrenoceptor expressed in CHO-K1 cell membrane measured after 1 hr by Cheng-prusoff equation analysis,B,Homo sapiens
CHEMBL5193853,O=C(N[C@@H](c1ccccc1)c1cccc(OCc2cccc(C(=O)OCCCCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)c1)O[C@H]1CN2CCC1CC2,Ki,0.02512,nM,10.60,CHEMBL5129800,Displacement of 125I-cyanopindolol from human beta2 adrenoceptor expressed in CHO-K1 cell membrane measured after 1 hr by Cheng-prusoff equation analysis,B,Homo sapiens
CHEMBL5200887,COc1cc(C(=O)OCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1COc1cccc([C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)c1,Ki,0.02512,nM,10.60,CHEMBL5129800,Displacement of 125I-cyanopindolol from human beta2 adrenoceptor expressed in CHO-K1 cell membrane measured after 1 hr by Cheng-prusoff equation analysis,B,Homo sapiens
CHEMBL4860528,CCCCCNC(=O)/N=C(\N)NCCCc1sc(N)nc1C,EC50,11748.98,nM,4.93,CHEMBL5151496,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL5207281,CCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,EC50,63095.73,nM,4.20,CHEMBL5151496,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL5206565,N/C(=N\C(=O)NCc1ccccc1)NCCCc1nnc(N)s1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,EC50,39810.72,nM,4.40,CHEMBL5151496,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL5201074,C[C@@H](NC(=O)/N=C(\N)NCCCc1ncn[nH]1)c1ccccc1.Cl.Cl,EC50,35481.34,nM,4.45,CHEMBL5151496,Displacement of [3H]CGP12177 from human beta-2 adrenergic receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,B,Homo sapiens
CHEMBL5192245,CC(C)(C)NC(CO)c1cc(Cl)c(N)c(C(F)(F)F)c1.Cl,EC50,60.92,nM,7.21,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5172759,Cl.Nc1c(Cl)cc(C(CO)NC2CCCC2)cc1C(F)(F)F,EC50,586.8,nM,6.23,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5191729,CCOCCCNC(CO)c1cc(Cl)c(N)c(C(F)(F)F)c1.Cl,EC50,345.4,nM,6.46,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5186069,CCCCNC(CO)c1cc(Cl)c(N)c(C(F)(F)F)c1.Cl,EC50,102.8,nM,6.99,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5186002,CC(C)(Cc1ccccc1)NC(CO)c1cc(Cl)c(N)c(C(F)(F)F)c1.Cl,EC50,143.8,nM,6.84,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5176025,CC(C)(C)NC(CO)c1cc(Br)c(N)c(C(F)(F)F)c1.Cl,EC50,1855.0,nM,5.73,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5194956,CC(C)(C)NC(CO)c1cc(F)c(N)c(S(C)(=O)=O)c1.Cl,EC50,7239.0,nM,5.14,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5183062,CC(C)(C)NC(CO)c1cc(F)c(N)c(Br)c1.Cl,EC50,19.42,nM,7.71,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5194651,CC(C)(C)NC(CO)c1cc(Br)c(N)c(C#N)c1.Cl,EC50,852.9,nM,6.07,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5201031,CC(C)(C)NC(CO)c1ccc(N)c([N+](=O)[O-])c1.Cl,EC50,3115.0,nM,5.51,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5192613,CC(C)NC(CO)c1cc(Br)c(N)c(C(F)(F)F)c1.Cl,EC50,3349.0,nM,5.47,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5190852,Cl.Nc1c(Br)cc(C(CO)NC2CCCC2)cc1C(F)(F)F,EC50,83.15,nM,7.08,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5197382,Cl.Nc1c(Br)cc(C(CO)NC2CCCCC2)cc1C(F)(F)F,EC50,2990.0,nM,5.52,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5187056,CCOCCCNC(CO)c1cc(Br)c(N)c(C(F)(F)F)c1.Cl,EC50,370.1,nM,6.43,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5190961,CCCCNC(CO)c1cc(Br)c(N)c(C(F)(F)F)c1.Cl,EC50,3163.0,nM,5.50,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5203966,CC(C)NC(CO)c1cc(F)c(N)c(Br)c1.Cl,EC50,237.2,nM,6.62,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5178340,CCCCNC(CO)c1cc(F)c(N)c(Br)c1.Cl,EC50,1513.0,nM,5.82,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5195910,CCOCCCNC(CO)c1cc(F)c(N)c(Br)c1.Cl,EC50,1177.0,nM,5.93,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5200165,Cl.Nc1c(F)cc(C(CO)NC2CCCC2)cc1Br,EC50,72.69,nM,7.14,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5180409,Cl.Nc1c(F)cc(C(CO)NC2CCCCC2)cc1Br,EC50,1643.0,nM,5.78,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5205567,Cl.Nc1c(F)cc(C(CO)NCc2ccccc2)cc1Br,EC50,10000.0,nM,5.00,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5176681,COc1ccc(CNC(CO)c2cc(F)c(N)c(Br)c2)cc1.Cl,EC50,10000.0,nM,5.00,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5201243,Cl.Nc1c(F)cc(C(CO)NCc2ccc(F)cc2)cc1Br,EC50,398.8,nM,6.40,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5200823,Cl.N#Cc1cc(C(CO)NC2CCCC2)cc(Br)c1N,EC50,142.3,nM,6.85,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5186459,Cl.N#Cc1cc(C(CO)NC2CCCCC2)cc(Br)c1N,EC50,9241.0,nM,5.03,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5208931,CCOCCCNC(CO)c1cc(Br)c(N)c(C#N)c1.Cl,EC50,440.2,nM,6.36,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL5196966,CCCCNC(CO)c1cc(Br)c(N)c(C#N)c1.Cl,EC50,99.47,nM,7.00,CHEMBL5163495,Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis,F,Homo sapiens
CHEMBL1933288,C[C@@H]1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21,IC50,1820.0,nM,5.74,CHEMBL5213136,"Selectivity interaction (Enzyme panel (receptors, ion channels, other enzymes)) EUB0000679a ADRB2",B,Homo sapiens
CHEMBL601773,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,Ki,2.4,nM,8.62,CHEMBL5346634,Binding affinity to human beta 2 adrenergic receptor assessed as inhibition constant,B,Homo sapiens
CHEMBL15245,COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O,Ki,0.04,nM,10.40,CHEMBL5346634,Binding affinity to human beta 2 adrenergic receptor assessed as inhibition constant,B,Homo sapiens
CHEMBL1326499,CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc21,EC50,8.71,nM,8.06,CHEMBL5355531,Agonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as CRE-SPAP production measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5397120,CCc1ccccc1OC[C@@H](O)CNCCC(c1ccccc1)c1ccccc1,EC50,138.04,nM,6.86,CHEMBL5355531,Agonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as CRE-SPAP production measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5430355,CC1(C)CC(=O)c2ccc(OC[C@@H](O)CNCCC(c3ccccc3)c3ccccc3)cc2O1,EC50,112.2,nM,6.95,CHEMBL5355531,Agonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as CRE-SPAP production measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5410388,CC1(C)CC(=O)c2ccc(OC[C@@H](O)CNCCc3ccc4c(c3)OCO4)cc2O1,EC50,10000.0,nM,5.00,CHEMBL5355531,Agonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as CRE-SPAP production measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5427527,O[C@@H](CNCC1COc2ccccc2O1)COc1cccc2cnccc12,EC50,10000.0,nM,5.00,CHEMBL5355531,Agonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as CRE-SPAP production measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5432967,CC1(C)CC(=O)c2ccc(OC[C@@H](O)CNCC3COc4ccccc4O3)cc2O1,Kd,6165.95,nM,5.21,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5422259,O=c1ccc2ccc(OC[C@@H](O)CNCC3COc4ccccc4O3)cc2o1,Kd,6606.93,nM,5.18,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5426087,CC1(C)CC(=O)c2ccc(OC[C@@H](O)CNCCCc3ccccc3)cc2O1,Kd,2290.87,nM,5.64,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5431834,CC1(C)CC(=O)c2ccc(OC[C@H](O)CNCCCc3ccccc3)cc2O1,Kd,1202.26,nM,5.92,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5395772,CC1(C)CC(=O)c2ccc(OC[C@H](O)CNCCc3ccc4c(c3)OCO4)cc2O1,Kd,5011.87,nM,5.30,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5432691,CC1(C)CC(=O)c2ccc(OC[C@H](O)CNCC3COc4ccccc4O3)cc2O1,Kd,3630.78,nM,5.44,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5428413,CC1(C)CC(=O)c2ccc(OC[C@H](O)CNCCC(c3ccccc3)c3ccccc3)cc2O1,Kd,724.44,nM,6.14,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5430136,O=c1ccc2ccc(OC[C@@H](O)CNCCc3ccc4c(c3)OCO4)cc2o1,Kd,6309.57,nM,5.20,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5415148,O[C@@H](CNCC1COc2ccccc2O1)COc1ccc2c(c1)OCO2,Kd,1548.82,nM,5.81,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5423415,O=C1COc2cc(OC[C@@H](O)CNCC3COc4ccccc4O3)ccc21,Kd,3630.78,nM,5.44,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5395432,COc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc4c(c3)OC(C)(C)CC4=O)cc2)cc1,Kd,3090.3,nM,5.51,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5403431,COc1ccc(S(=O)(=O)Nc2ccc(CCNC[C@H](O)COc3ccc4ccc(=O)oc4c3)cc2)cc1,Kd,1737.8,nM,5.76,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5413563,COc1ccc(S(=O)(=O)NCCCCCCNC[C@H](O)COc2ccc3c(c2)OC(C)(C)CC3=O)cc1,Kd,1412.54,nM,5.85,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5434276,COc1ccc(S(=O)(=O)NCCCCCCNC[C@H](O)COc2ccc3ccc(=O)oc3c2)cc1,Kd,1584.89,nM,5.80,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5416424,COc1ccc(S(=O)(=O)NCCCCNC[C@H](O)COc2ccc3c(c2)OC(C)(C)CC3=O)cc1,Kd,851.14,nM,6.07,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL5429806,COc1ccc(S(=O)(=O)NCCCCNC[C@H](O)COc2ccc3ccc(=O)oc3c2)cc1,Kd,1148.15,nM,5.94,CHEMBL5355536,Antagonist activity at human beta2-adrenergic receptor expressed in CHO-K1 cells co-expressing CRE-SPAP reporter gene assessed as inhibition of fenoterol-induced CRE-SPAP production by measuring rightward shift of the fenoterol concentration response curve measured after 5 hrs incubation,F,Homo sapiens
CHEMBL93298,CC(C)(C)NCC(O)CSc1nc(-c2ccc(C(N)=O)s2)cs1,Ki,0.5495,nM,9.26,CHEMBL5387528,Inhibition of beta-2 adrenoceptor (unknown origin),B,Homo sapiens
CHEMBL24778,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,Ki,32.83,nM,7.48,CHEMBL5442214,"PDSP Secondary Binding target: ADRB2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",B,Homo sapiens
CHEMBL1671,CC(C)NCC(O)COc1cccc2ccccc12.Cl,Ki,2.27,nM,8.64,CHEMBL5442214,"PDSP Secondary Binding target: ADRB2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",B,Homo sapiens
CHEMBL1691,CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1.Cl,Ki,278.42,nM,6.55,CHEMBL5442214,"PDSP Secondary Binding target: ADRB2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",B,Homo sapiens
CHEMBL1615374,Cl.N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,Ki,2490.29,nM,5.60,CHEMBL5442214,"PDSP Secondary Binding target: ADRB2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",B,Homo sapiens
CHEMBL1836317,CS(=O)(=O)NC[C@H]1CC[C@H](Nc2nc3c(s2)CCSc2ccccc2-3)CC1,Ki,7540.5,nM,5.12,CHEMBL5442214,"PDSP Secondary Binding target: ADRB2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",B,Homo sapiens
CHEMBL2030155,CN(C)S(=O)(=O)c1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Ki,5205.95,nM,5.28,CHEMBL5442214,"PDSP Secondary Binding target: ADRB2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",B,Homo sapiens
CHEMBL2105760,O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,Ki,968.73,nM,6.01,CHEMBL5442214,"PDSP Secondary Binding target: ADRB2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",B,Homo sapiens
CHEMBL5076314,CN1CCN(c2ccc(Nc3c4ccccc4nc4ccccc34)cc2)CC1.Cl.Cl.O,Ki,810.5,nM,6.09,CHEMBL5442214,"PDSP Secondary Binding target: ADRB2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",B,Homo sapiens
CHEMBL4743495,Cl.O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1,IC50,4327.23,nM,5.36,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL1256876,Cl.NC[C@@H]1O[C@H](C23CC4CC(CC(C4)C2)C3)Cc2c1ccc(O)c2O,IC50,1644.1,nM,5.78,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL9506,CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c2ccccc2)c2ccccc21,EC50,3830.0,nM,5.42,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL344159,Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1,EC50,3400.0,nM,5.47,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL1256864,CC(C)(C)NCC(O)COc1cccc2[nH]c(=O)[nH]c12.Cl,IC50,1.96,nM,8.71,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL267777,Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,EC50,4435.71,nM,5.35,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL79834,O=C1NCN(c2ccccc2)C12CCN(CCCOc1ccc(F)cc1)CC2,IC50,3044.66,nM,5.52,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL1707,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl,EC50,1336.92,nM,5.87,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL273083,CSc1ccc(C(=O)N[C@@H]2CCCC[C@@H]2NC(=O)CNC(=O)c2cc(C(F)(F)F)ccc2NC(=O)NC(C)C)cc1,EC50,917.0,nM,6.04,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL502182,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)[O-])c3ccccc3)c2=O)c1F.[Na+],EC50,5480.62,nM,5.26,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL2105510,CC(C)(Cc1ccccc1)NCC(O)c1ccc(O)c(NS(C)(=O)=O)c1.Cl,EC50,35.66,nM,7.45,CHEMBL5442703,GPCR PRESTO-Tango dose-response in agonist mode with target: ADRB2,F,Homo sapiens
CHEMBL3342358,CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(-c2ccccn2)n1,EC50,4226.62,nM,5.37,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL4803066,O=c1c2cccn2c2ccccc2n1CCCN1CCC(c2ccc(Cl)cc2)CC1,IC50,4677.38,nM,5.33,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL1938952,COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(C(F)(F)F)c1,IC50,4918.12,nM,5.31,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL469695,O=C(NCc1ccc(F)cc1)N1CCN2C(=O)OC(c3ccccc3)(c3ccccc3)C2C1,EC50,5806.46,nM,5.24,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL2111101,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,IC50,4549.68,nM,5.34,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL567,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,IC50,2777.1,nM,5.56,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL484929,CC(F)(F)CN1CCOc2c(nn(-c3ccccc3Cl)c2-c2ccc(Cl)cc2)C1=O,EC50,1438.21,nM,5.84,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL2178422,N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F,EC50,3200.0,nM,5.50,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL2181247,O=C1COc2nccc(-c3ccccc3F)c2CN1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1,IC50,1508.69,nM,5.82,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL1200517,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21.CS(=O)(=O)O,EC50,2830.0,nM,5.55,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL5087452,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)[C@H](O)[C@@H](O)C(=O)O,EC50,9380.02,nM,5.03,CHEMBL5442703,GPCR PRESTO-Tango dose-response in agonist mode with target: ADRB2,F,Homo sapiens
CHEMBL1722209,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O,EC50,3910.0,nM,5.41,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL1256784,Cc1ccc(OCC(O)C(C)NC(C)C)c2c1CCC2.Cl,IC50,1.493,nM,8.83,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL2331803,C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21.O=C(O)/C=C/C(=O)O,IC50,6138.89,nM,5.21,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL5084234,CSc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1.Cl,IC50,2661.78,nM,5.58,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL2074611,Cl.FC(F)(F)c1ccc(N2CCNCC2)nc1Cl,IC50,2728.0,nM,5.56,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL4531673,CN1CCN(c2nc3cc(C(F)(F)F)ccc3n3cccc23)CC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,IC50,2378.77,nM,5.62,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL1256645,CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccccc2)C1.Cl,EC50,4570.0,nM,5.34,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL1329567,O=C(NCCNCC(O)COc1ccc(O)cc1)N1CCOCC1.O=C(NCCNCC(O)COc1ccc(O)cc1)N1CCOCC1.O=C(O)/C=C/C(=O)O,IC50,1546.7,nM,5.81,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL5075931,NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12.O=C(O)C(=O)O,IC50,2932.72,nM,5.53,CHEMBL5442689,GPCR PRESTO-Tango dose-response in antagonist mode with target: ADRB2,F,Homo sapiens
CHEMBL5550055,O=C(N[C@@H](c1ccccc1)c1cccc(OCc2ccc(C(=O)NCCCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)c1)O[C@@H]1CN2CCC1CC2,Ki,0.01259,nM,10.90,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5555744,O=C(NCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)c1ccc(COc2cccc([C@@](O)(C(=O)OCC3CCN(Cc4ccccc4)CC3)c3ccccc3)c2)cc1,Ki,0.03162,nM,10.50,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5558368,O=C(NCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)c1ccc(COc2cccc([C@](O)(C(=O)OCC3CCN(Cc4ccccc4)CC3)c3ccccc3)c2)cc1,Ki,0.01995,nM,10.70,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5555665,O=C(NCCCOc1cccc([C@](O)(C(=O)OCC2CCN(Cc3ccccc3)CC2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,0.1,nM,10.00,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL6067687,O=C(NCCCOc1cccc([C@@](O)(C(=O)OCC2CCN(Cc3ccccc3)CC2)c2ccccc2)c1)c1ccc(CNCC(O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,0.05012,nM,10.30,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5523458,O=C(NCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)c1ccc(C(=O)NC2(C(=O)O[C@H]3CN4CCC3CC4)CCc3ccccc32)cc1,Ki,0.3981,nM,9.40,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5556153,O=C(NCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)c1cccc(C(=O)NC2(C(=O)O[C@H]3CN4CCC3CC4)CCc3ccccc32)c1,Ki,1.585,nM,8.80,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5512435,O=C(NCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)c1ccc(CNC2(C(=O)O[C@H]3CN4CCC3CC4)CCc3ccccc32)cc1,Ki,0.5012,nM,9.30,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5517637,O=C(N[C@@H](c1ccccc1)c1cccc(OCc2cccc(C(=O)NCCCCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)c2)c1)O[C@H]1CN2CCC1CC2,Ki,0.01259,nM,10.90,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5505816,O=C(NCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)c1ccc(CNC2(C(=O)OCC3CCN(Cc4ccccc4)CC3)CCc3ccccc32)s1,Ki,0.0631,nM,10.20,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5523340,O=C(NCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)c1ccc(C(=O)N2CCC(C(=O)O[C@H]3CN4CCC3CC4)(c3ccccc3)CC2)cc1,Ki,0.631,nM,9.20,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5505925,O=C(c1ccc(OCc2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1)N1CCC(C(=O)O[C@@H]2CN3CCC2CC3)(c2ccccc2)CC1,Ki,0.1995,nM,9.70,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5542735,O=C(c1ccc(OCc2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1)N1CC(C(=O)O[C@@H]2CN3CCC2CC3)(c2ccccc2)C1,Ki,0.631,nM,9.20,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5542602,O=C(NCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12)c1ccc(C(=O)C2CC(C(=O)O[C@H]3CN4CCC3CC4)(c3ccccc3)C2)cc1,Ki,0.1585,nM,9.80,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5556756,O=C(c1ccc(OCc2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1)N1CC(C(=O)OCC2CCN(Cc3ccccc3)CC2)(c2ccccc2)C1,Ki,0.2512,nM,9.60,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5543004,O=C(NCCCOc1cccc([C@](O)(C(=O)O)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,10.0,nM,8.00,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5555669,O=C(NCCCOc1cccc([C@](O)(C(=O)OCC2CCN(C3CCC3)CC2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,0.02512,nM,10.60,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5558825,O=C(NCCCOc1cccc([C@](O)(C(=O)OCC2CCN(C3CCCC3)CC2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,0.01995,nM,10.70,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5532469,O=C(NCCCOc1cccc([C@](O)(C(=O)OC[C@H]2CCN(Cc3ccccc3)C2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,0.1259,nM,9.90,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5558303,O=C(NCCCOc1cccc([C@](O)(C(=O)OC[C@@H]2CCN(Cc3ccccc3)C2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,0.07943,nM,10.10,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5542277,O=C(NCCCOc1cccc([C@](O)(C(=O)OC2CCN(Cc3ccccc3)CC2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,0.05012,nM,10.30,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5512578,O=C(NCCCOc1cccc([C@](O)(C(=O)O[C@@H]2CCN(Cc3ccccc3)C2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,0.1585,nM,9.80,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5523438,O=C(NCCCOc1cccc([C@](O)(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,0.3981,nM,9.40,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5558239,O=C(NCCCOc1cccc([C@](O)(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1.O=CO,Ki,0.3162,nM,9.50,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5557820,O=C(NCCCOc1cccc([C@](O)(C(=O)O[C@H]2CCCN(Cc3ccccc3)C2)c2ccccc2)c1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1.O=CO,Ki,0.5012,nM,9.30,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5518087,CN1CCC(COC(=O)[C@](O)(c2ccccc2)c2cccc(OCCCNC(=O)c3ccc(CNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)cc3)c2)CC1,Ki,0.03981,nM,10.40,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5523404,CN1CCC[C@H](OC(=O)[C@](O)(c2ccccc2)c2cccc(OCCCNC(=O)c3ccc(CNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)cc3)c2)C1.O=CO.O=CO,Ki,0.02512,nM,10.60,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5532029,CN1CCC[C@@H](OC(=O)[C@](O)(c2ccccc2)c2cccc(OCCCNC(=O)c3ccc(CNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)cc3)c2)C1,Ki,0.02512,nM,10.60,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5517803,CN1CCC[C@@H](OC(=O)[C@](O)(c2ccccc2)c2cccc(OCCCNC(=O)c3cnc(CNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)nc3)c2)C1.O=CO,Ki,0.02512,nM,10.60,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL6067688,CN1CCC[C@@H](OC(=O)[C@](O)(c2ccccc2)c2cccc(OCCCNC(=O)c3cccc(CNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)c3)c2)C1,Ki,1.995,nM,8.70,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL6067689,COc1cc(C(=O)NCCCOc2cccc([C@](O)(C(=O)O[C@@H]3CCCN(C)C3)c3ccccc3)c2)c(OC)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Ki,0.0631,nM,10.20,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5555388,COc1cc(C(=O)NCCCOc2cccc([C@](O)(C(=O)O[C@@H]3CCCN(C)C3)c3ccccc3)c2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Ki,0.02512,nM,10.60,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5505762,COc1cc(C(=O)NCCCOc2cccc([C@](O)(C(=O)O[C@@H]3CCCN(C)C3)c3ccccc3)c2)c(F)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Ki,0.01585,nM,10.80,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5557509,CN1CCC[C@@H](OC(=O)[C@](O)(c2ccccc2)c2cccc(OCCCNC(=O)c3ccc(CNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)nc3)c2)C1.O=CO.O=CO,Ki,0.02512,nM,10.60,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5556348,COc1cc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c(Cl)cc1C(=O)NCCCOc1cccc([C@](O)(C(=O)O[C@@H]2CCCN(C)C2)c2ccccc2)c1,Ki,0.1,nM,10.00,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5555464,COc1cc(C(=O)NCCCOc2cccc([C@](O)(C(=O)O[C@@H]3CCCN(C)C3)c3ccccc3)c2)ccc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Ki,0.01585,nM,10.80,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL6067690,CN1CCC[C@@H](OC(=O)[C@](O)(c2ccccc2)c2cccc(OCCCNC(=O)c3ccc(CNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)c(F)c3)c2)C1.O=CO,Ki,0.01259,nM,10.90,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5559271,Cc1cc(C(=O)NCCCOc2cccc([C@](O)(C(=O)O[C@@H]3CCCN(C)C3)c3ccccc3)c2)c(C)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Ki,0.01585,nM,10.80,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5557828,COc1cc(C(=O)NCCCOc2cccc([C@](O)(C(=O)OCC3CCN(Cc4ccccc4)CC3)c3ccccc3)c2)ccc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Ki,0.3981,nM,9.40,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5556228,COc1cc(C(=O)NCCCOc2cccc([C@](O)(C(=O)OCC3CCN(Cc4ccccc4)CC3)c3ccccc3)c2)c(F)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Ki,0.2512,nM,9.60,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5542534,O=C(c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)N1CC(COc2cccc([C@](O)(C(=O)OCC3CCN(Cc4ccccc4)CC3)c3ccccc3)c2)C1,Ki,1.0,nM,9.00,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5558093,O=C(NCc1ccc(-c2cccc([C@](O)(C(=O)OCC3CCN(Cc4ccccc4)CC3)c3ccccc3)c2)s1)c1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,Ki,2.512,nM,8.60,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5557651,CN1CCC(COC(=O)[C@@](O)(c2ccccc2)c2cccc(-c3ccc(CNC(=O)c4ccc(CNC[C@H](O)c5ccc(O)c6[nH]c(=O)ccc56)cc4)s3)c2)CC1,Ki,1.0,nM,9.00,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5542670,CN1CCC(COC(=O)[C@](O)(c2ccccc2)c2cccc(-c3ccc(CNC(=O)c4ccc(CNC[C@H](O)c5ccc(O)c6[nH]c(=O)ccc56)cc4)s3)c2)CC1,Ki,0.3981,nM,9.40,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5556694,COc1cc(C(=O)N2CCC(c3cccc([C@](O)(C(=O)OCC4CCN(Cc5ccccc5)CC4)c4ccccc4)c3)CC2)ccc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,Ki,0.5012,nM,9.30,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL6067691,O=C(c1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1)N1CCC(c2cccc([C@](O)(C(=O)OCC3CCN(Cc4ccccc4)CC3)c3ccccc3)c2)CC1,Ki,0.3981,nM,9.40,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5527849,COc1cc(C(=O)NCCCOc2cccc([C@](O)(C(=O)OCC3CCN(CC4CC4)CC3)c3ccccc3)c2)c(F)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12.O=CO.O=CO,Ki,0.3162,nM,9.50,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5527960,CCN1CCC(COC(=O)[C@](O)(c2ccccc2)c2cccc(OCCCNC(=O)c3cc(OC)c(CNC[C@H](O)c4ccc(O)c5[nH]c(=O)ccc45)cc3F)c2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,Ki,0.5012,nM,9.30,CHEMBL5503898,Displacement of [125I]-Cyanopindolol from human beta2 adrenoceptor assessed as inhibition constant incubated for 1 hrs by Microbeta scintillation counter,B,Homo sapiens
CHEMBL5562430,C#CCCNC[C@H](O)COc1ccccc1CC=C,IC50,79.43,nM,7.10,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5561419,C#CCCCNC[C@H](O)COc1ccccc1CC=C,IC50,173.78,nM,6.76,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5564893,CC(C)NC[C@H](O)COc1ccc(CCCN=[N+]=[N-])cc1,IC50,3981.07,nM,5.40,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5562644,CC(C)NC[C@H](O)COc1ccc(CCCCN=[N+]=[N-])cc1,IC50,4786.3,nM,5.32,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5564549,C=CCc1ccccc1OC[C@@H](O)CNCCCc1cn(CCCCc2ccc(OC[C@@H](O)CNC(C)C)cc2)nn1,IC50,4.467,nM,8.35,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5564461,C=CCc1ccccc1OC[C@@H](O)CNCCc1cn(CCCc2ccc(OC[C@@H](O)CNC(C)C)cc2)nn1,IC50,10.0,nM,8.00,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5568267,C=CCc1ccccc1OC[C@@H](O)CNCCc1cn(CCCCc2ccc(OC[C@@H](O)CNC(C)C)cc2)nn1,IC50,7.413,nM,8.13,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5556781,C=CCc1ccccc1OC[C@@H](O)CNCCCc1cn(CCCc2ccc(OC[C@@H](O)CNC(C)C)cc2)nn1,IC50,4.677,nM,8.33,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5562658,C=CCc1ccccc1OC[C@@H](O)CNCCCc1cn(CCCCc2ccc(OC)cc2)nn1,IC50,5.37,nM,8.27,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5557954,C=CCc1ccccc1OC[C@@H](O)CNCCCc1cn(CCCCc2ccccc2)nn1,IC50,4.677,nM,8.33,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5568144,C=CCc1ccccc1OC[C@@H](O)CNCCCc1cn(CCCC)nn1,IC50,18.2,nM,7.74,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5561967,CCCc1cn(CCCCc2ccc(OC[C@@H](O)CNC(C)C)cc2)nn1,IC50,3162.28,nM,5.50,CHEMBL5525955,Antagonist activity at beta-2 AR (unknown origin) overexpressed in HEK293 cell membrane assessed as inhibition of ISO-induced cAMP production at EC80 preincubated for 15 mins followed by agonist addition measured after 30 mins by TR-FRET assay,F,Homo sapiens
CHEMBL5571981,Cl.O=C1COc2c(C(O)CNC3CCCCC3)ccc(O)c2N1,EC50,0.0871,nM,10.06,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5572643,CCCCNCC(O)c1ccc(O)c2c1OCC(=O)N2.Cl,EC50,0.0257,nM,10.59,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5532178,CCCNCC(O)c1ccc(O)c2c1OCC(=O)N2.Cl,EC50,0.03162,nM,10.50,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5573592,Cl.O=C1COc2c(C(O)CNC3CC3)ccc(O)c2N1,EC50,0.02239,nM,10.65,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5571660,CCCCCCNCC(O)c1ccc(O)c2c1OCC(=O)N2.Cl,EC50,0.0309,nM,10.51,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5571445,Cl.O=C1COc2c(C(O)CNCCOc3ccccc3)ccc(O)c2N1,EC50,0.01585,nM,10.80,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5574770,Cl.O=C1COc2c(C(O)CNCCCCc3ccccc3)ccc(O)c2N1,EC50,0.02239,nM,10.65,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5566587,Cl.O=C1COc2c(C(O)CNCCC(c3ccccc3)c3ccccc3)ccc(O)c2N1,EC50,0.04677,nM,10.33,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5570917,Cl.O=C1COc2c(C(O)CNCCc3ccccc3F)ccc(O)c2N1,EC50,0.01148,nM,10.94,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5565495,Cl.O=C1COc2c(C(O)CNCCc3cccc(F)c3)ccc(O)c2N1,EC50,0.02399,nM,10.62,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5574011,COc1ccc(CCNCC(O)c2ccc(O)c3c2OCC(=O)N3)cc1.Cl,EC50,0.01318,nM,10.88,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5594574,Cc1ccc(CCNCC(O)c2ccc(O)c3c2OCC(=O)N3)cc1.Cl,EC50,0.04266,nM,10.37,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5594851,Cc1ccccc1CCNCC(O)c1ccc(O)c2c1OCC(=O)N2.Cl,EC50,0.02818,nM,10.55,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5593074,Cl.O=C1COc2c(C(O)CNCCc3ccc(Cl)cc3)ccc(O)c2N1,EC50,1.318,nM,8.88,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5571279,Cl.O=C1COc2c(C(O)CNCCc3cccc(Cl)c3)ccc(O)c2N1,EC50,0.02692,nM,10.57,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5571865,Cl.O=C1COc2c(C(O)CNCCc3ccccc3Cl)ccc(O)c2N1,EC50,0.01318,nM,10.88,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5592612,Cl.O=C1COc2c(C(O)CNCCCc3cccc(C(F)(F)F)c3)ccc(O)c2N1,EC50,0.0302,nM,10.52,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL5574906,COc1cc(CCCNCC(O)c2ccc(O)c3c2OCC(=O)N3)cc(OC)c1OC.Cl,EC50,0.0537,nM,10.27,CHEMBL5530376,Agonist activity at human beta2 adrenoceptor expressed in HEK293 cells assessed as induction of accumulation of cAMP by HTRF assay,F,Homo sapiens
CHEMBL384467,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,EC50,2.2,nM,8.66,CHEMBL5620834,Agonist activity at Adrenergic beta2 receptor (unknown origin),F,Homo sapiens
CHEMBL5855372,CN(CCCC(=O)Nc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)c1)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL5730576,"cAMP assays: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and resuspended in stimulation buffer containing IBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.). The amount of cAMP produced (pmol/well) was calculated based on the counts observed for the samples and cAMP standards as described in the manufacturer's user manual. Data were analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, Calif.) with the sigmoidal equation. The Cheng-Prusoff equation (Cheng Y, and Prusoff W H., Biochemical Pharmacology, 1973, 22, 23, 3099-108) was used to calculate the EC50 values.",B,Homo sapiens
CHEMBL3645364,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1cccc(C(=O)Nc2ccc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)c1,EC50,1.0,nM,9.00,CHEMBL5730576,"cAMP assays: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and resuspended in stimulation buffer containing IBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.). The amount of cAMP produced (pmol/well) was calculated based on the counts observed for the samples and cAMP standards as described in the manufacturer's user manual. Data were analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, Calif.) with the sigmoidal equation. The Cheng-Prusoff equation (Cheng Y, and Prusoff W H., Biochemical Pharmacology, 1973, 22, 23, 3099-108) was used to calculate the EC50 values.",B,Homo sapiens
CHEMBL3645297,COc1cc(NC(=O)c2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL5730576,"cAMP assays: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and resuspended in stimulation buffer containing IBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.). The amount of cAMP produced (pmol/well) was calculated based on the counts observed for the samples and cAMP standards as described in the manufacturer's user manual. Data were analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, Calif.) with the sigmoidal equation. The Cheng-Prusoff equation (Cheng Y, and Prusoff W H., Biochemical Pharmacology, 1973, 22, 23, 3099-108) was used to calculate the EC50 values.",B,Homo sapiens
CHEMBL3645300,CN(C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)c1cccc(C(=O)Nc2ccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)c1,EC50,1.0,nM,9.00,CHEMBL5730576,"cAMP assays: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and resuspended in stimulation buffer containing IBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.). The amount of cAMP produced (pmol/well) was calculated based on the counts observed for the samples and cAMP standards as described in the manufacturer's user manual. Data were analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, Calif.) with the sigmoidal equation. The Cheng-Prusoff equation (Cheng Y, and Prusoff W H., Biochemical Pharmacology, 1973, 22, 23, 3099-108) was used to calculate the EC50 values.",B,Homo sapiens
CHEMBL3645306,Cc1ccc(C(=O)Nc2ccc(CC(C)NC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)cc1N(C)C(=O)CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1,EC50,1.0,nM,9.00,CHEMBL5730576,"cAMP assays: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and resuspended in stimulation buffer containing IBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.). The amount of cAMP produced (pmol/well) was calculated based on the counts observed for the samples and cAMP standards as described in the manufacturer's user manual. Data were analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, Calif.) with the sigmoidal equation. The Cheng-Prusoff equation (Cheng Y, and Prusoff W H., Biochemical Pharmacology, 1973, 22, 23, 3099-108) was used to calculate the EC50 values.",B,Homo sapiens
CHEMBL3645318,CC(Cc1ccc(CC(=O)Nc2cccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)c2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL5730576,"cAMP assays: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and resuspended in stimulation buffer containing IBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.). The amount of cAMP produced (pmol/well) was calculated based on the counts observed for the samples and cAMP standards as described in the manufacturer's user manual. Data were analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, Calif.) with the sigmoidal equation. The Cheng-Prusoff equation (Cheng Y, and Prusoff W H., Biochemical Pharmacology, 1973, 22, 23, 3099-108) was used to calculate the EC50 values.",B,Homo sapiens
CHEMBL3645322,C[C@H](Cc1ccc(CCNC(=O)c2ccc(N(C)C(=O)CCN3CCC(OC(=O)Nc4ccccc4-c4ccccc4)CC3)cc2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,EC50,1.0,nM,9.00,CHEMBL5730576,"cAMP assays: cAMP assays were performed in a radioimmunoassay format using the Flashplate Adenylyl Cyclase Activation Assay System with [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences Inc., Boston, Mass.), according to the manufacturers instructions. For this assay, HEK-293 cell lines stably expressing cloned human 1 or 2 receptors were grown to near confluency in DMEM supplemented with 10% FBS and Geneticin (500 g/mL); or CHO-K1 cell lines stably expressing cloned human 3 adrenergic receptors were grown to near confluency in Hams F-12 media supplemented with 10% FBS and Geneticin (250 g/mL). Cells were rinsed with PBS and detached in dPBS (Dulbecco's Phosphate Buffered Saline, without CaCl2 and MgCl2) containing 2 mM EDTA or Trypsin-EDTA solution (0.05% trypsin/0.53 mM EDTA). After counting cells in Coulter cell counter, cells were pelleted by centrifugation at 1,000 rpm and resuspended in stimulation buffer containing IBMX (PerkinElmer Kit) pre-warmed to room temperature to a concentration of 1.6106 to 2.8106 cells/mL. About 40,000 to 80,000 cells per well were used in this assay. Test compounds (10 mM in DMSO) were diluted into PBS containing 0.1% BSA in Beckman Biomek-2000 and tested at 11 different concentrations ranging from 100 M to 1 pM. Reactions were incubated for 10 min at 37 C. and stopped by adding 100 L of cold detection buffer containing [125I]-cAMP (NEN SMP004, PerkinElmer Life Sciences, Boston, Mass.). The amount of cAMP produced (pmol/well) was calculated based on the counts observed for the samples and cAMP standards as described in the manufacturer's user manual. Data were analyzed by nonlinear regression analysis with the GraphPad Prism Software package (GraphPad Software, Inc., San Diego, Calif.) with the sigmoidal equation. The Cheng-Prusoff equation (Cheng Y, and Prusoff W H., Biochemical Pharmacology, 1973, 22, 23, 3099-108) was used to calculate the EC50 values.",B,Homo sapiens
CHEMBL5959314,CN(CCCn1ccc2cc(CNC[C@H](O)c3ccc(O)c4c3C=CCN4)ccc21)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,IC50,220.0,nM,6.66,CHEMBL5732615,"Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4. The affinity of each test compound to the receptor was determined by using ten different concentrations ran in duplicate. IC50s were calculated using Activity Base software from IDBS and the four parameters-log equation.",B,Homo sapiens
CHEMBL5965344,CN(CCN(C)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1)C(=O)COc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,IC50,34.0,nM,7.47,CHEMBL5732615,"Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4. The affinity of each test compound to the receptor was determined by using ten different concentrations ran in duplicate. IC50s were calculated using Activity Base software from IDBS and the four parameters-log equation.",B,Homo sapiens
CHEMBL5949911,CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](c2ccsc2[C@@](O)(C(=O)O)C2CCCC2)CC1,IC50,13.0,nM,7.89,CHEMBL5732615,"Binding Assay: The study of binding to human adrenergic beta1 and beta2 receptors was performed using commercial membranes prepared from Sf9 cells where they are overexpressed (Perkin Elmer). The membrane suspensions (16 g/well for beta1 and 5 g/well for beta2) in assay buffer (75 mM Tris/HCl with 12.5 mM MgCl2 and 2 mM EDTA pH=7.4) were incubated with 0.14 or 0.6 nM of 3H-CGP12177 (Amersham) for beta 1 and beta 2 receptors respectively in a final volume of 250 l, in GFC Multiscreen 96 well plates (Millipore) previously treated with assay buffer containing 0.3% PEI (Sigma). Non specific binding was measured in the presence of 1 M propanolol. Incubation was maintained for 60 minutes at room temperature and with gentle shaking. The binding reactions were terminated by filtration and washing with 2.5 volumes of Tris/HCl 50 mM pH=7.4. The affinity of each test compound to the receptor was determined by using ten different concentrations ran in duplicate. IC50s were calculated using Activity Base software from IDBS and the four parameters-log equation.",B,Homo sapiens
CHEMBL5862533,CC(C)(C)NC[C@H](O)c1cc(C(F)(F)F)ccn1,EC50,550.0,nM,6.26,CHEMBL5736523,"cAMP Gs dynamic HTRF assay: Compound preparation. Candidate beta-adrenergic compounds, dissolved to 10 mM in DMSO, were diluted in 1 stimulation buffer 1 (Cisbio Part #64SB1FDD) containing 1 mM 3-Isobutyl-1-methylxanthene (IBMX; Cayman Chemical Company, catalog #13347). Serial dilutions were made in a 96 well V-bottom polypropylene compound microplate (Corning, catalog #3363) in stimulation buffer containing 1 mM IBMX, to 2 of the final desired concentration. Standard serial dilution curves were 10-point, 5-fold dilutions starting from a highest concentration of 10 M. Controls present on every assay plate were 0.1% DMSO (vehicle control), 1 M isoproterenol (full beta-adrenergic agonist control) and 15 M xamoterol (partial beta-adrenergic agonist control). 5 L from the 2 compound plate was stamped into a white 384 round well small volume HiBase assay plate (Greiner Bio-One; catalog #784075) to provide 4 technical replicates per concentration, per compound. Assay plates were centrifuged at 500g for 10 seconds. Compounds and IBMX were prepared at 2 final dose to compensate for addition of cells.Cell preparation. 1 stimulation buffer, washing PBS (Dulbecco's phosphate-buffered saline, Mg Ca; Caisson Labs, catalog #PBL01), assay PBS (Dulbecco's phosphate-buffered saline, +Mg, +Ca; Caisson Labs, catalog #PBL02) and Versene (0.02% EDTA disodium salt solution in PBS without calcium or magnesium; Caisson Labs, catalog #EDL01) were pre-warmed to 37 C. Cells expressing beta-adrenergic receptor were washed in washing PBS to remove growth medium and then released from the surface by incubating with Versene for 5-10 minutes at 37 C. Cells were harvested using assay PBS, counted manually by hemocytometer or by an automated cell counter, pelleted by centrifugation (200g, 5 minutes) and resuspended in 37 C. 1 stimulation buffer to a final density of 1.510{circumflex over ()}6 cells/mL. 5 L of the suspended cell solution (7500 cell total) were added to all wells of the 384 well assay plate, the assay plate was covered with an Axygen plate seal (Corning PCR-SP) and incubated in a humidified 37 C. environment supplemented with 5% CO2 for 30 minutes.HTRF reagent addition, reading and data analysis. After 30 minutes of cell stimulation with test compound, the assay plates were centrifuged at 500g for 10 seconds, and incubation was stopped with the addition of 5 L cAMP-D2 acceptor, diluted 1:21 in detection and lysis buffer 2 (Cisbio 62CL2FDF) was added to all cells. Subsequently, 5 L Anti-cAMP-Eu Donor, diluted 1:21 in detection and lysis buffer 2, was added to cells. Plates were sealed and reactions gently vortexed at 900 rpm on a Heidolph Titramax 1000 for at least 30 minutes at room temperature. Plates were centrifuged again at 500g for 10 seconds, and HTRF was measured using a Tecan Spark plate reader at 50 flashes per well. HTRF ratios (665 nm/620 nm10,000) were determined and plotted in GraphPad Prism to generate a concentration-effect curve. Potency estimates (EC50) were derived from the four-parameter nonlinear regression of the concentration-effect curve and an estimate of relative efficacy was determined by comparing the magnitude of the test compound HTRF signal window (minmax dose) with the signal window of the full agonist control, isoproterenol.",B,Homo sapiens
